US20230130516A1 - 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS - Google Patents

1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS Download PDF

Info

Publication number
US20230130516A1
US20230130516A1 US17/792,878 US202117792878A US2023130516A1 US 20230130516 A1 US20230130516 A1 US 20230130516A1 US 202117792878 A US202117792878 A US 202117792878A US 2023130516 A1 US2023130516 A1 US 2023130516A1
Authority
US
United States
Prior art keywords
alkyl
alkanediyl
cancer
cycloalkyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/792,878
Inventor
Qian Zhang
Sanjeev Gangwar
Ashvinikumar V. Gavai
Qiang Cong
Yam B. POUDEL
Liqi He
Prasanna Sivaprakasam
Christine M. Tarby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to US17/792,878 priority Critical patent/US20230130516A1/en
Assigned to BRISTOL-MYERS SQUIBB COMPANY reassignment BRISTOL-MYERS SQUIBB COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ZHANG, QIAN, TARBY, CHRISTINE M., CONG, QIANG, GANGWAR, SANJEEV, HE, LIQI, SIVAPRAKASAM, Prasanna, GAVAI, ASHVINIKUMAR V., POUDEL, YAM B.
Publication of US20230130516A1 publication Critical patent/US20230130516A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • TLR7 Toll-like receptor 7
  • TLRs Toll-like receptors
  • PAMPs pathogen-associated molecular patterns
  • TLRs can be located either on a cell's surface or intracellularly. Activation of a TLR by the binding of its cognate PAMP signals the presence of the associated pathogen inside the host—i.e., an infection—and stimulates the host's immune system to fight the infection.
  • Humans have 10 TLRs, named TLR1, TLR2, TLR3, and so on.
  • TLR7 The activation of a TLR—with TLR7 being the most studied—by an agonist can have a positive effect on the action of vaccines and immunotherapy agents in treating a variety of conditions other than actual pathogen infection, by stimulating the immune response overall.
  • TLR7 agonists as vaccine adjuvants or as enhancers in cancer immunotherapy. See, for example, Vasilakos and Tomai 2013, Sato-Kaneko et al. 2017, Smits et al. 2008, and Ota et al. 2019.
  • TLR7 an intracellular receptor located on the membrane of endosomes, recognizes PAMPs associated with single-stranded RNA viruses. Its activation induces secretion of Type I interferons such as IFN ⁇ and IFN ⁇ (Lund et al. 2004). TLR7 has two binding sites, one for single stranded RNA ligands (Berghöfer et al. 2007) and one for small molecules such as guanosine (Zhang et al. 2016).
  • TLR7 can bind to, and be activated by, guanosine-like synthetic agonists such as imiquimod, resiquimod, and gardiquimod, which are based on a 1H-imidazo[4,5-c]quinoline scaffold.
  • guanosine-like synthetic agonists such as imiquimod, resiquimod, and gardiquimod, which are based on a 1H-imidazo[4,5-c]quinoline scaffold.
  • Synthetic TLR7 agonists based on a pteridinone molecular scaffold are also known, as exemplified by vesatolimod (Desai et al. 2015).
  • R, R′, and R′′ are structural variables, with R′′ typically containing an unsubstituted or substituted aromatic or heteroaromatic ring.
  • bioactive molecules having a purine-like scaffold and their uses in treating conditions such as fibrosis, inflammatory disorders, cancer, or pathogenic infections include: Akinbobuyi et al. 2015 and 2016; Barberis et al. 2012; Carson et al. 2014; Ding et al. 2016, 2017a, and 2017b; Graupe et al. 2015; Hashimoto et al. 2009; He et al. 2019a and 2019b; Holldack et al. 2012; Isobe et al. 2009a and 2012; Poudel et al. 2019a and 2019b; Pryde 2010; and Young et al. 2019.
  • the group R′′ can be pyridyl: Bonfanti et al. 2015a and 2015b; Halcomb et al. 2015; Hirota et al. 2000; Isobe et al. 2002, 2004, 2006, 2009a, 2009b, 2011, and 2012; Kasibhatla et al. 2007; Koga-Yamakawa et al. 2013; Musmuca et al. 2009; Nakamura 2012; Ogita et al. 2007; and Yu et al. 2013.
  • TLR7 modulators in which the two rings of a purine moiety are spanned by a macrocycle:
  • a TLR7 agonist can be conjugated to a partner molecule, which can be, for example, a phospholipid, a poly(ethylene glycol) (“PEG”), an antibody, or another TLR (commonly TLR2).
  • a partner molecule can be, for example, a phospholipid, a poly(ethylene glycol) (“PEG”), an antibody, or another TLR (commonly TLR2).
  • PEG poly(ethylene glycol)
  • exemplary disclosures include: Carson et al. 2013, 2015, and 2016, Chan et al. 2009 and 2011, Cortez et al. 2017, Gadd et al. 2015, Lioux et al. 2016, Maj et al. 2015, Vernejoul et al. 2014, and Zurawski et al. 2012.
  • a frequent conjugation site is at the R′′ group of formula (A).
  • TLR7 agonists including resiquimod are dual TLR7/TLR8 agonists. See, for example, Beesu et al. 2017, Embrechts et al. 2018, Lioux et al. 2016, and Vernejoul et al. 2014.
  • This specification relates to compounds having a 1H-pyrazolo[4,3d]pyrimidine aromatic system, having activity as TLR7 agonists.
  • TLR7 agonists have activity as TLR7 agonists and some can be conjugated to an antibody for targeted delivery to a target tissue or organ of intended action. They can also be PEGylated, to modulate their pharmaceutical properties.
  • Compounds disclosed herein, or their conjugates or their PEGylated derivatives can be used in the treatment of a subject suffering from a condition amenable to treatment by activation of the immune system, by administering to such subject a therapeutically effective amount of such a compound or a conjugate thereof or a PEGylated derivative thereof, especially in combination with a vaccine or a cancer immunotherapy agent.
  • one X in the moiety Ar of formula (I) is N and the remaining ones are CH, with one CH having the H replaced by W.
  • W is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • compounds of this disclosure are according to formula (Ia), wherein R 1 , R 5 , and W are as defined in respect of formula (I):
  • compounds of this disclosure are according to formula (Ib), wherein R 1 , R 3 , and R 5 are as defined in respect of formula (I):
  • R 3 is
  • R 3 is
  • R 3 is
  • compounds of this disclosure are according to formula (Ic), wherein R 1 , R 4 and R 5 are as defined in respect of formula (I):
  • this disclosure provides a compound having a structure according to formula (Id)
  • n 1, 2, or 3.
  • R 1 is selected from the following group (“preferred R 1 group”), consisting of:
  • R 3 is selected from the following group (“preferred R 3 group”), consisting of
  • Examples of groups R 4 include:
  • R 4 is selected from the following group (“preferred R 4 group”), consisting of
  • R 5 are H
  • compounds according to formula (Ib) have R 1 selected from the preferred R 1 group, R 3 selected from the preferred R 3 group, and R 5 equals H or Me.
  • compounds according to formula (Ic) have R 1 selected from the preferred R 1 group, R 4 selected from the preferred R 4 group, and R 5 equals H or Me.
  • bicycloalkyl groups include
  • W is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • W is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • W is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • W is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • W is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • W is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • R 5 is H (preferably) or Me
  • a compound of this disclosure has (a) a human TLR7 (hTLR7) Reporter Assay EC 50 value of less than 1,000 nM and (b) a human whole blood (hWB) CD69 induction EC 50 value of less than 1,000 nM. (Where an assay was performed multiple times, the reported value is an average.)
  • a pharmaceutical composition comprising a compound of as disclosed herein, or of a conjugate thereof, formulated together with a pharmaceutically acceptable carrier or excipient. It may optionally contain one or more additional pharmaceutically active ingredients, such as a biologic or a small molecule drug.
  • the pharmaceutical compositions can be administered in a combination therapy with another therapeutic agent, especially an anti-cancer agent.
  • the pharmaceutical composition may comprise one or more excipients.
  • Excipients that may be used include carriers, surface active agents, thickening or emulsifying agents, solid binders, dispersion or suspension aids, solubilizers, colorants, flavoring agents, coatings, disintegrating agents, lubricants, sweeteners, preservatives, isotonic agents, and combinations thereof.
  • the selection and use of suitable excipients is taught in Gennaro, ed., Remington: The Science and Practice of Pharmacy, 20th Ed. (Lippincott Williams & Wilkins 2003).
  • a pharmaceutical composition is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion).
  • the active compound may be coated in a material to protect it from the action of acids and other natural conditions that may inactivate it.
  • parenteral administration means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion.
  • the pharmaceutical composition can be administered via a non-parenteral route, such as a topical, epidermal or mucosal route of administration, for example, intranasally, orally, vaginally, rectally, sublingually or topically.
  • compositions can be in the form of sterile aqueous solutions or dispersions. They can also be formulated in a microemulsion, liposome, or other ordered structure suitable to achieve high drug concentration. The compositions can also be provided in the form of lyophilates, for reconstitution in water prior to administration.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the subject being treated and the particular mode of administration and will generally be that amount of the composition which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 0.01 percent to about ninety-nine percent of active ingredient, preferably from about 0.1 percent to about 70 percent, most preferably from about 1 percent to about 30 percent of active ingredient in combination with a pharmaceutically acceptable carrier.
  • Dosage regimens are adjusted to provide a therapeutic response. For example, a single bolus may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. “Dosage unit form” refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic response, in association with the required pharmaceutical carrier.
  • the dosage ranges from about 0.0001 to 100 mg/kg, and more usually 0.01 to 5 mg/kg, of the host body weight.
  • dosages can be 0.3 mg/kg body weight, 1 mg/kg body weight, 3 mg/kg body weight, 5 mg/kg body weight or 10 mg/kg body weight or within the range of 1-10 mg/kg, or alternatively 0.1 to 5 mg/kg.
  • Exemplary treatment regimens are administration once per week, once every two weeks, once every three weeks, once every four weeks, once a month, once every 3 months, or once every three to 6 months.
  • Preferred dosage regimens include 1 mg/kg body weight or 3 mg/kg body weight via intravenous administration, using one of the following dosing schedules: (i) every four weeks for six dosages, then every three months; (ii) every three weeks; (iii) 3 mg/kg body weight once followed by 1 mg/kg body weight every three weeks.
  • dosage is adjusted to achieve a plasma antibody concentration of about 1-1000 ⁇ g/mL and in some methods about 25-300 ⁇ g/mL.
  • a “therapeutically effective amount” of a compound of the invention preferably results in a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction.
  • a “therapeutically effective amount” preferably inhibits tumor growth by at least about 20%, more preferably by at least about 40%, even more preferably by at least about 60%, and still more preferably by at least about 80% relative to untreated subjects.
  • a therapeutically effective amount of a therapeutic compound can decrease tumor size, or otherwise ameliorate symptoms in a subject, which is typically a human but can be another mammal. Where two or more therapeutic agents are administered in a combination treatment, “therapeutically effective amount” refers to the efficacy of the combination as a whole, and not each agent individually.
  • the pharmaceutical composition can be a controlled or sustained release formulation, including implants, transdermal patches, and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. See, e.g., Sustained and Controlled Release Drug Delivery Systems , J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.
  • compositions can be administered via medical devices such as (1) needleless hypodermic injection devices; (2) microinfusion pumps; (3) transdermal devices; (4) infusion devices; and (5) osmotic devices.
  • the pharmaceutical composition can be formulated to ensure proper distribution in vivo.
  • the therapeutic compounds of the invention can be formulated in liposomes, which may additionally comprise targeting moieties to enhance selective transport to specific cells or organs.
  • TLR7 agonist compounds disclosed herein can be used for the treatment of a disease or condition that can be ameliorated by activation of TLR7.
  • the TLR7 agonist is used in combination with an anti-cancer immunotherapy agent—also known as an immuno-oncology agent.
  • An anti-cancer immunotherapy agent works by stimulating a body's immune system to attack and destroy cancer cells, especially through the activation of T cells.
  • the immune system has numerous checkpoint (regulatory) molecules, to help maintain a balance between its attacking legitimate target cells and preventing it from attacking healthy, normal cells. Some are stimulators (up-regulators), meaning that their engagement promotes T cell activation and enhances the immune response. Others are inhibitors (down-regulators or brakes), meaning that their engagement inhibits T cell activation and abates the immune response.
  • Binding of an agonistic immunotherapy agent to a stimulatory checkpoint molecule can lead to the latter's activation and an enhanced immune response against cancer cells.
  • binding of an antagonistic immunotherapy agent to an inhibitory checkpoint molecule can prevent down-regulation of the immune system by the latter and help maintain a vigorous response against cancer cells.
  • stimulatory checkpoint molecules are B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, CD40, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3 and CD28H.
  • inhibitory checkpoint molecules are CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, Galectin 9, CEACAM-1, BTLA, CD69, Galectin-1, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIR1, TIM-1, CD96 and TIM-4.
  • this specification provides a method of treating a cancer, comprising administering to a patient suffering from such cancer a therapeutically effective combination of an anti-cancer immunotherapy agent and a TLR7 agonist as disclosed herein.
  • the timing of administration can be simultaneous, sequential, or alternating.
  • the mode of administration can systemic or local.
  • the TLR7 agonist can be delivered in a targeted manner, via a conjugate.
  • Cancers that could be treated by a combination treatment as described above include acute myeloid leukemia, adrenocortical carcinoma, Kaposi sarcoma, lymphoma, anal cancer, appendix cancer, teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, bronchial tumor, carcinoid tumor, cardiac tumor, cervical cancer, chordoma, chronic lymphocytic leukemia, chronic myeloproliferative neoplasm, colon cancer, colorectal cancer, craniopharyngioma, bile duct cancer, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, Ewing sarcoma, eye cancer, fallopian tube cancer, gallbladder cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, germ cell tumor, hairy cell leukemia, head and neck cancer, heart cancer
  • Anti-cancer immunotherapy agents that can be used in combination therapies as disclosed herein include: AMG 557, AMP-224, atezolizumab, avelumab, BMS 936559, cemiplimab, CP-870893, dacetuzumab, durvalumab, enoblituzumab, galiximab, IMP321, ipilimumab, lucatumumab, MEDI-570, MEDI-6383, MEDI-6469, muromonab-CD3, nivolumab, pembrolizumab, pidilizumab, spartalizumab, tremelimumab, urelumab, utomilumab, varlilumab, vonlerolizumab.
  • Table B below lists their alternative name(s) (brand name, former name, research code, or synonym) and the respective target checkpoint molecule.
  • the anti-cancer immunotherapy agent is an antagonistic anti-CTLA-4, anti-PD-1, or anti-PD-L1 antibody.
  • the cancer can be lung cancer (including non-small cell lung cancer), pancreatic cancer, kidney cancer, head and neck cancer, lymphoma (including Hodgkin's lymphoma), skin cancer (including melanoma and Merkel skin cancer), urothelial cancer (including bladder cancer), gastric cancer, hepatocellular cancer, or colorectal cancer.
  • the anti-cancer immunotherapy agent is an antagonistic anti-CTLA-4 antibody, preferably ipilimumab.
  • the anti-cancer immunotherapy agent is an antagonistic anti-PD-1 antibody, preferably nivolumab or pembrolizumab.
  • TLR7 agonists disclosed herein also are useful as vaccine adjuvants.
  • NMR spectra were taken in either 400 Mz or 500 Mhz Bruker instrument using either DMSO-d6 or CDCl 3 as solvent and internal standard.
  • the crude NMR data was analyzed by using either ACD Spectrus version 2015-01 by ADC Labs or MestReNova software.
  • Preparative HPLC/MS Method B Column: XBridge C18, 150 mm ⁇ 19 mm, 5- m particles; Mobile Phase A: water with 0.05% TFA; Mobile Phase B: acetonitrile with 0.05% TFA; Gradient: a 2-minute hold at 10% B, 10-100% B over 20 minutes, then a 3-minute hold at 100% B; Flow Rate: 19 mL/min; Column Temperature: 25° C.
  • Analytical LC/MS Method D Column: Waters XBridge C18, 2.1 mm ⁇ 50 mm, 1.7 am particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% TFA; Mobile Phase B: 95:5 acetonitrile: water 0.1% TFA; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.50 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm).
  • Analytical LC/MS Method E Column: Acquity UPLC BEH C18, 2.1 mm ⁇ 50 mm, 1.7 am particles; Mobile Phase A: water with 0.1% formic acid; Mobile Phase B: acetonitrile with 0.1% formic acid; Temperature: 40° C.; Gradient: a 0.2 min hold at 5% B; 5% B to 95% B over 2.3 min, then a 0.20 min hold at 95% B; Flow: 1 mL/min; Detection: UV (254 nm & 220 nm).
  • Analytical LC/MS Method F Column: Acquity UPLC BEH C18, 2.1 mm ⁇ 50 mm, 1.7 am particles; Mobile Phase A: water with 0.1% formic acid; Mobile Phase B: acetonitrile with 0.1% formic acid; Temperature: 40° C.; Gradient: a 0.2 min hold at 50% B; 50% B to 95% B over 2.3 min, then a 0.20 min hold at 95% B; Flow: 1 mL/min; Detection: UV (254 nm & 220 nm).
  • the procedures disclosed herein produce a mixture of regioisomers, alkylated at the 1H or 2H position of the pyrazolopyrimidine ring system (which are also referred to as N1 and N2 regioisomers, respectively, alluding to the nitrogen that is alkylated).
  • N1 and N2 regioisomers are also referred to as N1 and N2 regioisomers, respectively, alluding to the nitrogen that is alkylated.
  • the N2 regioisomers are not shown, but it is to be understood that they are present in the initial product mixture and separated at a later time, for example by preparative HPLC.
  • the mixture of regioisomers can be separated at an early stage of the synthesis and the remaining synthetic steps carried out with the 1H regioisomer or, alternatively, the synthesis can be progressed carrying the mixture of regioisomers and separation effected at a later stage, as desired.
  • the compounds of the present disclosure can be prepared by a number of methods well known to one skilled in the art of synthetic organic chemistry. These methods include those described below, or variations thereof. Preferred methods include, but are not limited to, those described below in the Schemes below. The Schemes are intended to be generic, but in some instances a feature may be depicted specifically (e.g., a methyl ester or particular regioisomer) as a matter of convenience.
  • R b NHR c is, in Scheme 1 and other occurrences thereof, a primary or secondary amine.
  • R a , R b , and/or R c can have functional groups masked by protecting group that is removed at the appropriate time during the synthetic process.
  • Compound 9 can be prepared by a synthetic sequence outlined in Scheme 1.
  • Quinoline 1 (CAS Reg. No. 82867-40-6) is converted to hydrazine intermediate 2 with BOC protected hydrazine.
  • intermediate 3 is obtained.
  • Intermediate 4 is obtained by mixing ethyl-2-chloro-2-oxoacetate and (Z)-N,N-dimethyl-2-nitroethen-1-amine, and then adding intermediate 3.
  • Intermediate 4 is converted to intermediate 5 by reducing the nitro group to an amine group with zinc.
  • intermediate 6 is obtained.
  • Scheme 2 above shows an alternative method for the preparation of intermediate 6, by coupling quinoline 1 and methyl 4-nitro-1H-pyrazole-5-carboxylate (CAS Reg. No. 138786-86-9) to form intermediate 10.
  • Intermediate 11 is obtained by reducing the nitro group of intermediate 10 to an amine group with zinc.
  • Intermediate 6 is obtained by treating intermediate 11 with 1,3-bis(methoxycarbonyl)-2-thiopseudourea with acetic acid and then sodium methoxide, as shown in Step 3 of Scheme 2.
  • Scheme 3 above shows an alternative method for preparing compound 9, by hydroxylation of intermediate 6 to form acid 12. After amide coupling, intermediate 13 is obtained. In the last step, compound 9 is obtained by treating intermediate 13 with R a NH 2 in the presence of BOP and DBU.
  • R d is, in Scheme 4 and other occurrences thereof, for example, H, F, CO 2 Me (or Et), or cyano.
  • R e is, in Scheme 4 and other occurrences thereof, for example, H or CO 2 Me (or Et) or a protecting group.
  • Scheme 5 above shows an alternative method for the preparation of compound 20 by reductive amination.
  • Intermediate 17 is reduced to amine 18a (in the instance in which R d is a cyano group).
  • Amine 18a is then subjected to reductive amination with a corresponding ketone to form compound 20.
  • Scheme 6 above shows a method for the preparation of compound 23.
  • methylation can be effected by treating intermediate 19 with 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane and PdCl 2 (dppf)-CH 2 Cl 2 adduct to afford intermediate 21.
  • intermediate 22 is obtained.
  • compound 23 is obtained by amide formation of intermediate 22 with R b NHR c .
  • R f is, in Scheme 7 and other occurrences thereof, an amide or amine moiety and Hal is halogen, such as Cl or Br.
  • Compound 30 can be prepared the method of Scheme 7 above, by coupling a pyrazolopyrimidine core and a quinoline moiety.
  • the nitro group of starting material 24 is reduced to an amine group of compound 25.
  • Pyrazolopyrimidine 26 is obtained by treating intermediate 25 with 1,3-bis(methoxycarbonyl)-2-thiopseudourea with acetic acid and then sodium methoxide.
  • Quinoline compound 27 is prepared similarly to the reactions described in other Schemes hereinabove.
  • the coupling of pyrazolopyrimidine 26 with quinoline 27 affords intermediate 28.
  • Intermediate 29 is obtained by treating intermediate 28 with amine R a NH 2 in the presence of BOP and DBU. In the last step, carbamate protecting group of intermediate 29 is removed with sodium hydroxide to generate compound 30.
  • Starting material 31 (CAS Reg. No. 611-32-5) is converted to intermediate 32 by bromination. After coupling with tert-butyl 4-(3,3,4,4-tetramethylborolan-1-yl)-3,6-dihydropyridine-1(2H)-carboxylate, intermediate 33 is obtained. Intermediate 34 is obtained by hydrogenation. After treated with NBS and AIBN, Intermediate 35 is obtained. Intermediate 37 is obtained by mixing intermediate 35 and 36 with base. By coupling with intermediate 38, Intermediate 37 is converted to intermediate 39. Iodo group of intermediate 39 is removed by reduction to form intermediate 40. By hydrolysis with Sodium Hydroxide and acids, Compound 41 is obtained. Compound 42 is obtained by reductive amination of Compound 41 with a ketone R b R c ( ⁇ O).
  • Step 1 TEA (1.493 mL, 10.71 mmol) was added to a solution of methyl 8-(bromo-methyl)quinoline-5-carboxylate (1 g, 3.57 mmol), tert-butyl hydrazinecarboxylate (2.359 g, 17.85 mmol) in DMF (4 mL). The reaction mixture was stirred at 75° C. for 4 h, diluted with 100 mL of water, and extracted with EtOAc (3 ⁇ 75 mL).
  • Step 2 HCl in dioxane (5.36 mL, 21.43 mmol) was added to a solution of methyl 8-((2-(tert-butoxycarbonyl)hydrazineyl)methyl)quinoline-5-carboxylate (0.71 g, 2.143 mmol) in MeOH (10 mL). The reaction mixture was stirred at RT overnight, after which it turned into a slurry. The precipitate was collected by filtration and dried under high vacuum for 1 h to yield the HCl salt of methyl 8-(hydrazineylmethyl)quinoline-5-carboxylate (0.58 g, 1.705 mmol, 79.6% yield).
  • Step 3 A solution of (Z)-N,N-dimethyl-2-nitroethen-1-amine (1.528 g, 13.16 mmol) in DCM (26 mL) and pyridine (17.49 mL, 216 mmol) was cooled to ⁇ 10° C. Ethyl 2-chloro-2-oxoacetate (2.226 mL, 19.89 mmol) was added slowly. The reaction mixture was warmed to RT over 2 h and stirred at RT overnight. The reaction mixture was concentrated to 20 mL. Methyl 8-(hydrazineylmethyl)quinoline-5-carboxylate HCl salt (1 g, 4.32 mmol) was added. The resultant mixture was stirred at RT for 2 h.
  • the reaction mixture was concentrated and purified by reverse phase column chromatography: Column: 50 g CombiFlash Aq column; Mobile Phase A: water with 0.05 TFA; Mobile Phase B: acetonitrile with 0.05% TFA; Gradient: a 1 min hold at 0% B, 0-50% B over 12 min, then a 3 min hold at 100% B; Flow Rate: 40 mL/min; Column Temperature: 25° C.
  • the fractions containing the expected product were combined and freeze-dried to yield methyl 8-((5-(ethoxycarbonyl)-4-nitro-1H-pyrazol-1-yl)methyl)quinoline-5-carboxylate (627 mg, 1.633 mmol, 37.8% yield) as a solid.
  • Step 4 Zinc (358 mg, 5.48 mmol) was added to a solution of methyl 8-((5-(ethoxycarbonyl)-4-nitro-1H-pyrazol-1-yl)methyl)quinoline-5-carboxylate (421 mg, 1.095 mmol) and ammonium formate (691 mg, 10.95 mmol) in MeOH (3 mL) and THF (5 mL). The reaction mixture was stirred at RT for 1 h. LCMS analysis showed the reaction was complete.
  • Step 5 Acetic acid (0.64623 mL, 11.28 mmol) and TFA (0.07 mL) were added to a mixture of 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea (279 mg, 1.355 mmol) and methyl 8-((4-amino-5-(ethoxycarbonyl)-1H-pyrazol-1-yl)methyl)quinoline-5-carboxylate (400 mg, 1.129 mmol) in MeOH (20 mL). The reaction mixture was stirred at RT overnight. LCMS analysis showed conversion to an intermediate (LC-MS m/z 513.3 [M+H] + ). NaOMe (4.2 mL, 33.87 mmol) was added.
  • Step 6 ((1H-Benzo[d][1,2,3]triazol-1-yl)oxy)tris(dimethylamino)phosphonium hexafluorophosphate(V) (401 mg, 0.906 mmol) was added to a solution of methyl 8-((7-hydroxy-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylate (185 mg, 0.453 mmol), (S)-3-aminohexan-1-ol (HCl salt, 348 mg, 2.265 mmol) and 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine (0.305 mL, 2.039 mmol) in DMSO (1.5 mL).
  • Step 7 DIPEA (0.032 mL, 0.184 mmol) was added to a solution of (S)-8-((5-amino-7-((1-hydroxyhexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylic acid (20 mg, 0.046 mmol), 2-(piperazin-1-yl)ethan-1-ol (0.023 mL, 0.184 mmol) and HATU (26.2 mg, 0.069 mmol) in DMF (0.5 mL). The reaction mixture was stirred at 20° C. for 3 h, neutralized with 0.05 mL acetic acid, and purified by Method C. Fractions containing Compound 111 were combined and dried via centrifugal evaporation (2.74 mg, 0.005 mmol, 14.5%).
  • Step 1 LiCl (0.908 g, 21.42 mmol) was added to a solution of methyl 8-(bromo-methyl)quinoline-5-carboxylate (3 g, 10.71 mmol) in DMF (20 mL). The reaction mixture was stirred at RT for 30 min. LCMS analysis showed the starting material converted to a chloro intermediate (LC-MS m/z 236.1 [M+H] + ). Methyl 4-nitro-1H-pyrazole-5-carboxylate (3 g, 17.53 mmol) and Cs 2 CO 3 (6.98 g, 21.42 mmol) were added. The reaction mixture was stirred at RT overnight.
  • Step 2 Zinc (785 mg, 12.00 mmol) was added portion-wise over 1 h to a solution of methyl 8-((5-(methoxycarbonyl)-4-nitro-1H-pyrazol-1-yl)methyl)quinoline-5-carboxylate (635 mg, 1.715 mmol) in MeOH (7 mL) and THF (15 mL). The reaction mixture was stirred at RT for 2 h, diluted with EtOAc (50 mL), and filtered. The filtrate was concentrated and dried to yield methyl 8-((4-amino-5-(methoxycarbonyl)-1H-pyrazol-1-yl)methyl)quinoline-5-carboxylate salt (685 mg, 2.013 mmol, 117% yield).
  • Step 3 Acetic acid (0.530 mL, 9.26 mmol) and TFA (0.4 mL) were added to a solution of 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea (458 mg, 2.221 mmol) and methyl 8-((4-amino-5-(methoxycarbonyl)-1H-pyrazol-1-yl)methyl)quinoline-5-carboxylate (630 mg, 1.851 mmol) in MeOH (15 mL). The reaction mixture was stirred at RT overnight. LCMS analysis showed the reaction was complete, affording an intermediate (LC-MS m/z 499.2 [M+H] + ).
  • Step 4 DIPEA (50 uL) was added to a solution of 8-((5-amino-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylic acid (28 mg, 0.083 mmol) and HATU (38.0 mg, 0.100 mmol) in DMF (0.5 mL). The reaction mixture was stirred at RT for 1 h, neutralized with 0.1 ml of acetic acid, and purified by Method B.
  • Step 5 ((1H-benzo[d][1,2,3]triazol-1-yl)oxy)tris(dimethylamino)phosphonium hexafluorophosphate(V) (51.1 mg, 0.116 mmol) was added to a solution of 8-((5-amino-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-N-(1-methylpiperidin-4-yl)quinoline-5-carboxamide (25 mg, 0.058 mmol), 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine (0.039 mL, 0.260 mmol) and (S)-3-aminohexan-1-ol (27.1 mg, 0.231 mmol) in DMSO (1.25 mL).
  • Step 1 ((1H-benzo[d][1,2,3]triazol-1-yl)oxy)tris(dimethylamino)phosphonium hexafluorophosphate(V) (26.0 mg, 0.059 mmol) was added to a solution of methyl (7-hydroxy-1-(quinolin-8-ylmethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (10.3 mg, 0.029 mmol; prepared analogously per Example 1 from 8-(bromomethyl)quinoline), (S)-3-aminohexan-1-ol (17.23 mg, 0.147 mmol) and 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine (8.79 ⁇ l, 0.059 mmol) in DMSO (0.5 mL).
  • Step 2 Aqueous NaOH (0.3 mL, 3.00 mmol) was added to methyl (S)-(7-((1-hydroxy-hexan-3-yl)amino)-1-(quinolin-8-ylmethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (7.3 mg, 0.016 mmol) in dioxane (0.6 mL). The reaction mixture was stirred at 70° C. for 4 h, neutralized with HOAc, and purified by Method B to yield Compound 110 (0.80 mg, 0.002 mmol, 12.6%).
  • Step 1 1-Bromopyrrolidine-2,5-dione (N-bromo succinimide (NBS), 2.059 g, 11.57 mmol) was added to a solution of methyl (7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (2.2 g, 10.52 mmol) in DMF (20 mL). The reaction mixture was stirred at RT for 1 h and with EtOAc, water and brine. The organic phases were combined, concentrated and dried under high vacuum for 1 h to yield methyl (3-bromo-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (2.85 g, 9.89 mmol, 94% yield).
  • NBS N-bromo succinimide
  • Steps 2 & 3 LiCl (143 mg, 3.37 mmol) was added to a solution of methyl 8-(bromomethyl)quinoline-5-carboxylate (236 mg, 0.842 mmol) in DMF (3 mL). The reaction mixture was stirred at RT for 30 min. LCMS analysis showed complete formation of the chloro intermediate, LC-MS m/z 236.1 [M+H] + . Methyl (3-bromo-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (291 mg, 1.010 mmol) and Cs 2 CO 3 (1098 mg, 3.37 mmol) were added.
  • Step 4 ((1H-Benzo[d][1,2,3]triazol-1-yl)oxy)tris(dimethylamino)phosphonium hexafluorophosphate(V) (178 mg, 0.402 mmol) was added to a solution of methyl 8-((3-bromo-7-hydroxy-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylate (98 mg, 0.201 mmol), (S)-3-aminohexan-1-ol HCl salt (155 mg, 1.006 mmol) and 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine (92 mg, 0.603 mmol) in DMSO (2.5 mL).
  • Step 5 A mixture of methyl (S)-8-((3-bromo-7-((1-hydroxyhexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylate (50 mg, 0.085 mmol), K 2 CO 3 (41.2 mg, 0.298 mmol) and PdCl 2 (dppf)-CH 2 Cl 2 adduct (6.24 mg, 8.53 ⁇ mol) in dioxane (0.35 mL) and H 2 O (0.07 mL) was bubbled with N 2 for 1 min.
  • Step 1 To a solution of methyl 8-(bromomethyl)quinoline-5-carboxylate (236 mg, 0.842 mmol) in DMF (3 mL), LiCl (236 mg, 5.57 mmol) was added. The reaction mixture was stirred at RT for 2 h. LCMS analysis showed the reaction was complete (chloro intermediate, LC-MS m/z 236.1 [M+H] + ). 3-Bromo-N7-butyl-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine (200 mg, 0.701 mmol) and Cs 2 CO 3 (914 mg, 2.81 mmol) were added. The reaction mixture was stirred at RT for over weekend.
  • Step 2 To a solution of methyl 8-((5-amino-3-bromo-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylate (161 mg, 0.332 mmol) in MeOH (10 mL), Pd—C(10%, 53 mg) was added. The reaction mixture was stirred under hydrogen balloon overnight and filtered. The filtrate was concentrated and dried under high vacuum to yield methyl 8-((5-amino-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-4-carboxylate (128 mg, 0.316 mmol, 95.2%).
  • Step 3 To a solution of methyl 8-((5-amino-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylate (60 mg, 0.148 mmol) in THF (1 mL) and MeOH (0.1 mL), LiBH 4 in THF (0.740 mL, 0.740 mmol) was added. The reaction mixture was stirred at 40° C. for 1 h, neutralized with 0.07 mL of HOAc, and purified with Method B.
  • Step 4 To a solution of (8-((5-amino-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinolin-5-yl)methanol (25 mg, 0.066 mmol) in THF (1 mL), sulfurous dichloride (0.024 mL, 0.331 mmol) was added. The reaction mixture was stirred at RT for 5 min. LCMS analysis showed the reaction was complete (LC-MS m/z 396.3 [M+H] + ). The reaction mixture was concentrated under vacuum and co-evaporated with dry DCM (2 ⁇ 5 mL). The residue was dried under high vacuum for 10 min and dissolved in DMF (1 mL).
  • Tetrahydro-2H-pyran-4-amine (67.0 mg, 0.662 mmol) was added. The reaction mixture was stirred at 25° C. for 4 h and purified with Method A. Fractions containing the desired product were combined and dried via centrifugal evaporation to yield Compound 109 (14.49 mg, 0.021 mmol, 31.9%).
  • Step 1 Imidazole (1.452 g, 21.33 mmol) was added to a solution of (S)-3-aminohexan-1-ol (1 g, 8.53 mmol) and tert-butylchlorodiphenylsilane (TBPDSCl3.28 mL, 12.80 mmol) in DMF (6 mL). The reaction mixture was stirred at RT overnight and worked up with EtOAc, water and brine.
  • TBPDSCl3.28 mL, 12.80 mmol tert-butylchlorodiphenylsilane
  • Step 2 BOP (433 mg, 0.979 mmol) was added to a solution of methyl 8-((7-hydroxy-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylate (200 mg, 0.490 mmol), (S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-amine (871 mg, 2.449 mmol) and DBU (0.148 mL, 0.979 mmol) in DMSO (3 mL). The reaction mixture was stirred at 70° C.
  • Step 3 LiBH 4 (2N, 0.4 mL) was added to a solution of methyl (S)-8-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylate (121 mg, 0.162 mmol) in THF (1.8 mL) and MeOH (0.2 mL). The reaction mixture was stirred at 40° C. for 1 h, neutralized with 0.2 mL acetic acid, and purified by Method B.
  • Step 4 SOCl 2 (0.024 mL, 0.334 mmol) was added to a solution of methyl (S)-(7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-1-((5-(hydroxymethyl)quinolin-8-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (48 mg, 0.067 mmol) in THF (1 mL). The reaction mixture was stirred at RT for 5 min. LCMS analysis showed that the starting material was completely converted to a chloro intermediate (LC-MS m/z 736.3 [M+H] + ).
  • the reaction mixture was concentrated under vacuum and co-evaporated with dry DCM (2 ⁇ 5 mL). The residue was dried under high vacuum for 10 min to a residue. The residue was dissolved in DMF (1 ml) and DIEA (0.070 mL, 0.401 mmol) and 3-methoxyazetidine (34.9 mg, 0.401 mmol) were added. The reaction mixture was stirred at 70° C.
  • Step 5 NaOH in water (0.3 ml, 3.00 mmol) was added to a solution of methyl (S)-(7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-1-((5-((3-methoxyazetidin-1-yl)methyl)-quinolin-8-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (52.1 mg, 0.066 mmol) in 1,4-dioxane (0.6 mL). The reaction mixture was stirred at 70° C.
  • Step 1 Bromine (3.60 ml, 69.8 mmol) was added to a solution of 8-methylquinoline (9.51 ml, 69.8 mmol) and silver sulfate (32.7 g, 105 mmol) in concentrated H 2 SO 4 (98%, 100 mL) cooled to 0° C. in an ice batch. The reaction mixture was stirred at 25° C. for 4 h and diluted with ice. NH 4 OH solution was added slowly (14. 8 M) raise the pH above 7. The reaction mixture was extracted with EtOAc (4 ⁇ 250 mL).
  • Step 2 A mixture of 5-bromo-8-methylquinoline (1 g, 4.50 mmol), tert-butyl 4-(3,3,4,4-tetramethylborolan-1-yl)-3,6-dihydropyridine-1(2H)-carboxylate (1.787 g, 5.85 mmol) and 5-bromo-8-methylquinoline (1 g, 4.50 mmol), tert-butyl 4-(3,3,4,4-tetramethylborolan-1-yl)-3,6-dihydropyridine-1(2H)-carboxylate (1.787 g, 5.85 mmol) in DMF (15 mL) was bubbled with N 2 for 3 min.
  • Step 3 A mixture of tert-butyl 4-(8-methylquinolin-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate (1.35 g, 4.16 mmol) and Pd—C(0.222 g, 0.21 mmol) in MeOH (15 mL) was stirred under hydrogen balloon. The reaction was monitored with LCMS. The reaction was 40% completed in 8 hrs.
  • the reaction mixture was filtered and the filtrate was concentrated and purified by column chromatography: Column: 40 g CombiFlash column; Mobile Phase A: hexanes; Mobile Phase B: ethyl acetate; Gradient: a 1 min hold at 0% B, 0-10% over 14 min, then a 1 min hold at 10% B; Flow Rate: 40 mL/min; hexanes with 0.05% TEA; Column Temperature: 25° C. The fractions containing expected product were combined, concentrated and dried under high vacuum to yield tert-butyl 4-(8-methylquinolin-5-yl)piperidine-1-carboxylate (0.412 g, 1.262 mmol, 30.3% yield).
  • Step 5 DBU (0.371 mL, 2.464 mmol) was added to a solution of tert-butyl 4-(8-((7-hydroxy-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinolin-5-yl)piperidine-1-carboxylate (325 mg, 0.493 mmol), (S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-amine (350 mg, 0.986 mmol) and BOP (436 mg, 0.986 mmol) in DMSO (4.5 mL). The reaction mixture was stirred at 45° C.
  • Step 7 TFA (0.5 mL) was added to a solution of tert-butyl (S)-4-(8-((5-amino-7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-quinolin-5-yl)piperidine-1-carboxylate (32 mg, 0.039 mmol) in DCM (0.5 mL), The reaction mixture was stirred at 25° C. for 30 min. LCMS showed Boc protecting group removed. The reaction mixture was concentrated and dissolved in Dioxane (0.5 ml).
  • TLR7 agonists The biological activity of compounds disclosed herein as TLR7 agonists can be assayed by the procedures following.
  • This procedure describes a method for assaying human TLR7 (hTLR7) agonist activity of the compounds disclosed in this specification.
  • HEK-BlueTM TLR cells Engineered human embryonic kidney blue cells (HEK-BlueTM TLR cells; Invivogen) possessing a human TLR7-secreted embryonic alkaline phosphatase (SEAP) reporter transgene were suspended in a non-selective, culture medium (DMEM high-glucose (Invitrogen), supplemented with 10% fetal bovine serum (Sigma)).
  • DMEM high-glucose (Invitrogen) supplemented with 10% fetal bovine serum (Sigma)
  • HEK-BlueTM TLR7 cells were added to each well of a 384-well tissue-culture plate (15,000 cells per well) and incubated 16-18 h at 37° C., 5% CO 2 .
  • Type I interferon (IFN) MX-1 genes and the B-cell activation marker CD69 are downstream events that occur upon activation of the TLR7 pathway.
  • the following is a human whole blood assay that measures their induction in response to a TLR7 agonist.
  • Heparinized human whole blood was harvested from human subjects and treated with test TLR7 agonist compounds at 1 mM.
  • the blood was diluted with RPMI 1640 media and Echo was used to predot 10 nL per well giving a final concentration of 1 uM (10 nL in 10 uL of blood).
  • Fixing/lysis buffer was prepared (5 ⁇ ->1 ⁇ in H 2 O, warm at 37° C.; Cat #BD 558049) and kept the perm buffer (on ice) for later use.
  • CD69 For surface markers staining (CD69): prepared surface Abs: 0.045 ul hCD14-FITC (ThermoFisher Cat #MHCD1401)+0.6 ul hCD19-ef450 (ThermoFisher Cat #48-0198-42)+1.5 ul hCD69-PE (cat #BD555531)+0.855 ul FACS buffer. Added 3 ul/well, spin1000 rpm for 1 min and mixed on shaker for 30 sec, put on ice for 30 min. Stop stimulation after 30 minutes with 70 uL of prewarmed 1 ⁇ fix/lysis buffer and use Feliex mate to resuspend (15 times, change tips for each plate) and incubate at 37 C for 10 minutes.
  • TNF-alpha and Type I IFN response genes are downstream events that occur upon activation of the TLR7 pathway.
  • the following is an assay that measures their induction in whole mouse blood in response to a TLR7 agonist.
  • Heparinized mouse whole blood was diluted with RPMI 1640 media with Pen-Strep in the ratio of 5:4 (50 uL whole blood and 40 uL of media).
  • a volume of 90 uL of the diluted blood was transferred to wells of Falcon flat bottom 96-well tissue culture plates, and the plates were incubated at 4° C. for 1 h.
  • Test compounds in 100% DMSO stocks were diluted 20-fold in the same media for concentration response assays, and then 10 uL of the diluted test compounds were added to the wells, so that the final DMSO concentration was 0.5%.
  • Control wells received 10 uL media containing 5% DMSO. The plates were then incubated at 37° C. in a 5% CO 2 incubator for 17 h.
  • the frozen samples were thawed and mRNA was extracted using the Invitrogen mRNA Catcher Plus kit (Cat #K1570-02) according to the manufacturer's instructions. Half yield of mRNA from RNA extraction were used to synthesize cDNA in 20 ⁇ L reverse transcriptase reactions using Invitrogen SuperScript IV VILO Master Mix (Cat #11756500).
  • TaqMan® real-time PCR was performed using QuantStudio Real-Time PCR system from ThermoFisher (Applied Biosystems). All real-time PCR reactions were run in duplicate using commercial predesigned TaqMan assays for mouse IFIT1, IFIT3, MX1 and PPIA gene expression and TaqMan Master Mix. PPIA was utilized as the housekeeping gene. The recommendations from the manufacturer were followed. All raw data (Ct) were normalized by average housekeeping gene (Ct) and then the comparative Ct ( ⁇ Ct) method were utilized to quantify relative gene expression (RQ) for experimental analysis.
  • “Aliphatic” means a straight- or branched-chain, saturated or unsaturated, non-aromatic hydrocarbon moiety having the specified number of carbon atoms (e.g., as in “C 3 aliphatic,” “C 1-5 aliphatic,” “C 1 -C 5 aliphatic,” or “C 1 to C 5 aliphatic,” the latter three phrases being synonymous for an aliphatic moiety having from 1 to 5 carbon atoms) or, where the number of carbon atoms is not explicitly specified, from 1 to 4 carbon atoms (2 to 4 carbons in the instance of unsaturated aliphatic moieties).
  • Alkyl means a saturated aliphatic moiety, with the same convention for designating the number of carbon atoms being applicable.
  • C 1 -C 4 alkyl moieties include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, t-butyl, 1-butyl, 2-butyl, and the like.
  • Alkanediyl (sometimes also referred to as “alkylene”) means a divalent counterpart of an alkyl group, such as
  • Alkenyl means an aliphatic moiety having at least one carbon-carbon double bond, with the same convention for designating the number of carbon atoms being applicable.
  • C 2 -C 4 alkenyl moieties include, but are not limited to, ethenyl (vinyl), 2-propenyl (allyl or prop-2-enyl), cis-1-propenyl, trans-1-propenyl, E- (or Z-) 2-butenyl, 3-butenyl, 1,3-butadienyl (but-1,3-dienyl) and the like.
  • Alkynyl means an aliphatic moiety having at least one carbon-carbon triple bond, with the same convention for designating the number of carbon atoms being applicable.
  • C 2 -C 4 alkynyl groups include ethynyl (acetylenyl), propargyl (prop-2-ynyl), 1-propynyl, but-2-ynyl, and the like.
  • Cycloaliphatic means a saturated or unsaturated, non-aromatic hydrocarbon moiety having from 1 to 3 rings, each ring having from 3 to 8 (preferably from 3 to 6) carbon atoms.
  • Cycloalkyl means a cycloaliphatic moiety in which each ring is saturated.
  • Cycloalkenyl means a cycloaliphatic moiety in which at least one ring has at least one carbon-carbon double bond.
  • Cycloalkynyl means a cycloaliphatic moiety in which at least one ring has at least one carbon-carbon triple bond.
  • cycloaliphatic moieties include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, and adamantyl.
  • Preferred cycloaliphatic moieties are cycloalkyl ones, especially cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • Cycloalkanediyl (sometimes also referred to as “cycloalkylene”) means a divalent counterpart of a cycloalkyl group.
  • bicycloalkanediyl (osr “bicycloalkylene”) and “spiroalkanediyl” (or “spiroalkylene”) refer to divalent counterparts of a bicycloalkyl and spiroalkyl (or “spirocycloalkyl”) group.
  • spirocycloalkyl or “spirocycloalkyl”
  • Heterocycloaliphatic means a cycloaliphatic moiety wherein, in at least one ring thereof, up to three (preferably 1 to 2) carbons have been replaced with a heteroatom independently selected from N, O, or S, where the N and S optionally may be oxidized and the N optionally may be quaternized. Preferred cycloaliphatic moieties consist of one ring, 5- to 6-membered in size.
  • heterocycloalkyl “heterocycloalkenyl,” and “heterocycloalkynyl” means a cycloalkyl, cycloalkenyl, or cycloalkynyl moiety, respectively, in which at least one ring thereof has been so modified.
  • heterocycloaliphatic moieties include aziridinyl, azetidinyl, 1,3-dioxanyl, oxetanyl, tetrahydrofuryl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothiopyranyl sulfone, morpholinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, 1,3-dioxolanyl, tetrahydro-1,1-dioxothienyl, 1,4-dioxanyl, thietanyl, and the like.
  • “Heterocycloalkylene” means a divalent counterpart of a heterocycloalkyl group.
  • Alkoxy means —O(alkyl), —O(aryl), —S(alkyl), and —S(aryl), respectively. Examples are methoxy, phenoxy, methylthio, and phenylthio, respectively.
  • Halogen or “halo” means fluorine, chlorine, bromine or iodine, unless a narrower meaning is indicated.
  • Aryl means a hydrocarbon moiety having a mono-, bi-, or tricyclic ring system (preferably monocyclic) wherein each ring has from 3 to 7 carbon atoms and at least one ring is aromatic.
  • the rings in the ring system may be fused to each other (as in naphthyl) or bonded to each other (as in biphenyl) and may be fused or bonded to non-aromatic rings (as in indanyl or cyclohexylphenyl).
  • aryl moieties include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthryl, anthracenyl, and acenaphthyl.
  • “Arylene” means a divalent counterpart of an aryl group, for example 1,2-phenylene, 1,3-phenylene, or 1,4-phenylene.
  • Heteroaryl means a moiety having a mono-, bi-, or tricyclic ring system (preferably 5- to 7-membered monocyclic) wherein each ring has from 3 to 7 carbon atoms and at least one ring is an aromatic ring containing from 1 to 4 heteroatoms independently selected from from N, O, or S, where the N and S optionally may be oxidized and the N optionally may be quaternized.
  • Such at least one heteroatom containing aromatic ring may be fused to other types of rings (as in benzofuranyl or tetrahydroisoquinolyl) or directly bonded to other types of rings (as in phenylpyridyl or 2-cyclopentylpyridyl).
  • heteroaryl moieties include pyrrolyl, furanyl, thiophenyl (thienyl), imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridyl, N-oxopyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolynyl, quinazolinyl, cinnolinyl, quinozalinyl, naphthyridinyl, benzofuranyl, indolyl, benzothiophenyl, oxadiazolyl, thiadiazolyl, phenothiazolyl, benzimidazolyl, benzotriazolyl, dibenzofuranyl, carbazolyl, dibenzothiophenyl,
  • a moiety may be substituted, such as by use of “unsubstituted or substituted” or “optionally substituted” phrasing as in “unsubstituted or substituted C 1 -C 5 alkyl” or “optionally substituted heteroaryl,” such moiety may have one or more independently selected substituents, preferably one to five in number, more preferably one or two in number. Substituents and substitution patterns can be selected by one of ordinary skill in the art, having regard for the moiety to which the substituent is attached, to provide compounds that are chemically stable and that can be synthesized by techniques known in the art as well as the methods set forth herein. Where a moiety is identified as being “unsubstituted or substituted” or “optionally substituted,” in a preferred embodiment such moiety is unsubstituted.
  • Arylalkyl (heterocycloaliphatic)alkyl,” “arylalkenyl,” “arylalkynyl,” “biarylalkyl,” and the like mean an alkyl, alkenyl, or alkynyl moiety, as the case may be, substituted with an aryl, heterocycloaliphatic, biaryl, etc., moiety, as the case may be, with the open (unsatisfied) valence at the alkyl, alkenyl, or alkynyl moiety, for example as in benzyl, phenethyl, N-imidazoylethyl, N-morpholinoethyl, and the like.
  • alkylaryl “alkenylcycloalkyl,” and the like mean an aryl, cycloalkyl, etc., moiety, as the case may be, substituted with an alkyl, alkenyl, etc., moiety, as the case may be, for example as in methylphenyl (tolyl) or allylcyclohexyl.
  • “Hydroxyalkyl,” “haloalkyl,” “alkylaryl,” “cyanoaryl,” and the like mean an alkyl, aryl, etc., moiety, as the case may be, substituted with one or more of the identified substituent (hydroxyl, halo, etc., as the case may be).
  • permissible substituents include, but are not limited to, alkyl (especially methyl or ethyl), alkenyl (especially allyl), alkynyl, aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, halo (especially fluoro), haloalkyl (especially trifluoromethyl), hydroxyl, hydroxyalkyl (especially hydroxyethyl), cyano, nitro, alkoxy, —O(hydroxyalkyl), —O(haloalkyl) (especially —OCF 3 ), —O(cycloalkyl), —O(heterocycloalkyl), —O(aryl), alkylthio, arylthio, ⁇ O, ⁇ NH, ⁇ N(alkyl), ⁇ NOH, ⁇ NO(alkyl), —C( ⁇ O)(alkyl), —C( ⁇ O)H, —CO 2 H, —C( ⁇ O)NH
  • substituents are aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, halo, hydroxyl, cyano, nitro, alkoxy, —O(hydroxyalkyl), —O(haloalkyl), —O(cycloalkyl), —O(heterocycloalkyl), —O(aryl), alkylthio, arylthio, ⁇ O, ⁇ NH, ⁇ N(alkyl), ⁇ NOH, ⁇ NO(alkyl), —CO 2 H, —C( ⁇ O)NHOH, —C( ⁇ O)O(alkyl), —C( ⁇ O)O(hydroxyalkyl), —C( ⁇ O)NH 2 , —C( ⁇ O)NH(alkyl), —C( ⁇ O)N(alkyl) 2 , —OC( ⁇ O)(alkyl), —OC( ⁇ O)(alkyl), —OC( ⁇ O)(alkyl),
  • substituents are halo, hydroxyl, cyano, nitro, alkoxy, —O(aryl), ⁇ O, ⁇ NOH, ⁇ NO(alkyl), —OC( ⁇ O)(alkyl), —OC( ⁇ O)O(alkyl), —OC( ⁇ O)NH 2 , —OC( ⁇ O)NH(alkyl), —OC( ⁇ O)N(alkyl) 2 , azido, —NH 2 , —NH(alkyl), —N(alkyl) 2 , —NH(aryl), —NHC( ⁇ O)(alkyl), —NHC( ⁇ O)H, —NHC( ⁇ O)NH 2 , —NHC( ⁇ O)NH(alkyl), —NHC( ⁇ O)N(alkyl) 2 , and —NHC( ⁇ NH)NH 2 .
  • substituents are alkyl, alkenyl, alkynyl, halo, haloalkyl, hydroxyl, hydroxyalkyl, cyano, nitro, alkoxy, —O(hydroxyalkyl), —O(haloalkyl), —O(aryl), —O(cycloalkyl), —O(heterocycloalkyl), alkylthio, arylthio, —C( ⁇ O)(alkyl), —C( ⁇ O)H, —CO 2 H, —C( ⁇ O)NHOH, —C( ⁇ O)O(alkyl), —C( ⁇ O)O(hydroxyalkyl), —C( ⁇ O)NH 2 , —C( ⁇ O)NH(alkyl), —C( ⁇ O)N(alkyl) 2 , —OC
  • substituents are alkyl, alkenyl, halo, haloalkyl, hydroxyl, hydroxyalkyl, cyano, nitro, alkoxy, —O(hydroxyalkyl), —C( ⁇ O)(alkyl), —C( ⁇ O)H, —CO 2 H, —C( ⁇ O)NHOH, —C( ⁇ O)O(alkyl), —C( ⁇ O)O(hydroxyalkyl), —C( ⁇ O)NH 2 , —C( ⁇ O)NH(alkyl), —C( ⁇ O)N(alkyl) 2 , —OC( ⁇ O)(alkyl), —OC( ⁇ O)(hydroxyalkyl), —OC( ⁇ O)O(alkyl), —OC( ⁇ O)O(hydroxyalkyl), —OC( ⁇ O)NH 2 , —OC( ⁇ O)NH(alkyl), —OC( ⁇ O)N(alkyl) 2 , —NH(
  • stereoisomers are specifically indicated (e.g., by a bolded or dashed bond at a relevant stereocenter in a structural formula, by depiction of a double bond as having E or Z configuration in a structural formula, or by use stereochemistry-designating nomenclature or symbols), all stereoisomers are included within the scope of the invention, as pure compounds as well as mixtures thereof. Unless otherwise indicated, racemates, individual enantiomers (whether optically pure or partially resolved), diastereomers, geometrical isomers, and combinations and mixtures thereof are all encompassed by this invention.
  • “Pharmaceutically acceptable ester” means an ester that hydrolyzes in vivo (for example in the human body) to produce the parent compound or a salt thereof or has per se activity similar to that of the parent compound.
  • Suitable esters include C 1 -C 5 alkyl, C 2 -C 5 alkenyl or C 2 -C 5 alkynyl esters, especially methyl, ethyl or n-propyl.
  • “Pharmaceutically acceptable salt” means a salt of a compound suitable for pharmaceutical formulation. Where a compound has one or more basic groups, the salt can be an acid addition salt, such as a sulfate, hydrobromide, tartrate, mesylate, maleate, citrate, phosphate, acetate, pamoate (embonate), hydroiodide, nitrate, hydrochloride, lactate, methyl-sulfate, fumarate, benzoate, succinate, mesylate, lactobionate, suberate, tosylate, and the like.
  • an acid addition salt such as a sulfate, hydrobromide, tartrate, mesylate, maleate, citrate, phosphate, acetate, pamoate (embonate), hydroiodide, nitrate, hydrochloride, lactate, methyl-sulfate, fumarate, benzoate, succinate, mesylate, lactobionate, sub
  • the salt can be a salt such as a calcium salt, potassium salt, magnesium salt, meglumine salt, ammonium salt, zinc salt, piperazine salt, tromethamine salt, lithium salt, choline salt, diethylamine salt, 4-phenylcyclohexylamine salt, benzathine salt, sodium salt, tetramethylammonium salt, and the like. Polymorphic crystalline forms and solvates are also encompassed within the scope of this invention.
  • Subject refers to an animal, including, but not limited to, a primate (e.g., human), monkey, cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse.
  • a primate e.g., human
  • monkey cow, pig, sheep, goat
  • horse dog, cat, rabbit, rat
  • patient is used interchangeably herein in reference, for example, to a mammalian subject, such as a human.
  • treat in the context of treating a disease or disorder, are meant to include alleviating or abrogating a disorder, disease, or condition, or one or more of the symptoms associated with the disorder, disease, or condition; or to slowing the progression, spread or worsening of a disease, disorder or condition or of one or more symptoms thereof.
  • the “treatment of cancer”, refers to one or more of the following effects: (1) inhibition, to some extent, of tumor growth, including, (i) slowing down and (ii) complete growth arrest; (2) reduction in the number of tumor cells; (3) maintaining tumor size; (4) reduction in tumor size; (5) inhibition, including (i) reduction, (ii) slowing down or (iii) complete prevention, of tumor cell infiltration into peripheral organs; (6) inhibition, including (i) reduction, (ii) slowing down or (iii) complete prevention, of metastasis; (7) enhancement of anti-tumor immune response, which may result in (i) maintaining tumor size, (ii) reducing tumor size, (iii) slowing the growth of a tumor, (iv) reducing, slowing or preventing invasion and/or (8) relief, to some extent, of the severity or number of one or more symptoms associated with the disorder.
  • a wavy line ( ) transverse to a bond or an asterisk (*) at the end of the bond denotes a covalent attachment site.
  • a bond traversing an aromatic ring between two carbons thereof means that the group attached to the bond may be located at any of the positions of the aromatic ring made available by removal of the hydrogen that is implicitly there (or explicitly there, if written out).
  • isotopes of atoms occurring in the compounds described herein include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include deuterium and tritium.
  • isotopes of carbon include 13 C and 14 C.
  • Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.
  • a C 1 -C 3 alkyl group can be undeuterated, partially deuterated, or fully deuterated and “CH 3 ” includes CH 3 , 13 CH 3 , 14 CH 3 , CH 2 T, CH 2 D, CHD 2 , CD 3 , etc.
  • the various elements in a compound are present in their natural isotopic abundance.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
Figure US20230130516A1-20230427-C00001

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application Ser. No. 63/057,661, filed Jul. 28, 2020, and U.S. Provisional Application Ser. No. 62/966,092, filed Jan. 27, 2020; the disclosures of which are incorporated herein by reference.
    • BACKGROUND OF THE DISCLOSURE
  • This disclosure relates to Toll-like receptor 7 (“TLR7”) agonists and conjugates thereof, and methods for the preparation and use of such agonists and their conjugates.
  • Toll-like receptors (“TLRs”) are receptors that recognize pathogen-associated molecular patterns (“PAMPs”), which are small molecular motifs conserved in certain classes of pathogens. TLRs can be located either on a cell's surface or intracellularly. Activation of a TLR by the binding of its cognate PAMP signals the presence of the associated pathogen inside the host—i.e., an infection—and stimulates the host's immune system to fight the infection. Humans have 10 TLRs, named TLR1, TLR2, TLR3, and so on.
  • The activation of a TLR—with TLR7 being the most studied—by an agonist can have a positive effect on the action of vaccines and immunotherapy agents in treating a variety of conditions other than actual pathogen infection, by stimulating the immune response overall. Thus, there is considerable interest in the use of TLR7 agonists as vaccine adjuvants or as enhancers in cancer immunotherapy. See, for example, Vasilakos and Tomai 2013, Sato-Kaneko et al. 2017, Smits et al. 2008, and Ota et al. 2019.
  • TLR7, an intracellular receptor located on the membrane of endosomes, recognizes PAMPs associated with single-stranded RNA viruses. Its activation induces secretion of Type I interferons such as IFNα and IFNβ (Lund et al. 2004). TLR7 has two binding sites, one for single stranded RNA ligands (Berghöfer et al. 2007) and one for small molecules such as guanosine (Zhang et al. 2016).
  • TLR7 can bind to, and be activated by, guanosine-like synthetic agonists such as imiquimod, resiquimod, and gardiquimod, which are based on a 1H-imidazo[4,5-c]quinoline scaffold. For a review of small-molecule TLR7 agonists, see Cortez and Va 2018.
  • Figure US20230130516A1-20230427-C00002
  • Synthetic TLR7 agonists based on a pteridinone molecular scaffold are also known, as exemplified by vesatolimod (Desai et al. 2015).
  • Figure US20230130516A1-20230427-C00003
  • Other synthetic TLR7 agonists based on a purine-like scaffold have been disclosed, frequently according to the general formula (A):
  • Figure US20230130516A1-20230427-C00004
  • where R, R′, and R″ are structural variables, with R″ typically containing an unsubstituted or substituted aromatic or heteroaromatic ring.
  • Disclosures of bioactive molecules having a purine-like scaffold and their uses in treating conditions such as fibrosis, inflammatory disorders, cancer, or pathogenic infections include: Akinbobuyi et al. 2015 and 2016; Barberis et al. 2012; Carson et al. 2014; Ding et al. 2016, 2017a, and 2017b; Graupe et al. 2015; Hashimoto et al. 2009; He et al. 2019a and 2019b; Holldack et al. 2012; Isobe et al. 2009a and 2012; Poudel et al. 2019a and 2019b; Pryde 2010; and Young et al. 2019.
  • The group R″ can be pyridyl: Bonfanti et al. 2015a and 2015b; Halcomb et al. 2015; Hirota et al. 2000; Isobe et al. 2002, 2004, 2006, 2009a, 2009b, 2011, and 2012; Kasibhatla et al. 2007; Koga-Yamakawa et al. 2013; Musmuca et al. 2009; Nakamura 2012; Ogita et al. 2007; and Yu et al. 2013.
  • There are disclosures of related molecules in which the 6,5-fused ring system of formula (A)—a pyrimidine six member ring fused to an imidazole five member ring—is modified. (a) Dellaria et al. 2007, Jones et al. 2010 and 2012, and Pilatte et al. 2017 disclose compounds in which the pyrimidine ring is replaced by a pyridine ring. (b) Chen et al. 2011, Coe et al. 2017, Poudel et al. 2020a and 2020b, and Zhang et al. 2018 disclose compounds in which the imidazole ring is replaced by a pyrazole ring. (c) Cortez et al. 2017 and 2018; Li et al. 2018; and McGowan et al. 2016a, 2016b, and 2017 disclose compounds in which the imidazole ring is replaced by a pyrrole ring.
  • Bonfanti et al. 2015b and 2016 and Purandare et al. 2019 disclose TLR7 modulators in which the two rings of a purine moiety are spanned by a macrocycle:
  • A TLR7 agonist can be conjugated to a partner molecule, which can be, for example, a phospholipid, a poly(ethylene glycol) (“PEG”), an antibody, or another TLR (commonly TLR2). Exemplary disclosures include: Carson et al. 2013, 2015, and 2016, Chan et al. 2009 and 2011, Cortez et al. 2017, Gadd et al. 2015, Lioux et al. 2016, Maj et al. 2015, Vernejoul et al. 2014, and Zurawski et al. 2012. A frequent conjugation site is at the R″ group of formula (A).
  • Jensen et al. 2015 discloses the use of cationic lipid vehicles for the delivery of TLR7 agonists.
  • Some TLR7 agonists, including resiquimod are dual TLR7/TLR8 agonists. See, for example, Beesu et al. 2017, Embrechts et al. 2018, Lioux et al. 2016, and Vernejoul et al. 2014.
  • Full citations for the documents cited herein by first author or inventor and year are listed at the end of this specification.
    • BRIEF SUMMARy OF THE DISCLOSURE
  • This specification relates to compounds having a 1H-pyrazolo[4,3d]pyrimidine aromatic system, having activity as TLR7 agonists.
  • Figure US20230130516A1-20230427-C00005
  • In one aspect, there is provided a compound with a structure according to formula I
  • Figure US20230130516A1-20230427-C00006
  • wherein
    • Ar is
  • Figure US20230130516A1-20230427-C00007
    • W is H, halo, C1-C3 alkyl, CN, (C1-C4 alkanediyl)OH,
  • Figure US20230130516A1-20230427-C00008
    • each X is independently N or CR2;
    • R1 is (C1-C5 alkyl),
      • (C2-C5 alkenyl),
      • (C1-C8 alkanediyl)0-1(C3-C6 cycloalkyl),
      • (C1-C8 alkanediyl)0-1(C5-C10 spiroalkyl),
      • (C2-C8 alkanediyl)OH,
      • (C2-C8 alkanediyl)O(C1-C3 alkyl),
      • (C1-C4 alkanediyl)0-1(5-6 membered heteroaryl),
      • (C1-C4 alkanediyl)0-1phenyl,
      • (C1-C4 alkanediyl)CF3,
      • (C2-C8 alkanediyl)N[C(═O)](C1-C3 alkyl),
      • or
      • (C2-C8 alkanediyl)NRxRy;
    • each R2 is independently H, O(C1-C3 alkyl), S(C1-C3 alkyl), SO2(C1-C3 alkyl), C1-C3 alkyl, O(C3-C4 cycloalkyl), S(C3-C4 cycloalkyl), SO2(C3-C4 cycloalkyl), C3-C4 cycloalkyl, Cl, F, CN, or [C(═O)]0-1NRxRy;
    • R3 is H, halo, OH, CN,
      • NH2,
      • NH[C(═O)]0-1(C1-C5 alkyl),
      • N(C1-C5 alkyl)2,
      • NH[C(═O)]0-1(C1-C4 alkanediyl)0-1(C3-C5 cycloalkyl),
      • NH[C(═O)]0-1(C1-C4 alkanediyl)0-1(C4-C10 bicycloalkyl),
      • NH[C(═O)]0-1(C1-C4 alkanediyl)0-1(C5-C10 spiroalkyl),
      • N(C3-C6 cycloalkyl)2,
      • O(C1-C4 alkanediyl)0-1(C3-C5 cycloalkyl),
      • O(C1-C4 alkanediyl)0-1(C4-C5 bicycloalkyl),
      • O(C1-C4 alkanediyl)0-1(C5-C10 spiroalkyl),
      • O(C1-C4 alkanediyl)0-1(C1-C6 alkyl),
      • N[C1-C3 alkyl]C(═O)(C1-C6 alkyl),
      • NH(SO2)(C1-C5 alkyl),
      • NH(SO2)(C1-C4 alkanediyl)0-1(C3-C5 cycloalkyl),
      • NH(SO2)(C1-C4 alkanediyl)0-1(C4-C10 bicycloalkyl),
      • NH(SO2)(C1-C4 alkanediyl)0-1(C5-C10 spiroalkyl),
      • a 6-membered aromatic or heteroaromatic moiety,
      • a 5-membered heteroaromatic moiety, or
      • a moiety having the structure
  • Figure US20230130516A1-20230427-C00009
    • R4 is NH2,
      • NH(C1-C5 alkyl),
      • N(C1-C5 alkyl)2,
      • NH(C1-C4 alkanediyl)0-1(C3-C5 cycloalkyl),
      • NH(C1-C4 alkanediyl)0-1(C4-C10 bicycloalkyl),
      • NH(C1-C4 alkanediyl)0-1(C5-C10 spiroalkyl),
      • N(C3-C6 cycloalkyl)2,
      • or
      • a moiety having the structure
  • Figure US20230130516A1-20230427-C00010
    • R5 is H, C1-C5 alkyl, C2-C5 alkenyl, C3-C6 cycloalkyl, halo, O(C1-C5 alkyl), (C1-C4 alkanediyl)OH, (C1-C4 alkanediyl)O(C1-C3 alkyl), phenyl, NH(C1-C5 alkyl), 5 or 6 membered heteroaryl,
  • Figure US20230130516A1-20230427-C00011
    • R6 is NH2,
      • (NH)0-1(C1-C5 alkyl),
      • N(C1-C5 alkyl)2,
      • (NH)0-1(C1-C4 alkanediyl)0-1(C3-C5 cycloalkyl),
      • (NH)0-1(C1-C4 alkanediyl)0-1(C4-C10 bicycloalkyl),
      • (NH)0-1(C1-C4 alkanediyl)0-1(C5-C10 spiroalkyl),
      • N(C3-C6 cycloalkyl)2,
      • or
      • a moiety having the structure
  • Figure US20230130516A1-20230427-C00012
    • Rx and Ry are independently H or C1-C3 alkyl or Rx and Ry combine with the nitrogen to which they are bonded to form a 3- to 7-membered heterocycle;
    • n is 1, 2, or 3;
    • and
    • p is 0, 1, 2, or 3;
    • wherein in R1, R2, R3, R4, R5, and R6
      • an alkyl, cycloalkyl, alkanediyl, bicycloalkyl, spiroalkyl, cyclic amine, 6-membered aromatic or heteroaromatic moiety, 5-membered heteroaromatic moiety or a moiety of the formula
  • Figure US20230130516A1-20230427-C00013
      • is optionally substituted with one or more substituents selected from OH, halo, CN, (C1-C3 alkyl), O(C1-C3 alkyl), C(═O)(C1-C3 alkyl), SO2(C1-C3 alkyl), NRxRy, (C1-C4 alkanediyl)OH, (C1-C4 alkanediyl)O(C1-C3 alkyl);
      • and
      • an alkyl, alkanediyl, cycloalkyl, bicycloalkyl, spiroalkyl, or a moiety of the formula
  • Figure US20230130516A1-20230427-C00014
      • may have a CH2 group replaced by O, SO2, CF2, C(═O), NH, N[C(═O)]0-1(C1-C3 alkyl), N[C(═O)]0-1(C1-C4 alkanediyl)0-1CF3, or N[C(═O)]0-1(C1-C4 alkanediyl)0-1(C3-C5 cycloalkyl).
  • Compounds disclosed herein have activity as TLR7 agonists and some can be conjugated to an antibody for targeted delivery to a target tissue or organ of intended action. They can also be PEGylated, to modulate their pharmaceutical properties.
  • Compounds disclosed herein, or their conjugates or their PEGylated derivatives, can be used in the treatment of a subject suffering from a condition amenable to treatment by activation of the immune system, by administering to such subject a therapeutically effective amount of such a compound or a conjugate thereof or a PEGylated derivative thereof, especially in combination with a vaccine or a cancer immunotherapy agent.
    • DETAILED DESCRIPTION OF THE DISCLOSURE Compounds
  • In one aspect, one X in the moiety Ar of formula (I) is N and the remaining ones are CH, with one CH having the H replaced by W.
  • In one aspect, W is
  • Figure US20230130516A1-20230427-C00015
  • (preferably n equals 1) or
  • Figure US20230130516A1-20230427-C00016
  • In one aspect, compounds of this disclosure are according to formula (Ia), wherein R1, R5, and W are as defined in respect of formula (I):
  • Figure US20230130516A1-20230427-C00017
  • In another aspect, compounds of this disclosure are according to formula (Ib), wherein R1, R3, and R5 are as defined in respect of formula (I):
  • Figure US20230130516A1-20230427-C00018
  • In one embodiment of compounds according to formula (Ib), R3 is
      • NH(C1-C5 alkyl),
      • N(C1-C5 alkyl)2,
      • NH(C1-C4 alkanediyl)0-1(C3-C8 cycloalkyl),
      • NH(C1-C4 alkanediyl)0-1(C4-C10 bicycloalkyl),
      • NH(C1-C4 alkanediyl)0-1(C5-C10 spiroalkyl),
      • N(C3-C6 cycloalkyl)2,
      • N[C1-C3 alkyl](C1-C6 alkyl),
      • or
      • a moiety having the structure
  • Figure US20230130516A1-20230427-C00019
  • In another embodiment of compounds according to formula (Ib), R3 is
      • NH[C(═O)](C1-C5 alkyl),
      • NH[C(═O)](C1-C4 alkanediyl)0-1(C3-C5 cycloalkyl),
      • NH[C(═O)](C1-C4 alkanediyl)0-1(C4-C10 bicycloalkyl),
      • NH[C(═O)](C1-C4 alkanediyl)0-1(C5-C10 spiroalkyl),
      • or
      • N[C1-C3 alkyl]C(═O)(C1-C6 alkyl).
  • In another embodiment of compounds according to formula (Ib), R3 is
      • O(C1-C4 alkanediyl)0-1(C3-C5 cycloalkyl),
      • O(C1-C4 alkanediyl)0-1(C4-C5 bicycloalkyl),
      • O(C1-C4 alkanediyl)0-1(C5-C10 spiroalkyl),
      • or
      • O(C1-C4 alkanediyl)0-1(C1-C6 alkyl).
  • In another aspect, compounds of this disclosure are according to formula (Ic), wherein R1, R4 and R5 are as defined in respect of formula (I):
  • Figure US20230130516A1-20230427-C00020
  • In one aspect, this disclosure provides a compound having a structure according to formula (Id)
  • Figure US20230130516A1-20230427-C00021
  • wherein W is
  • Figure US20230130516A1-20230427-C00022
  • In one embodiment, where W is
  • Figure US20230130516A1-20230427-C00023
  • n is 1, 2, or 3.
  • In another embodiment, compounds of this disclosure are according to formula (Ie)
  • Figure US20230130516A1-20230427-C00024
  • wherein
    • R1 is
  • Figure US20230130516A1-20230427-C00025
    • R5 is H or Me; and
    • R7 is H, C1-C5 alkyl, or C3-C6 cycloalkyl; wherein the cycloalkyl group optionally has a CH2 group replaced by O, NH, or N(C1-C3)alkyl.
  • Examples of groups R1 are
  • Figure US20230130516A1-20230427-C00026
  • Preferably, R1 is selected from the following group (“preferred R1 group”), consisting of:
  • Figure US20230130516A1-20230427-C00027
  • Examples of groups R3 include
  • Figure US20230130516A1-20230427-C00028
    Figure US20230130516A1-20230427-C00029
    Figure US20230130516A1-20230427-C00030
  • Preferably R3 is selected from the following group (“preferred R3 group”), consisting of
  • Figure US20230130516A1-20230427-C00031
  • Examples of groups R4 include:
  • Figure US20230130516A1-20230427-C00032
    Figure US20230130516A1-20230427-C00033
  • Preferably, R4 is selected from the following group (“preferred R4 group”), consisting of
  • Figure US20230130516A1-20230427-C00034
  • Examples of groups, R5 are H,
  • Figure US20230130516A1-20230427-C00035
  • Preferably, R5 is H or Me.
  • In one embodiment, compounds according to formula (Ib) have R1 selected from the preferred R1 group, R3 selected from the preferred R3 group, and R5 equals H or Me.
  • In one embodiment, compounds according to formula (Ic) have R1 selected from the preferred R1 group, R4 selected from the preferred R4 group, and R5 equals H or Me.
  • By way of exemplification and not of limitation, moieties of the formula
  • Figure US20230130516A1-20230427-C00036
  • include
  • Figure US20230130516A1-20230427-C00037
  • By way of exemplification and not of limitation, spiroalkyl groups include
  • Figure US20230130516A1-20230427-C00038
  • By way of exemplification and not of limitation, moieties of the formula
  • Figure US20230130516A1-20230427-C00039
  • include
  • Figure US20230130516A1-20230427-C00040
    Figure US20230130516A1-20230427-C00041
  • By way of exemplification and not of limitation, bicycloalkyl groups include
  • Figure US20230130516A1-20230427-C00042
  • By way of exemplification and not of limitation, moieties of the formula
  • Figure US20230130516A1-20230427-C00043
  • include
  • Figure US20230130516A1-20230427-C00044
  • In one aspect, W is
  • Figure US20230130516A1-20230427-C00045
  • especially
  • Figure US20230130516A1-20230427-C00046
  • with specific exemplary embodiments being
  • Figure US20230130516A1-20230427-C00047
  • In one aspect, W is
  • Figure US20230130516A1-20230427-C00048
  • especially
  • Figure US20230130516A1-20230427-C00049
  • with a specific exemplary embodiment being
  • Figure US20230130516A1-20230427-C00050
  • In one aspect, W is
  • Figure US20230130516A1-20230427-C00051
  • with specific exemplary embodiments being
  • Figure US20230130516A1-20230427-C00052
  • In one aspect, W is
  • Figure US20230130516A1-20230427-C00053
  • with specific exemplary embodiments being
  • Figure US20230130516A1-20230427-C00054
  • In one aspect, W is
  • Figure US20230130516A1-20230427-C00055
  • with a specific exemplary embodiment being
  • Figure US20230130516A1-20230427-C00056
  • In one aspect, W is
  • Figure US20230130516A1-20230427-C00057
  • with specific exemplary embodiments being
  • Figure US20230130516A1-20230427-C00058
  • In one aspect, W is
  • Figure US20230130516A1-20230427-C00059
  • especially
  • Figure US20230130516A1-20230427-C00060
  • with a specific exemplary embodiment being
  • Figure US20230130516A1-20230427-C00061
  • In one aspect, W is
  • Figure US20230130516A1-20230427-C00062
  • especially
  • Figure US20230130516A1-20230427-C00063
  • with specific exemplary embodiments being
  • Figure US20230130516A1-20230427-C00064
  • In one aspect, W is
  • Figure US20230130516A1-20230427-C00065
  • with specific exemplary embodiments being
  • Figure US20230130516A1-20230427-C00066
  • In one aspect, W is
  • Figure US20230130516A1-20230427-C00067
  • with specific exemplary embodiments being
  • Figure US20230130516A1-20230427-C00068
  • In one aspect, W is
  • Figure US20230130516A1-20230427-C00069
  • with specific exemplary embodiments being
  • Figure US20230130516A1-20230427-C00070
  • In one aspect, compounds of this disclosure are according to formula (Ia)
  • Figure US20230130516A1-20230427-C00071
  • wherein
    • R1 is
  • Figure US20230130516A1-20230427-C00072
  • R5 is H (preferably) or Me;
    and
    • W is
  • Figure US20230130516A1-20230427-C00073
  • Some of the above exemplary alkyl, cycloalkyl, spiroalkyl, bicyloalkyl, etc., groups and moieties of the formula
  • Figure US20230130516A1-20230427-C00074
  • bear optional substituents and/or optionally have one or more CH2 groups replaced by 0, SO2, etc., as described in the BRIEF SUMMARY OF THE DISCLOSURE above.
  • Specific examples of compounds disclosed herein are shown in the following Table A. The table also provides data relating to biological activity: human TLR7 agonism reporter assay and/or induction of the CD69 gene in human whole blood, determined per the procedures provided hereinbelow. The right-most column contains analytical data (mass spectrum, LC/MS retention time, and NMR). In one embodiment, a compound of this disclosure has (a) a human TLR7 (hTLR7) Reporter Assay EC50 value of less than 1,000 nM and (b) a human whole blood (hWB) CD69 induction EC50 value of less than 1,000 nM. (Where an assay was performed multiple times, the reported value is an average.)
  • Figure US20230130516A1-20230427-C00075
  • TABLE A
    Compounds According to Formula (Ia)
    Structure TLR7 hWB Analytical Data
    Cpd. (R5 = H unless noted Agonism CD69 (Mass spectrum, LC/MS Retention Time, 1H
    No. otherwise) EC50 (nM) EC50 (nM) NMR (500 MHz, DMSO-d6))
    101
    Figure US20230130516A1-20230427-C00076
      
    Figure US20230130516A1-20230427-C00077
          		 93.3 47.1 LC/MS [M + H]+ 430.9 LC/MS RT (min)/Method: 1.17/D δ 9.21 (s, 1H), 9.02 (d, J = 4.2 Hz, 1H), 8.75- 8.69 (m, 1H), 7.79-7.72 (m, 3H), 7.67 (d, J = 7.3 Hz, 1H), 6.22 (s, 2H), 4.53 (s, 2H), 3.84- 3.75 (m, 1H), 3.66-3.59 (m, 1H), 3.15 (s, 1H), 2.16 (q, J = 10.7, 9.7 Hz, 4H), 1.82-1.72 (m, 2H), 1.58 (q, J = 7.5 Hz, 2H), 1.28 (q, J = 7.4 Hz, 2H), 0.86 (t, J = 7.4 Hz, 3H).
    N7-butyl-1-({5-[(cyclobutyl-
    amino)methyl]quinolin-8-
    yl}methyl)-1H-pyrazolo[4,3-
    d]pyrimidine-5,7-diamine
    102
    Figure US20230130516A1-20230427-C00078
      
    Figure US20230130516A1-20230427-C00079
          		 30.8 12.2 LC/MS [M + H]+: 490.9 LC/MS RT (min)/Method: 1.09/D δ 9.04-8.99 (m, 1H), 8.69 (dd, J = 8.7, 1.7 Hz, 1H), 7.67 (dd, J = 8.5, 4.3 Hz, 1H), 7.60 (s, 1H), 7.46 (d, J = 7.4 Hz, 1H), 7.12 (d, J = 7.3 Hz, 1H), 6.33-6.24 (m, 2H), 6.10 (d, J = 16.7 Hz, 1H), 5.62 (s, 2H), 4.24 (s, 1H), 3.98-3.89 (m, 2H), 3.20 (qd, J = 13.5, 12.2, 6.1 Hz, 2H), 3.10 (s, 3H), 2.87 (q, J = 6.9 Hz, 2H), 1.89 (s, 2H), 1.52 (dd, J = 13.0, 6.3 Hz, 2H), 1.34-1.20 (m, 2H), 1.02 (dt, J = 13.9, 7.3 Hz, 1H), 0.80 (s, 1H), 0.59 (t, J = 7.3 Hz, 3H)
    (3S)-3-{[5-amino-1-({5-[(3-
    methoxyazetidin-1-
    yl)methyl]quinolin-8-
    yl}methyl)-1H-pyrazolo[4,3-
    d]pyrimidin-7-
    yl]amino}hexan-1-ol
    103
    Figure US20230130516A1-20230427-C00080
      
    Figure US20230130516A1-20230427-C00081
          		 13.8 10.6 LC/MS [M + H]+: 475.2 LC/MS RT (min)/Method: 1.11/D δ 9.01 (dd, J = 4.2, 1.7 Hz, 1H), 8.72 (dd, J = 8.6, 1.8 Hz, 1H), 7.66 (dd, J = 8.5, 4.3 Hz, 1H), 7.60 (s, 1H), 7.48 (d, J = 7.4 Hz, 1H), 7.15 (d, J = 7.4 Hz, 1H), 6.31-6.24 (m, 2H), 6.11 (d, J = 16.5 Hz, 1H), 5.60 (s, 2H), 4.29-4.19 (m, 1H), 4.01 (s, 1H), 3.21-3.11 (m, 2H), 2.04 (d, J = 9.5 Hz, 3H), 1.89 (s, 3H), 1.66 (t, J = 9.2 Hz, 2H), 1.52 (ddt, J = 26.4, 18.3, 8.8 Hz, 3H), 1.36-1.18 (m, 2H), 1.02 (dd, J = 13.9, 8.6 Hz, 1H), 0.84 (s, 2H), 0.61 (t, J = 7.3 Hz, 3H)
    (3S)-3-{[5-amino-1-({5-
    [(cyclobutylamino)methyl]-
    quinolin-8-yl}methyl)-1H-
    pyrazolo[4,3-d]pyrimidin-7-
    yl]amino}hexan-1-ol
    104
    Figure US20230130516A1-20230427-C00082
      
    Figure US20230130516A1-20230427-C00083
          		 44.8 13.4 LC/MS [M + H]+: 505.2 LC/MS RT (min)/Method: 0.87/D δ 9.02 (d, J = 4.2 Hz, 1H), 8.72 (d, J = 8.5 Hz, 1H), 7.68 (dd, J = 8.6, 4.2 Hz, 1H), 7.62-7.53 (m, 2H), 7.20 (d, J = 7.3 Hz, 1H), 6.39 (d, J = 8.9 Hz, 1H), 6.27 (d, J = 16.6 Hz, 1H), 6.12 (d, J = 16.4 Hz, 1H), 5.64 (s, 2H), 4.27-4.18 (m, 3H), 3.81 (d, J = 11.5 Hz, 2H), 3.29-3.21 (m, 2H), 3.18 (s, 1H), 3.22-3.13 (m, 1H), 2.77 (s, 1H), 1.86 (d, J = 32.1 Hz, 4H), 1.58-1.48 (m, 1H), 1.31 (s, 4H), 1.12-1.00 (m, 1H), 0.85 (s, 2H), 0.62 (t, J = 7.3 Hz, 3H)
    (3S)-3-({5-amino-1-[(5-
    {[(oxan-4-yl)amino]-
    methyl}quinolin-8-yl)methyl]-
    1H-pyrazolo[4,3-d]pyrimidin-
    7-yl}amino)hexan-1-ol
    105
    Figure US20230130516A1-20230427-C00084
      
    Figure US20230130516A1-20230427-C00085
          		 49.4 13.8 LC/MS [M + H]+: 477.1 LC/MS RT (min)/Method: 1.13/D δ 9.02 (d, J = 4.1 Hz, 1H), 8.69 (d, J = 8.8 Hz, 1H), 7.67 (dd, J = 8.5, 4.2 Hz, 1H), 7.60 (s, 1H), 7.44 (d, J = 7.3 Hz, 1H), 7.12 (d, J = 7.3 Hz, 1H), 6.33-6.21 (m, 2H), 6.11 (d, J = 16.5 Hz, 1H), 5.60 (s, 2H), 4.25 (s, 1H), 4.14 (t, J = 6.2 Hz, 1H), 3.95 (d, J = 5.3 Hz, 2H), 3.89 (s, 1H), 3.20 (s, 2H), 2.80 (t, J = 7.0 Hz, 2H), 1.85 (s, 3H), 1.51 (s, 1H), 1.28 (s, 2H), 1.07-0.95 (m, 1H), 0.88-0.75 (m, 2H), 0.60 (t, J = 7.3 Hz, 3H)
    1-({8-[(5-amino-7-{[(3S)-1-
    hydroxyhexan-3-yl]amino}-
    1H-pyrazolo[4,3-d]pyrimidin-
    1-yl)methyl]quinolin-5-
    yl}methyl)azetidin-3-ol
    106
    Figure US20230130516A1-20230427-C00086
      
    Figure US20230130516A1-20230427-C00087
          		 19.3 48.1 LC/MS [M + H]+: 531.2 LC/MS RT (min)/Method: 0.87/D δ 9.01 (dd, J = 4.3, 1.6 Hz, 1H), 8.71 (d, J = 8.5 Hz, 1H), 7.68 (dd, J = 8.6, 4.3 Hz, 1H), 7.63 (s, 1H), 7.49 (d, J = 7.3 Hz, 1H), 7.15 (d, J = 7.3 Hz, 1H), 6.52-6.47 (s, 1H), 6.31 (d, J = 16.6 Hz, 1H), 6.11 (d, J = 16.7 Hz, 1H), 5.88 (s, 1H), 4.30-4.23 (m, 2H), 4.10-4.01 (m, 2H), 3.20 (d, J = 6.7 Hz, 4H), 3.07 (s, 2H), 1.62 (t, J = 5.2 Hz, 5H), 1.54 (dd, J = 13.0, 6.1 Hz, 1H), 1.27 (s, 2H), 1.05 (s, 1H), 0.84 (s, 2H), 0.60 (t, J = 7.3 Hz, 3H).
    (3S)-3-[(5-amino-1-{[5-({7-
    oxa-2-azaspiro[3.5]nonan-2-
    yl}methyl)quinolin-8-
    yl]methyl}-1H-pyrazolo[4,3-
    d]pyrimidin-7-
    yl)amino]hexan-1-ol
    107
    Figure US20230130516A1-20230427-C00088
      
    Figure US20230130516A1-20230427-C00089
          		 155.6 320.6 LC/MS [M + H]+: 447.1 LC/MS RT (min)/Method: 1.13/D δ 9.02 (dd, J = 4.3, 1.6 Hz, 1H), 8.80 (dd, J = 8.5, 1.8 Hz, 1H), 7.68 (dd, J = 8.6, 4.2 Hz, 1H), 7.57 (s, 1H), 7.48 (d, J = 7.3 Hz, 1H), 7.27 (d, J = 7.3 Hz, 1H), 6.15 (s, 2H), 5.64 (s, 2H), 3.85 (s, 2H), 3.48(s, 4H), 2.36 (s, 4H), 1.90 (s, 2H), 1.37 (p, J = 7.2 Hz, 2H), 1.06 (p, J = 7.4 Hz, 2H), 0.73 (t, J = 7.4 Hz, 3H)
    N7-butyl-1-({5-[(morpholin-4-
    yl)methyl]quinolin-8-
    yl}methyl)-1H-pyrazolo[4,3-
    d]pyrimidine-5,7-diamine
    108
    Figure US20230130516A1-20230427-C00090
      
    Figure US20230130516A1-20230427-C00091
          		 67.6 109.9 LC/MS [M + H]+: 505.2 LC/MS RT (min)/Method: 1.23/D δ 9.06 (d, J = 4.0 Hz, 1H), 8.57 (d, J = 8.7 Hz, 1H), 7.72 (dd, J = 8.7, 4.2 Hz, 1H), 7.62 (d, J = 9.4 Hz, 2H), 7.09 (t, J = 6.9 Hz, 1H), 6.35 (dd, J = 17.1, 10.7 Hz, 1H), 6.22 (ddd, J = 39.7, 16.0, 7.5 Hz, 2H), 5.61 (s, 2H), 4.34-4.26 (m, 1H), 4.24 (s, 1H), 4.19 (s, 1H), 4.09-4.00 (m, 1H), 3.92-3.88 (m, 1H), 3.14 (s, 4H), 1.88 (s, 2H), 1.54-1.48 (m, 1H), 1.36-1.20 (m, 2H), 1.12- 1.00 (m, 1H), 0.82 (d, J = 17.1 Hz, 2H), 0.58 (q, J = 7.7 Hz, 3H).
    (3S)-3-[(5-amino-1-{[5-(3-
    methoxyazetidine-1-car-
    bonyl)quinolin-8-yl]methyl}-
    1H-pyrazolo[4,3-d]pyrimidin-
    7-yl)amino]hexan-1-ol
    109
    Figure US20230130516A1-20230427-C00092
      
    Figure US20230130516A1-20230427-C00093
          		 55.2 41.5 LC/MS [M + H]+: 461.2 LC/MS RT (min)/Method: 1.16/E δ 9.20 (s, 1H), 9.03 (dd, J = 4.1, 1.5 Hz, 1H), 8.74 (dd, J = 8.5, 1.8 Hz, 1H), 7.82-7.72 (m, 3H), 7.69 (d, J = 7.4 Hz, 1H), 6.24 (s, 2H), 4.69 (s, 2H), 3.95 (dd, J = 11.5, 4.3 Hz, 2H), 3.64 (q, J = 6.9 Hz, 1H), 3.36-3.31(m, 1H), 2.09 (d, J = 12.4 Hz, 2H), 1.71-1.56 (m, 4H), 1.30 (h, J = 7.4 Hz, 2H), 0.87 (t, J = 7.4 Hz, 3H)
    N7-butyl-1-[(5-{[(oxan-4-
    yl)amino]methyl}quinolin-8-
    yl)methyl]-1H-pyrazolo[4,3-
    d]pyrimidine-5,7-diamine
    110
    Figure US20230130516A1-20230427-C00094
          		 286.9 729.2 LC/MS [M + H]+: 392.2 LC/MS RT(min)/Method: 1.32 δ 9.04 (dd, J = 4.2, 1.7 Hz, 1H), 8.48 (dd, J = 8.4, 1.7 Hz, 1H), 7.97 (d, J = 8.2 Hz, 1H), 7.67 (dd, J = 8.3, 4.2 Hz, 1H), 7.61 (s, 1H), 7.55 (t, J = 7.7 Hz, 1H), 7.22 (d, J = 7.2 Hz, 1H), 6.37- 6.27 (m, 2H), 6.14 (d, J = 16.7 Hz, 1H), 5.62 (s,
    W = H 2H), 4.25 (s, 1H), 3.25-3.14 (m, 1H), 1.57-
    (3S)-3-({5-amino-1-[(quinolin- 1.49 (m, 1H), 1.38 (s, 2H), 1.27 (s, 1H), 1.04
    8-yl)methyl]-1H-pyrazolo[4,3- (d, J = 8.8 Hz, 1H), 0.85 (s, 2H), 0.80 (s, 1H),
    d]pyrimidin-7-yl}amino)- 0.60 (t, J = 7.3 Hz, 3H).
    hexan-1-ol
    111
    Figure US20230130516A1-20230427-C00095
      
    Figure US20230130516A1-20230427-C00096
          		 66.0 57.7 LC/MS [M + H]+: 548.1 LC/MS RT (min)/Method: 1.02/D δ 9.09-9.04 (m, 1H), 8.27 (dd, J = 8.5, 1.7 Hz, 1H), 7.76-7.66 (m, 2H), 7.49 (d, J = 7.2 Hz, 1H), 7.20 (s, 1H), 6.39 (s, 1H), 6.31 (s, 2H), 6.17 (s, 1H), 4.32 (s, 1H), 3.27 (s, 1H), 3.10 (s, 1H), 3.04 (s, 1H), 2.60 (s, 2H), 2.44 (s, 2H), 2.36 (s, 1H), 1.89 (s, 1H), 1.57 (s, 2H), 1.46 (s, 1H), 1.33 (s, 2H), 1.21 (s, 2H), 0.91 (s, 2H), 0.64 (s, 3H).
    (3S)-3-{[5-amino-1-({5-[4-(2-
    hydroxyethyl)piperazine-1-
    carbonyl]quinolin-8-yl}me-
    thyl)-1H-pyrazolo[4,3-d]
    pyrimidin-7-yl]amino}
    hexan-1-ol
    112
    Figure US20230130516A1-20230427-C00097
      
    Figure US20230130516A1-20230427-C00098
          		 4.9 5.1 LC/MS [M + H]+: 518.1 LC/MS RT (min)/Method: 1.00/D δ 9.08- 9.03 (m, 1H), 8.27 (dd, J = 8.5, 1.9 Hz, 1H), 7.73 (dd, J = 8.6, 4.2 Hz, 1H), 7.51 (d, J = 7.4 Hz, 1H), 7.25(s, 1H), 7.11 (s, 1H), 6.57 (s, 1H), 6.35(s, 2H), 6.19 (s, 2H), 4.36 (s, 1H), 3.85 (s, 1H), 3.56-3.47 (m, 1H), 3.32-3.22 (m, 1H), (s, 1H), 3.15 (s, 1H), 2.97 (s, 3H), 2.26 (s, 2H), 1.75 (d, J = 9.2 Hz, 1H), 1.56 (s, 2H), 1.42-1.33 (m, 2H), 1.31-1.19 (m, 2H), 0.94 (s, 2H), 0.65 (s, 3H).
    (3S)-3-[(5-amino-1-{[5-(4-
    methylpiperazine-1-carbonyl)
    quinolin-8-yl]methyl}-1H-
    pyrazolo[4,3-d]pyrimidin-7-
    yl)amino]hexan-1-ol
    113
    Figure US20230130516A1-20230427-C00099
      
    Figure US20230130516A1-20230427-C00100
          		 186.3 131.6 LC/MS [M + H]+: 505.1 LC/MS RT (min)/Method: 1.22/D δ 9.10-9.05 (m, 1H), 8.32 (dd, J = 8.5, 1.9 Hz, 1H), 7.73 (dd, J = 8.6, 4.2 Hz, 1H), 7.67 (s, 1H), 7.52 (d, J = 7.4 Hz, 1H), 7.18 (s, 1H), 6.37 (s, 2H), 6.16 (s, 2H), 4.31 (s, 1H), 3.71 (s, 1H), 3.15 (s, 1H), 3.11 (s, 1H), 3.02 (s, 1H), 1.89 (d, J = 1.2 Hz, 1H), 1.56 (s, 2H), 1.33 (s, 2H), 1.19 (d, J = 13.3 Hz, 2H), 0.90 (s, 3H), 0.63 (s, 3H).
    (3S)-3-[(5-amino-1-{[5-
    (morpholine-4-carbonyl)
    quinolin-8-yl]methyl}-1H-
    pyrazolo[4,3-d]pyrimidin-7-
    yl)amino]hexan-1-ol
    114
    Figure US20230130516A1-20230427-C00101
      
    Figure US20230130516A1-20230427-C00102
          		 75.2 369.3 LC/MS [M + H]+: 519.2 LC/MS RT (min)/Method: 1.25/D δ 9.05 (d, J = 4.0 Hz, 1H), 8.71 (d, J = 8.7 Hz, 1H), 8.54 (d, J = 7.8 Hz, 1H), 7.71 (dd, J = 8.7, 4.3 Hz, 1H), 7.66-7.61 (m, 2H), 7.17 (d, J = 7.4 Hz, 1H), 6.44-6.34 (m, 2H), 6.17 (d, J = 16.6 Hz, 1H), 5.79 (s, 2H), 4.26 (s, 1H), 4.03 (s, 1H), 3.85 (d, J = 11.4 Hz, 2H), 3.41-3.36 (m, 1H), 3.22 (s, 2H), 1.89 (d, J = 1.5 Hz, 1H), 1.80 (s, 2H), 1.51 (s, 3H), 1.41-1.31 (m, 1H), 1.27 (s, 1H), 1.08 (s, 1H), 0.88 (s, 1H), 0.82 (s, 1H), 0.62 (t, J = 7.3 Hz, 3H).
    8-[(5-amino-7-{[(3S)-1-
    hydroxyhexan-3-yl]amino}-
    1H-pyrazolo[4,3-d]pyrimidin-
    1-yl)methyl]-N-(oxan-4-
    yl)quinoline-5-carboxamide
    115
    Figure US20230130516A1-20230427-C00103
      
    Figure US20230130516A1-20230427-C00104
          		 467.6 756.2 LC/MS [M + H]+: 542.3 LC/MS RT (min)/Method: 1.22/D δ 9.21 (d, J = 4.3 Hz, 1H), 8.37 (d, J = 7.9 Hz, 1H), 7.84 (dd, 7 = 8.5, 4.1 Hz, 1H), 7.72 (s, 1H), 7.59 (d, J = 7.6 Hz, 1H), 7.32 (d, J = 7.5 Hz, 1H), 6.38 (s, 1H), 6.32 (s, 1H), 5.79 (s, 2H), 3.17-3.12 (m, 2H), 2.49 (t, J = 6.2 Hz, 2H), 2.40 (s, 1H), 2.25 (s, 2H), 1.98-1.86 (m, 10H), 1.70 (s, 2H), 0.95-0.93 (m, 1H), 0.37 (s, 3H).
    2-{4-[8-({5-amino-7-[({spiro-
    [2.3]hexan-5-yl}methyl)-
    amino]-1H-pyrazolo[4,3-
    d]pyrimidin-1-yl}methyl)-
    quinoline-5-carbonyl]-
    piperazin-1-yl}ethan-1-ol
    116
    Figure US20230130516A1-20230427-C00105
      
    Figure US20230130516A1-20230427-C00106
          		 280.2 291.3 LC/MS [M + H]+: 526.2 LC/MS RT (min)/Method: 1.31/D δ 9.15 (s, 1H), 9.01 (d, J = 4.1 Hz, 1H), 8.76 (s, 1H), 8.67 (d, J = 8.6 Hz, 1H), 7.75 (s, 1H), 7.72- 7.66 (m, 2H), 7.58 (s, 1H), 6.24 (s, 2H), 4.10- 4.01 (m, 1H), 3.78 (s, 2H), 3.45 (s, 2H), 3.15 (s, 1H), 3.10 (s, 1H), 2.75 (s, 3H), 2.10 (s, 2H), 2.00 (s, 2H), 1.84 (d, J = 7.7 Hz, 2H), 1.73 (s, 2H), 0.33 (s, 4H).
    8-({5-amino-7-[({spiro-
    [2.3]hexan-5-yl}methyl)-
    amino]-1H-pyrazolo[4,3-
    d]pyrimidin-1-yl}methyl)-N-
    (1-methylpiperidin-4-
    yl)quinoline-5-carboxamide
    117
    Figure US20230130516A1-20230427-C00107
      
    Figure US20230130516A1-20230427-C00108
          		 447.2 266.5 LC/MS [M + H]+: 512.4 LC/MS RT (min)/Method: 1.30/D δ 9.09 (d, J = 4.2 Hz, 1H), 8.34 (d, J = 8.5 Hz, 1H), 8.11 (s, 1H), 7.71 (dd,J = 8.7, 4.3 Hz, 1H), 7.61 (s, 1H), 7.55 (dd, J = 19.4, 7.3 Hz, 1H), 7.37 (s, 1H), 7.22 (dd, J = 21.5, 7.4 Hz, 1H), 6.25 (s, 2H), 5.78 (s, 2H), 4.23 (s, 1H), 3.22 (s, 2H), 3.02 (s, 2H), 1.88 (d, J = 14.1 Hz, 1H), 1.84 (d, J = 9.3 Hz, 2H), 1.62 (d, J = 8.9 Hz, 2H), 0.27 (s, 4H).
    4-[8-({5-amino-7-[({spiro-
    [2.3]hexan-5-yl}methyl)-
    amino]-1H-pyrazolo[4,3-
    d]pyrimidin-1-yl}methyl)-
    quinoline-5-carbonyl]-
    piperazin-2-one
    118
    Figure US20230130516A1-20230427-C00109
      
    Figure US20230130516A1-20230427-C00110
          		 311.2 208.1 LC/MS [M + H]+: 517.9 LC/MS RT (min)/Method: 1.09/D δ 9.07 (d, J = 4.2 Hz, 1H), 8.33 (d, J = 8.5 Hz, 1H), 8.12 (s, 1H), 7.71 (dd, J = 8.5, 4.2 Hz, 1H), 7.63 (s, 1H), 7.54 (dd, J = 16.8, 7.4 Hz, 1H), 7.18-7.10 (m, 1H), 6.35 (s, 2H), 6.18 (d,J = 17.5 Hz, 1H), 5.66 (s, 1H), 4.23 (s, 1H), 3.69 (s, 3H), 3.34 (s, 1H), 3.24 (s, 2H), 3.06 (s, 2H), 1.53 (s, 1H), 1.29 (s, 2H), 1.16-1.09 (m, 1H), 0.90-0.82 (m, 2H), 0.61 (t, J = 7.6 Hz, 3H)
    4-{8-[(5-amino-7-{[(3S)-1-
    hydroxyhexan-3-yl]amino}-
    1H-pyrazolo[4,3-d]pyrimidin-
    1-yl)methyl]quinoline-5-
    carbonyl}piperazin-2-one
    119
    Figure US20230130516A1-20230427-C00111
      
    Figure US20230130516A1-20230427-C00112
       R5 = Me    		 605.5 1,000.0 LC/MS [M + H]+: 533.2 LC/MS RT (min)/Method: 1.05/D δ 9.03 (dd, J = 4.4, 1.7 Hz, 1H), 8.70 (dd, J = 8.5, 1.7 Hz, 1H), 8.56 (d, J = 7.7 Hz, 1H), 7.70 (dd, J = 8.7, 4.3 Hz, 1H), 7.64 (d, J = 7.4 Hz, 1H), 7.25 (d, J = 7.4 Hz, 1H), 6.63(s, 1H), 6.25 (d, J = 16.7 Hz, 1H), 6.07 (d, J = 16.5 Hz, 1H), 5.83 (s, 1H), 4.35-4.24 (m, 1H), 4.04 (d, J = 10.5 Hz, 1H), 3.85 (d, J = 11.5 Hz, 2H), 3.59- 3.44 (m, 1H), 3.39 (t, J = 11.4 Hz, 1H), 3.30- 3.21 (m, 2H), 2.26 (s, 3H), 1.90 (s, 1H), 1.86- 1.77 (m, 2H), 1.64-1.46 (m, 3H), 1.45-1.37 (m, 1H), 1.36-1.27 (m, 1H), 1.21-1.10 (m, 1H), 1.01-0.81 (m, 2H), 0.65 (t, J = 7.3 Hz, 3H).
    8-[(5-amino-7-{[(3S)-1-hydro-
    xyhexan-3-yl]amino}-3-
    methyl-1H-pyrazolo[4,3-
    d]pyrimidin-1-yl)methyl]-N-
    (oxan-4-yl)quinoline-5-
    carboxamide
    120
    Figure US20230130516A1-20230427-C00113
      
    Figure US20230130516A1-20230427-C00114
       R5 = Me    		 881.5 1,000.0 LC/MS [M + H]+: 562.3 LC/MS RT (min)/Method: 1.08/D δ 9.05 (d, J = 4.4 Hz, 1H), 8.26 (d, J = 8.5 Hz, 1H), 7.72 (dd, J = 8.5, 4.1 Hz, 1H), 7.48 (d, J = 7.3 Hz, 1H), 7.21 (s, 1H), 6.68 (s, 1H), 6.26 (s, 1H), 6.16 (s, 2H), 5.96 (s, 1H), 4.32 (s, 2H), 3.53-3.45 (m, 2H), 3.27 (s, 1H), 3.16 (s, 1H), 3.09 (s, 1H), 3.03 (s, 1H), 2.58 (s, 2H), 2.42 (s, 2H), 2.34 (d, J = 15.0 Hz, 1H), 2.27 (s, 3H), 1.89 (s, 1H), 1.57 (s, 2H), 1.45(s, 1H), 1.33 (s, 2H), 1.20 (s, 1H), 0.91 (s, 2H), 0.62 (s, 3H).
    (3S)-3-{[5-amino-1-({5-[4-(2-
    hydroxyethyl)piperazine-1-
    carbonyl]quinolin-8-
    yl}methyl)-3-methyl-1H-
    pyrazolo[4,3-d]pyrimidin-7-
    yl]amino}hexan-1-ol
    121
    Figure US20230130516A1-20230427-C00115
      
    Figure US20230130516A1-20230427-C00116
          		 267.0 152.6 LC/MS [M + H]+: 532.3 LC/MS RT(min)/Method: 0.76/D δ 9.05 (d, J = 3.4 Hz, 1H), 8.70 (d, J = 8.7 Hz, 1H), 8.46 (d, J = 7.6 Hz, 1H), 7.70 (dd, J = 8.6, 4.2 Hz, 1H), 7.64-7.58 (m, 2H), 7.16 (d, J = 7.4 Hz, 1H), 6.36 (d, J = 16.6 Hz, 1H), 6.30- 6.22 (m, 1H), 6.16 (d, J = 16.7 Hz, 1H), 5.60 (s, 2H), 4.24 (d, J = 8.8 Hz, 1H), 3.76 (s, 1H), 3.49 (s, 2H), 3.21 (t, J = 6.5 Hz, 1H), 2.13 (s, 3H), 1.96 (t, J = 11.4 Hz, 2H), 1.85 (s, 1H), 1.80 (s, 2H), 1.63 (s, 1H), 1.52 (m, 5H), 1.06 (d, J = 8.7 Hz, 1H), 0.85 (m, 1H), 0.61 (t, J = 7.3 Hz, 3H).
    8-[(5-amino-7-{[(3S)-1-
    hydroxyhexan-3-yl]amino}-
    1H-pyrazolo[4,3-d]pyrimidin-
    1-yl)methyl]-N-(1-methyl-
    piperidin-4-yl)quinoline-5-
    carboxamide
    122
    Figure US20230130516A1-20230427-C00117
      
    Figure US20230130516A1-20230427-C00118
          		 308.7 54.0 LC/MS [M + H]+: 527.3 LC/MS RT (min)/Method: 1.01/D δ 8.84 (dd, J = 4.1, 1.7 Hz, 1H), 8.78 (s, 1H), 8.64 (d, J = 8.9 Hz, 1H), 7.77 (s, 1H), 7.72- 7.61 (m, 3H), 6.24 (s, 2H), 6.18 (s, 1H), 4.88 (d, J = 5.4 Hz, 2H), 4.18 (d, J = 5.8 Hz, 1H), 4.06 (s, 1H), 3.10 (s, 1H), 2.33 (s, 3H), 2.11 (s, 3H), 2.00 (s, 2H), 1.73 (d, J = 12.5 Hz, 2H), 1.62 (s, 2H), 1.52 (s, 2H).
    8-[(5-amino-7-{[(5-methyl-
    1,2-oxazol-3-yl)methyl]-
    amino}-1H-pyrazolo[4,3-
    d]pyrimidin-1-yl)methyl]-N-
    (1-methylpiperidin-4-
    yl)quinoline-5-carboxamide
    123
    Figure US20230130516A1-20230427-C00119
      
    Figure US20230130516A1-20230427-C00120
       R5 = Me    		 731.6 660.7 LC/MS [M + H]+: 546.1 LC/MS RT (min)/Method: 1.12/D δ 9.03 (dd, J = 4.3, 1.6 Hz, 1H), 8.68 (dd, J = 8.7, 1.8 Hz, 1H), 8.47 (d, J = 7.8 Hz, 1H), 7.69 (dd, J = 8.6, 4.2 Hz, 1H), 7.61 (d, J = 7.4 Hz, 1H), 7.20 (d,J = 7.4 Hz, 1H), 6.37 (d, J = 9.1 Hz, 1H), 6.22 (d, J = 16.5 Hz, 1H), 6.06 (d, J = 16.6 Hz, 1H), 5.58 (s, 2H), 4.29-4.21 (m, 1H), 3.77 (s, 1H), 3.63 (s, 1H), 3.56 (d, J = 2.9 Hz, 1H), 3.22 (s, 2H), 2.97 (s, 1H), 2.73 (d, J = 11.0 Hz, 2H), 2.25 (s, 3H), 2.14 (s, 3H), 2.00 (t, J = 11.6 Hz, 2H), 1.81 (s, 2H), 1.60-1.48 (m,3H), 1.29 (dd, J = 14.4, 9.1 Hz, 1H), 0.85 (s, 2H), 0.62 (t, J = 7.4 Hz, 3H).
    8-[(5-amino-7-{[(3S)-1-
    hydroxyhexan-3-yl]amino}-3-
    methyl-1H-pyrazolo[4,3-
    d]pyrimidin-1-yl)methyl]-N-
    (1-methylpiperidin-4-
    yl)quinoline-5-carboxamide
    124
    Figure US20230130516A1-20230427-C00121
      
    Figure US20230130516A1-20230427-C00122
          		 440.2 247.9 LC/MS [M + H]+: 516.2 LC/MS RT (min)/Method: 1.05/D δ 9.06 (d, J = 3.5 Hz, 1H), 8.58 (d, J = 8.5 Hz, 1H), 7.71 (dd, J = 8.6, 4.2 Hz, 1H), 7.65-7.57 (m, 2H), 7.07 (d, J = 7.4 Hz, 1H), 6.34 (d, J = 17.0 Hz, 1H), 6.28-6.16 (m, 2H), 5.62 (s, 2H), 4.21 (s, 2H), 4.00 (q, J = 9.5 Hz, 2H), 3.80 (s, 2H), 3.76-3.65 (m, 3H), 3.17 (dd, J = 13.2, 6.2 Hz, 2H), 1.83 (d, J = 3.3 Hz, 3H), 1.52 (s, 1H), 1.27 (s, 2H), 1.08 (dt, J = 14.0, 7.6 Hz, 1H), 0.84 (s, 2H), 0.60 (t, J = 7.3 Hz, 3H)
    (3S)-3-({5-amino-1-[(5-{2,6-
    diazaspiro[3.3]heptane-2-
    carbonyl}quinolin-8-yl)
    methyl]-1H-pyrazolo[4,3-d]pyri-
    midin-7-yl}amino)hexan-1-ol
    125
    Figure US20230130516A1-20230427-C00123
      
    Figure US20230130516A1-20230427-C00124
          		 33.7 83.3 LC/MS [M + H]+: 544.2 LC/MS RT (min)/Method: 1.06/D δ 9.03 (d, J = 3.8 Hz, 1H), 8.39 (s, 1H), 8.18 (d, J = 11.9 Hz, 1H), 7.89 (s, 1H), 7.81 (s, 1H), 7.71 (s, 1H), 7.67-7.56 (m, 2H), 7.42 (d, J = 7.3 Hz, 1H), 6.40 (dd, J = 16.1, 6.3 Hz, 1H), 6.26 (t, J = 17.0 Hz, 1H), 4.50 (s, 2H), 3.97 (s, 1H), 3.84(s, 1H), 3.60 (s, 1H), 3.08 (s, 1H), 2.82 (s, 4H), 1.76-1.65(m, 3H), 1.64-1.57 (m, 3H), 1.46 (s, 4H), 1.08 (s, 3H), 0.74 (q, J = 7.1 Hz, 3H).
    (3S)-3-{[1-([5-[(3aR,6aS)-5-
    methyl-octahydropyrrolo
    [3,4-c]pyrrole-2-
    carbonyl]quinolin-8-
    yl}methyl)-5-amino-1H-
    pyrazolo[4,3-d]pyrimidin-7-
    yl]amino}hexan-1-ol
    126
    Figure US20230130516A1-20230427-C00125
      
    Figure US20230130516A1-20230427-C00126
       (3S)-3-{[5-amino-1-({5-    		 191.3 49.7 LC/MS [M + H]+: 530.4 LC/MS RT (min)/Method: 1.05/D δ 9.07 (d, J = 4.1 Hz, 1H), 8.34 (t, J = 7.9 Hz, 1H), 7.72 (dt, J = 8.2, 3.6 Hz, 1H), 7.63 (d, J = 2.7 Hz, 1H), 7.54 (d, J = 7.4 Hz, 1H), 7.12 (dd, J = 7.5, 3.8 Hz, 1H), 6.33 (dd, J = 16.6, 10.2 Hz, 2H), 6.21 (dd, J = 16.8, 4.9 Hz, 1H), 5.64 (s, 2H), 4.73 (s, 1H), 4.26 (s, 1H), 3.17 (s, 2H), 3.06-2.94 (m, 1H), 2.88 (d, J = 9.7 Hz, 1H), 2.30 (s, 3H), 2.22 (s, 1H), 1.89 (s, 2H), 1.86 (d, J = 10.0 Hz, 1H), 1.76 (d, J = 9.5 Hz, 1H), 1.69 (s, 1H), 1.52 (dt, J = 12.9, 6.4 Hz, 1H), 1.30 (dq, J = 14.0, 6.9, 5.9 Hz, 1H), 1.14 (dq, J = 15.0, 7.8 Hz, 2H), 0.88 (p, J = 7.8 Hz, 2H), 0.62 (q, J = 7.6 Hz, 3H).
    [(1R,4R)-5-methyl-2,5-diaza-
    bicyclo[2.2.1]heptane-2-
    carbonyl]quinolin-8-yl}methyl)-
    1H-pyrazolo[4,3-d]pyrimidin-
    7-yl]amino}hexan-1-ol
    127
    Figure US20230130516A1-20230427-C00127
      
    Figure US20230130516A1-20230427-C00128
          		 54.8 91.9 LC/MS [M + H]+: 517.2 LC/MS RT (min)/Method: 0.96/D δ 9.06 (dd, 7 = 4.2,1.7 Hz, 1H), 8.58 (dd, J = 8.5, 1.7 Hz, 1H), 7.71 (dd, J = 8.6, 4.2 Hz, 1H), 7.65-7.57 (m, 2H), 7.09 (d, J = 7.4 Hz, 1H), 6.38-6.28 (m, 2H), 6.20 (d, J = 17.0 Hz, 1H), 5.69 (s, 2H), 4.66 (dd, J = 6.9, 3.0 Hz, 2H), 4.60- 4.54 (m, 2H), 4.28 (s, 2H), 4.11-4.02 (m, 2H), 3.21-3.13 (m, 2H), 1.89 (s, 1H), 1.51 (dt, J = 12.5, 6.4 Hz, 1H), 1.29 (ddt, J = 20.5, 14.3, 7.2 Hz, 2H), 1.11 (dd, J = 14.2, 6.4 Hz, 2H), 0.88 (t, J = 7.5 Hz, 2H), 0.61 (t, J = 7.3 Hz, 3H)
    (3S)-3-({5-amino-1-[(5-{2-
    oxa-6-azaspiro[3.3]heptane-
    6-carbonyl}quinolin-8-
    yl)methyl]-1H-pyrazolo[4,3-
    d]pyrimidin-7-
    yl}amino)hexan-1-ol
    128
    Figure US20230130516A1-20230427-C00129
      
    Figure US20230130516A1-20230427-C00130
          		 54.6 102.0 LC/MS [M + H]+: 533.3 LC/MS RT (min)/Method: 1.13 δ 9.06 (dd, J = 4.5, 1.6 Hz, 1H), 8.58 (d, J = 8.6 Hz, 1H), 7.72 (dd, J = 8.6, 4.2 Hz, 1H), 7.66- 7.58 (m, 2H), 7.12-7.07 (m, 1H), 6.41-6.30 (m, 2H), 6.18 (d, J = 17.0 Hz, 1H), 5.74 (s, 1H), 4.26 (s, 1H), 4.18 (t, J = 9.2 Hz, 1H), 3.92 (dq, J = 18.6, 10.0, 9.3 Hz, 1H), 3.79-3.74 (m, 1H), 3.24 (t, J = 6.2 Hz, 1H), 3.20 (s, 3H), 3.13 (s, 3H), 2.66-2.59 (m,1H), 2.53 (s, 2H), 1.76 (tt, J = 14.2, 7.8 Hz, 2H), 1.53 (dt, J = 13.3, 6.3 Hz, 1H), 1.33 (dq, J = 13.9, 6.0 Hz, 1H), 1.26 (s, 1H), 1.08 (s, 1H), 0.83 (dt, J = 14.5, 7.2 Hz, 2H), 0.59 (td, J = 7.3, 2.6 Hz, 3H)
    (3S)-3-{[5-amino-1-({5-[3-(2-
    methoxyethyl)azetidine-1-
    carbonyl]quinolin-8-
    yl}methyl)-1H-pyrazolo[4,3-
    d]pyrimidin-7-
    yl]amino}hexan-1-ol
    129
    Figure US20230130516A1-20230427-C00131
      
    Figure US20230130516A1-20230427-C00132
          		 33.7 83.3 LC/MS [M + H]+: 533.1 LC/MS RT (min)/Method: 1.31/D δ 9.08 (d, J = 4.4 Hz, 1H), 8.21 (dd, J = 19.3, 8.3 Hz, 1H), 7.75-7.66 (m, 1H), 7.70 (s, 1H), 7.65 (s, 1H), 7.48 (d, J = 7.6 Hz, 1H), 7.18 (d, J = 7.3 Hz, 1H), 6.37 (d, J = 16.9 Hz, 1H), 6.20 (d, J = 17.5 Hz, 1H), 5.91 (s, 1H), 4.30 (s, 2H), 4.00-3.93 (m, 1H), 3.22 (s, 1H), 2.99 (s, 2H), 2.57 (s, 3H), 1.90 (s, 1H), 1.81 (s, 2H), 1.70 (s, 1H), 1.56 (s, 2H), 1.30 (s, 3H), 1.22-1.15 (m, 1H), 1.06 (s, 1H), 0.90 (d, J = 7.3 Hz, 2H), 0.63 (t, J = 7.4 Hz, 3H)
    8-[(5-amino-7-{[(3S)-1-
    hydroxyhexan-3-yl]amino}-
    1H-pyrazolo[4,3-
    d]pyrimidin-1-yl)methyl]-N-
    methyl-N-(oxan-4-
    yl)quinoline-5-carboxamide
    130
    Figure US20230130516A1-20230427-C00133
      
    Figure US20230130516A1-20230427-C00134
          		 191.3 49.7 LC/MS [M + H]+: 530.2 LC/MS RT (min)/Method: 1.11/D δ 9.06 (d, J = 4.3 Hz, 1H), 8.62-8.56 (m, 1H), 7.71 (dd, J = 8.5, 4.2 Hz, 1H), 7.65-7.58 (m, 2H), 7.05 (d, J = 7.5 Hz, 1H), 6.36 (d, J = 17.1 Hz, 1H), 6.25-6.16 (m, 2H), 5.63 (s, 2H), 4.24 (s, 2H), 4.17 (s, 2H), 3.95 (q, J = 9.3 Hz, 2H), 3.48 (s, 1H), 3.31 (d, J = 7.3 Hz, 1H), 3.18 (dd, J = 13.5, 7.4 Hz, 3H), 2.15 (s, 3H), 1.89 (s, 2H), 1.52 (dt, J = 13.4, 6.5 Hz, 1H), 1.33-1.24 (m, 1H), 1.09 (dd, J = 14.0, 5.8 Hz, 1H), 0.85 (dd, J = 15.2, 7.7 Hz, 2H), 0.60 (t, J = 7.3 Hz, 3H)
    (3S)-3-({5-amino-1-[(5-{6-
    methyl-2,6-diazaspiro-
    [3.3]heptane-2-carbonyl}-
    quinolin-8-yl)methyl]-1H-
    pyrazolo[4,3-d]pyrimidin-7-
    yl}amino)hexan-1-ol
    131
    Figure US20230130516A1-20230427-C00135
      
    Figure US20230130516A1-20230427-C00136
          		 54.8 91.9 LC/MS [M + H]+: 562.2 LC/MS RT (min)/Method: 1.09/D δ 9.07 (s, 1H), 8.25 (d, J = 8.3 Hz, 1H), 7.72 (dd, J = 8.6, 4.4 Hz, 1H), 7.63 (s, 1H), 7.47 (d, J = 7.2 Hz, 1H), 7.16 (s, 1H), 6.44 (s, 2H), 6.26 (s, 1H), 6.18-6.09 (m, 1H), 5.79 (s, 1H), 4.26 (s, 1H), 3.41-3.35 (m, 2H), 3.24 (s, 1H), 3.17 (s, 3H), 3.07 (s, 1H), 2.96 (s, 2H), 2.49 (s, 2H), 2.30 (s, 1H), 2.16 (s, 2H), 1.89 (s, 1H), 1.53 (s, 2H), 1.29 (s,2H), 1.14 (s, 2H), 0.90 (s, 1H) 0.82 (s, 1H), 0.67-0.53 (m, 4H)
    (3S)-3-{[5-amino-1-({5-[4-(2-
    methoxyethyl)piperazine-1-
    carbonyl]quinolin-8-
    yl}methyl)-1H-pyrazolo[4,3-
    d]pyrimidin-7-
    yl]amino}hexan-1-ol
    132
    Figure US20230130516A1-20230427-C00137
      
    Figure US20230130516A1-20230427-C00138
       (3S)-3-{[5-amino-1-({5-[3-(2-    		 54.6 102.0 LC/MS [M + H]+: 519.0 LC/MS RT (min)/Method: 1.19/D δ 9.07-9.02 (m, 1H), 8.56 (d, J = 8.6 Hz, 1H), 7.72 (dd, J = 8.6, 4.2 Hz, 1H), 7.65-7.57 (m, 2H), 7.12 (d, J = 7.9 Hz, 1H), 6.44-6.32 (m, 2H), 6.16 (d, J = 16.9 Hz, 1H), 5.78 (s, 1H), 4.25 (s, 1H), 4.19 (t, J = 9.3 Hz, 1H), 3.93 (dt, J = 17.6, 8.6 Hz, 1H), 3.79-3.65 (m, 2H), 3.57- 3.46 (m, 1H), 3.33 (t, J = 6.2 Hz, 2H), 3.19 (q, J = 7.1 Hz, 2H), 2.96(s, 1H), 2.68-2.61 (m, 1H), 1.66 (s, 2H), 1.52 (dt, J = 12.6, 6.5 Hz, 1H), 1.34 (s, 1H), 1.26 (s, 1H), 1.08 (s, 1H), 0.82 (dt, J = 14.9, 7.2 Hz, 2H), 0.58 (td, J = 7.3, 2.8 Hz, 3H).
    hydroxyethyl)azetidine-1-
    carbonyl]quinolin-8-yl}me-
    thyl)-1H-pyrazolo[4,3-
    d]pyrimidin-7-yl]amino}-
    hexan-1-ol
    133
    Figure US20230130516A1-20230427-C00139
      
    Figure US20230130516A1-20230427-C00140
          		 408.7 592.8 LC/MS [M + H]+: 478.0 LC/MS RT (min)/Method: 1.05/D δ 9.08 (d, J = 4.2 Hz, 1H), 8.80 (d, J = 8.6 Hz, 1H), 8.75 (s, 1H), 7.77-7.69 (m, 2H), 7.64 (s, 1H), 7.16 (d, J = 7.5 Hz, 1H), 6.36 (t, J = 15.9 Hz, 1H), 6.20 (d, J = 16.7 Hz, 1H), 5.64 (s, 2H), 3.22 (d, J = 6.2 Hz, 2H), 2.85 (s, 2H), 1.87 (s, 3H), 1.59- 1.52 (m, 1H), 1.48 (s, 1H), 1.37 (s, 1H), 1.29 (d, J = 10.8 Hz, 1H), 1.12 (d, J = 8.2 Hz, 1H), 0.96-0.86 (m, 2H), 0.64 (t, J = 7.3 Hz, 3H)
    8-[(5-amino-7-{[(3S)-1-hy-
    droxyhexan-3-yl]amino}-
    1H-pyrazolo[4,3-
    d]pyrimidin-1-yl)methyl]-N-
    (2-aminoethyl)quinoline-5-
    carboxamide
    134
    Figure US20230130516A1-20230427-C00141
      
    Figure US20230130516A1-20230427-C00142
          		 35.4 193.5 LC/MS [M + H]+: 547.2 LC/MS RT (min)/Method: 1.26/D δ 9.07 (d, J = 4.2 Hz, 1H), 8.31-8.18 (s, 1H), 7.72 (s, 1H), 7.66 (s, 1H), 7.55-7.40 (m, 1H), 7.16 (s, 1H), 6.56 (s, 1H), 6.46-6.37 (m, 1H), 6.28 (s, 1H), 6.16 (s, 1H), 5.97 (s, 1H), 4.59 (s, 1H), 3.14 (d, J = 13.7 Hz, 1H), 3.00-2.82 (m, 1H), 2.87 (s, 2H), 1.90 (s, 1H), 1.78 (d, J = 13.1 Hz, 1H), 1.63 (s, 2H), 1.45 (s, 2H), 1.33 (s, 5H), 1.17 (s, 3H), 0.93 (s, 1H), 0.85 (s, 1H), 0.66 (s, 2H), 0.60 (s,2H)
    (3S)-3-{[5-amino-1-({5-[4-(2-
    hydroxyethyl)piperidine-1-
    carbonyl]quinolin-8-
    yl}methyl)-1H-pyrazolo[4,3-
    d]pyrimidin-7-
    yl]amino}hexan-1-ol
    135
    Figure US20230130516A1-20230427-C00143
      
    Figure US20230130516A1-20230427-C00144
          		 125.7 80.1 LC/MS [M + H]+: 491.0 LC/MS RT (min)/Method: 1.15 δ 9.07 (d, J = 4.0 Hz, 1H), 8.59 (d, J = 8.5 Hz, 1H), 7.73 (dd, J = 8.5, 4.2 Hz, 1H), 7.66-7.57 (m, 2H), 7.09 (t, J = 7.4 Hz, 1H), 6.34 (tt, J = 23.2, 10.4 Hz, 2H), 6.19 (dd, J = 17.3, 5.3 Hz, 1H), 5.71 (s, 1H), 4.46 (s, 1H), 4.03 (d, J = 10.4 Hz, 1H), 3.84 (d, J = 9.9 Hz, 1H), 3.66 (s, 1H), 3.20 (s, 2H), 1.89 (s, 1H), 1.53 (d, J = 9.2 Hz, 1H), 1.34 (d, J = 6.0 Hz, 1H), 1.28 (s, 1H), 1.11 (s, 1H), 0.85 (s, 3H), 0.60 (q, J = 7.0 Hz, 3H).
    1-{8-[(5-amino-7-{[(3S)-1-
    hydroxyhexan-3-yl]amino}-
    1H-pyrazolo[4,3-d]pyrimidin-
    1-yl)methyl]quinoline-5-
    carbonyl}azetidin-3-ol
    136
    Figure US20230130516A1-20230427-C00145
      
    Figure US20230130516A1-20230427-C00146
          		 230.5 418.1 LC/MS [M + H]+: 506.9 LC/MS RT(min)/Method: 1.20 δ 9.07-9.02 (m, 1H), 8.72 (d, J = 8.5 Hz, 1H), 8.55 (s, 1H), 7.70 (dd, J = 8.6, 4.2 Hz, 1H), 7.63 (t, J = 3.7 Hz, 2H), 7.16 (d, J = 7.5 Hz, 1H), 6.43- 6.33 (m, 2H), 6.17 (d, J = 16.7 Hz, 1H), 5.73 (s, 1H), 4.26 (s, 1H), 3.28 (s, 1H), 3.22 (s, 2H), 1.55 (d, J = 15.8 Hz, 1H), 1.55 (s, 3H), 1.50- 1.43 (m, 2H), 1.40-1.32 (m, 2H), 1.28 (s, 2H), 1.09 (d, J = 7.6 Hz, 1H), 0.88 (s, 1H), 0.82 (s, 1H), 0.61 (t, J = 7.3 Hz, 3H)
    8-[(5-amino-7-{[(3S)-1-hy-
    droxyhexan-3-yl]amino}-1H-
    pyrazolo[4,3-d]pyrimidin-1-
    yl)methyl]-N-(4-hydroxybutyl)
    quinoline-5-carboxamide
    137
    Figure US20230130516A1-20230427-C00147
      
    Figure US20230130516A1-20230427-C00148
          		 60.9 20.4 LC/MS [M + H]+: 504.0 LC/MS RT (min)/Method: 1.06/D δ 9.11-9.06 (m, 1H), 8.32-8.26 (m, 1H), 7.72 (dd, J = 8.5, 4.3 Hz, 1H), 7.63 (d, J = 1.9 Hz, 1H), 7.49 (d, J = 7.4 Hz, 1H), 7.14 (s, 1H), 6.27 (s, 2H), 6.13 (s, 1H), 5.65 (s, 1H), 4.26 (s, 1H), 3.77 (s, 1H), 3.28-3.20 (m, 1H), 3.07 (s, 2H), 2.89 (s, 2H), 2.63 (s, 2H), 1.89 (d, J = 1.9 Hz, 2H), 1.53 (s, 1H), 1.40 (s, 1H), 1.28 (s, 2H), 1.14 (s, 1H), 0.95-0.76 (m, 2H), 0.61 (s, 3H).
    (3S)-3-[(5-amino-1-{[5-
    (piperazine-1-carbonyl)
    quinolin-8-yl]methyl}-1H-
    pyrazolo[4,3-d]pyrimidin-7-
    yl)amino]hexan-1-ol
    138
    Figure US20230130516A1-20230427-C00149
      
    Figure US20230130516A1-20230427-C00150
         		274.6 41.7 LC/MS [M + H]+: 524.9 LC/MS RT (min)/Method: 1.02/D δ 8.92 (dd, J = 4.1, 1.7 Hz, 1H), 8.57 (d, J = 9.1 Hz, 1H), 7.65 (dt, J = 13.4, 3.9 Hz, 3H), 7.27 (d, J = 7.3 Hz, 1H), 6.21 (s, 2H), 5.93 (s, 1H), 5.77 (s, 2H), 4.67 (d, J = 5.1 Hz, 2H), 4.17 (s, 2H), 3.19 (d, J = 7.6 Hz, 1H), 2.28 (s, 3H), 2.14 (s, 4H), 1.89 (s, 3H).
    N7-[(5-methyl-1,2-oxazol-3-
    yl)methyl]-1-[(5-{6-methyl-
    2,6-diazaspiro[3.3]heptane-
    2-carbonyl}quinolin-8-
    yl)methyl]-1H-pyrazolo[4,3-
    d]pyrimidine-5,7-diamine
    139
    Figure US20230130516A1-20230427-C00151
      
    Figure US20230130516A1-20230427-C00152
          		 5.5 16.2 LC-MS [M + H]+ 534.3 LC/MS RT (min)/Method: 1.14/D δ 9.02 (dd, J = 4.3, 1.7 Hz, 1H), 8.79 (dd, J = 8.6, 1.7 Hz, 1H), 7.68 (dd, J = 8.6, 4.2 Hz, 1H), 7.60 (s, 1H), 7.44 (d, J = 7.3 Hz, 1H), 7.09 (d, J = 7.3 Hz, 1H), 6.32 (d, J = 16.7 Hz, 1H), 6.25 (d, J = 8.7 Hz, 1H), 6.11 (d, J = 16.8 Hz, 1H), 5.63 (s, 2H), 4.27-4.21 (m, 1H), 3.91-3.77 (m, 1H), 3.26-3.12 (m, 2H), 2.53 (s, 3H), 2.37 (s, 7H), 2.32 (t, J = 6.3 Hz, 2H), 1.90 (s, 4H), 1.52 (dd, J = 13.4, 6.5 Hz, 1H), 1.27 (ddd, J = 27.4, 13.2, 6.6 Hz, 2H), 1.04 (dt, J = 13.9, 7.2 Hz, 1H), 0.81 (dd, J = 14.9, 7.7 Hz, 2H), 0.58 (t, J = 7.3 Hz, 3H)
    (3S)-3-({5-amino-1-[(5-{[4-(2-
    hydroxyethyl)piperazin-1-
    yl]methyl}quinolin-8-
    yl)methyl]-1H-pyrazolo[4,3-
    d]pyrimidin-7-
    yl}amino)hexan-1-ol
    140
    Figure US20230130516A1-20230427-C00153
      
    Figure US20230130516A1-20230427-C00154
          		 8.3 21.1 LC-MS [M + H]+ 530.3 LC/MS RT (min)/Method: 1.05/D δ 9.01 (dd, 7 = 4.2,1.8 Hz, 1H), 8.81 (dd, J = 8.6, 1.9 Hz, 1H), 7.66 (dd, J = 8.6, 4.1 Hz, 1H), 7.60 (d, J = 3.0 Hz, 1H), 7.45 (d, J = 7.3 Hz, 1H), 7.10 (d, J = 7.3 Hz, 1H), 6.29 (t, J = 12.4 Hz, 2H), 6.10 (d, J = 16.7 Hz, 1H), 5.61 (s, 1H), 4.25 (s, 1H), 3.91 (s, 2H), 3.24-3.13 (m, 2H), 2.41 (s, 2H), 2.20 (d, J = 6.7 Hz, 2H), 2.15- 2.07 (m, 5H), 1.87 (s, 4H), 1.51 (d, J = 14.5 Hz, 1H), 1.27 (ddd, J = 35.2, 17.0, 10.2 Hz, 2H), 1.03 (dt, J = 14.4, 7.2 Hz, 1H), 0.81 (dt, J = 15.5, 7.3 Hz, 2H), 0.58 (t, J = 7.3 Hz, 3H).
    (3S)-3-({1-[(5-{[(3aR,6aS)-5-
    methyl-octahydropyrrolo
    [3,4-c]pyrrol-2-yl]methyl}-
    quinolin-8-yl)methyl]-5-amino-
    1H-pyrazolo[4,3-d]pyrimidin-
    7-yl}amino)hexan-1-ol
    141
    Figure US20230130516A1-20230427-C00155
      
    Figure US20230130516A1-20230427-C00156
          		 21.7 0.3 LC-MS [M + H]+ 475.2 LC/MS RT (min)/Method: 1.14/D δ 9.09-9.04 (m, 1H), 8.80 (d, J = 8.7 Hz, 1H), 7.73 (dd, J = 8.5, 4.2 Hz, 1H), 7.62 (s, 1H), 7.44 (d, J = 7.7 Hz, 1H), 7.19 (d, J = 7.7 Hz, 1H), 6.33 (d, J = 16.7 Hz, 1H), 6.14 (d, J = 16.7 Hz, 1H), 5.65 (s, 2H), 4.26 (s, 1H), 3.90 (s, 1H), 3.37 (d, J = 12.3 Hz, 1H), 3.24-3.08 (m, 2H), 1.95 (d, J = 12.9 Hz, 1H), 1.91 (s, 7H), 1.86 (s, 2H), 1.56-1.50 (m, 1H), 1.29 (d, J = 8.0 Hz, 2H), 1.06-0.98 (m, 1H), 0.82 (dd, J = 14.3, 7.0 Hz, 2H), 0.60 (t, J = 7.4 Hz, 3H)
    (3S)-3-[(5-amino-1-{[5-
    (piperid in-4-yl)quinolin-8-
    yl]methyl}-1H-pyrazolo[4,3-
    d]pyrimidin-7-
    yl)amino]hexan-1-ol
    142
    Figure US20230130516A1-20230427-C00157
      
    Figure US20230130516A1-20230427-C00158
          		 8.6 LC-MS [M + H]+ 559.3 LC/MS RT (min)/method: 1.34/D δ 9.04 (dd, J = 4.2, 1.6 Hz, 1H), 8.74 (d, J = 8.7 Hz, 1H), 7.71 (dd, J = 8.6, 4.2 Hz, 1H), 7.62 (s, 1H), 7.47 (d, J = 7.6 Hz, 1H), 7.19 (d, J = 7.6 Hz, 1H), 6.32 (d, J = 16.6 Hz, 2H), 6.11 (d, J = 16.6 Hz, 1H), 5.71 (s, 2H), 4.26 (s, 1H), 3.93 (d, J = 9.2 Hz, 2H), 3.31 (t, J = 11.6 Hz, 1H), 3.18 (t, J = 6.5 Hz, 1H), 2.67 (s, 2H), 2.60- 2.50 (m, 2H), 1.91 (s, 7H), 1.81 (d, J = 12.2 Hz, 3H), 1.57-1.49 (m, 4H), 1.34-1.25 (m, 2H), 1.00 (d, J = 9.4 Hz, 1H), 0.82-0.77 (m, 2H), 0.59 (t, J = 7.3 Hz, 3H)
    (3S)-3-{[5-amino-1-({5-[1-
    (oxan-4-yl)piperidin-4-
    yl]quinolin-8-yl}methyl)-1H-
    pyrazolo[4,3-d]pyrimidin-7-
    yl]amino}hexan-1-ol
    143
    Figure US20230130516A1-20230427-C00159
      
    Figure US20230130516A1-20230427-C00160
         		6.1 LC-MS [M + H]+ 517.0 LC/MS RT (min)/method: 1.25
    (3S)-3-{[5-amino-1-({5-[1-
    (propan-2-yl)piperidin-4-
    yl]quinolin-8-yl}methyl)-1H-
    pyrazolo[4,3-d]pyrimidin-7-
    yl]amino}hexan-1-ol
    • Pharmaceutical Compositions and Administration
  • In another aspect, there is provided a pharmaceutical composition comprising a compound of as disclosed herein, or of a conjugate thereof, formulated together with a pharmaceutically acceptable carrier or excipient. It may optionally contain one or more additional pharmaceutically active ingredients, such as a biologic or a small molecule drug. The pharmaceutical compositions can be administered in a combination therapy with another therapeutic agent, especially an anti-cancer agent.
  • The pharmaceutical composition may comprise one or more excipients. Excipients that may be used include carriers, surface active agents, thickening or emulsifying agents, solid binders, dispersion or suspension aids, solubilizers, colorants, flavoring agents, coatings, disintegrating agents, lubricants, sweeteners, preservatives, isotonic agents, and combinations thereof. The selection and use of suitable excipients is taught in Gennaro, ed., Remington: The Science and Practice of Pharmacy, 20th Ed. (Lippincott Williams & Wilkins 2003).
  • Preferably, a pharmaceutical composition is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion). Depending on the route of administration, the active compound may be coated in a material to protect it from the action of acids and other natural conditions that may inactivate it. The phrase “parenteral administration” means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion. Alternatively, the pharmaceutical composition can be administered via a non-parenteral route, such as a topical, epidermal or mucosal route of administration, for example, intranasally, orally, vaginally, rectally, sublingually or topically.
  • Pharmaceutical compositions can be in the form of sterile aqueous solutions or dispersions. They can also be formulated in a microemulsion, liposome, or other ordered structure suitable to achieve high drug concentration. The compositions can also be provided in the form of lyophilates, for reconstitution in water prior to administration.
  • The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the subject being treated and the particular mode of administration and will generally be that amount of the composition which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 0.01 percent to about ninety-nine percent of active ingredient, preferably from about 0.1 percent to about 70 percent, most preferably from about 1 percent to about 30 percent of active ingredient in combination with a pharmaceutically acceptable carrier.
  • Dosage regimens are adjusted to provide a therapeutic response. For example, a single bolus may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. “Dosage unit form” refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic response, in association with the required pharmaceutical carrier.
  • The dosage ranges from about 0.0001 to 100 mg/kg, and more usually 0.01 to 5 mg/kg, of the host body weight. For example dosages can be 0.3 mg/kg body weight, 1 mg/kg body weight, 3 mg/kg body weight, 5 mg/kg body weight or 10 mg/kg body weight or within the range of 1-10 mg/kg, or alternatively 0.1 to 5 mg/kg. Exemplary treatment regimens are administration once per week, once every two weeks, once every three weeks, once every four weeks, once a month, once every 3 months, or once every three to 6 months. Preferred dosage regimens include 1 mg/kg body weight or 3 mg/kg body weight via intravenous administration, using one of the following dosing schedules: (i) every four weeks for six dosages, then every three months; (ii) every three weeks; (iii) 3 mg/kg body weight once followed by 1 mg/kg body weight every three weeks. In some methods, dosage is adjusted to achieve a plasma antibody concentration of about 1-1000 μg/mL and in some methods about 25-300 μg/mL.
  • A “therapeutically effective amount” of a compound of the invention preferably results in a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction. For example, for the treatment of tumor-bearing subjects, a “therapeutically effective amount” preferably inhibits tumor growth by at least about 20%, more preferably by at least about 40%, even more preferably by at least about 60%, and still more preferably by at least about 80% relative to untreated subjects. A therapeutically effective amount of a therapeutic compound can decrease tumor size, or otherwise ameliorate symptoms in a subject, which is typically a human but can be another mammal. Where two or more therapeutic agents are administered in a combination treatment, “therapeutically effective amount” refers to the efficacy of the combination as a whole, and not each agent individually.
  • The pharmaceutical composition can be a controlled or sustained release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. See, e.g., Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.
  • Therapeutic compositions can be administered via medical devices such as (1) needleless hypodermic injection devices; (2) microinfusion pumps; (3) transdermal devices; (4) infusion devices; and (5) osmotic devices.
  • In certain embodiments, the pharmaceutical composition can be formulated to ensure proper distribution in vivo. For example, to ensure that the therapeutic compounds of the invention cross the blood-brain barrier, they can be formulated in liposomes, which may additionally comprise targeting moieties to enhance selective transport to specific cells or organs.
    • Industrial Applicability and Uses
  • TLR7 agonist compounds disclosed herein can be used for the treatment of a disease or condition that can be ameliorated by activation of TLR7.
  • In one embodiment, the TLR7 agonist is used in combination with an anti-cancer immunotherapy agent—also known as an immuno-oncology agent. An anti-cancer immunotherapy agent works by stimulating a body's immune system to attack and destroy cancer cells, especially through the activation of T cells. The immune system has numerous checkpoint (regulatory) molecules, to help maintain a balance between its attacking legitimate target cells and preventing it from attacking healthy, normal cells. Some are stimulators (up-regulators), meaning that their engagement promotes T cell activation and enhances the immune response. Others are inhibitors (down-regulators or brakes), meaning that their engagement inhibits T cell activation and abates the immune response. Binding of an agonistic immunotherapy agent to a stimulatory checkpoint molecule can lead to the latter's activation and an enhanced immune response against cancer cells. Reciprocally, binding of an antagonistic immunotherapy agent to an inhibitory checkpoint molecule can prevent down-regulation of the immune system by the latter and help maintain a vigorous response against cancer cells. Examples of stimulatory checkpoint molecules are B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, CD40, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3 and CD28H. Examples of inhibitory checkpoint molecules are CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, Galectin 9, CEACAM-1, BTLA, CD69, Galectin-1, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIR1, TIM-1, CD96 and TIM-4.
  • Whichever the mode of action of an anti-cancer immunotherapy agent, its effectiveness can be increased by a general up-regulation of the immune system, such as by the activation of TLR7. Thus, in one embodiment, this specification provides a method of treating a cancer, comprising administering to a patient suffering from such cancer a therapeutically effective combination of an anti-cancer immunotherapy agent and a TLR7 agonist as disclosed herein. The timing of administration can be simultaneous, sequential, or alternating. The mode of administration can systemic or local. The TLR7 agonist can be delivered in a targeted manner, via a conjugate.
  • Cancers that could be treated by a combination treatment as described above include acute myeloid leukemia, adrenocortical carcinoma, Kaposi sarcoma, lymphoma, anal cancer, appendix cancer, teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, bronchial tumor, carcinoid tumor, cardiac tumor, cervical cancer, chordoma, chronic lymphocytic leukemia, chronic myeloproliferative neoplasm, colon cancer, colorectal cancer, craniopharyngioma, bile duct cancer, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, Ewing sarcoma, eye cancer, fallopian tube cancer, gallbladder cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, germ cell tumor, hairy cell leukemia, head and neck cancer, heart cancer, liver cancer, hypopharngeal cancer, pancreatic cancer, kidney cancer, laryngeal cancer, chronic myelogenous leukemia, lip and oral cavity cancer, lung cancer, melanoma, Merkel cell carcinoma, mesothelioma, mouth cancer, oral cancer, osteosarcoma, ovarian cancer, penile cancer, pharyngeal cancer, prostate cancer, rectal cancer, salivary gland cancer, skin cancer, small intestine cancer, soft tissue sarcoma, testicular cancer, throat cancer, thyroid cancer, urethral cancer, uterine cancer, vaginal cancer, and vulvar cancer.
  • Anti-cancer immunotherapy agents that can be used in combination therapies as disclosed herein include: AMG 557, AMP-224, atezolizumab, avelumab, BMS 936559, cemiplimab, CP-870893, dacetuzumab, durvalumab, enoblituzumab, galiximab, IMP321, ipilimumab, lucatumumab, MEDI-570, MEDI-6383, MEDI-6469, muromonab-CD3, nivolumab, pembrolizumab, pidilizumab, spartalizumab, tremelimumab, urelumab, utomilumab, varlilumab, vonlerolizumab. Table B below lists their alternative name(s) (brand name, former name, research code, or synonym) and the respective target checkpoint molecule.
  • TABLE B
    Immunotherapy Agent Alternative Name(s) Target
    AMG 557 B7RP-1 (ICOSL)
    AMP-224 PD-1
    Atezolizumab MPDL3280A, RO5541267, PD-L1
    TECENTRIQ ®
    Avelumab BAVENCIO ® PD-L1
    BMS 936559 PD-L1
    Cemiplimab LIBTAYO ® PD-1
    CP-870893 CD40
    Dacetuzumab CD40
    Durvalumab IMFINZI ® PD-L1
    Enoblituzumab MGA271 B7-H3
    Galiximab B7-1 (CD80)
    IMP321 LAG-3
    Ipilimumab YERVOY ® CTLA-4
    Lucatumumab CD40
    MEDI-570 ICOS (CD278)
    MEDI-6383 OX40
    MEDI-6469 OX40
    Muromonab-CD3 CD3
    Nivolumab OPDIVO ® PD-1
    Pembrolizumab KEYTRUDA ® PD-1
    Pidilizumab MDV9300 PD-1
    Spartalizumab PDR001 PD-1
    Tremelimumab Ticilimumab, CP-675, CTLA-4
    CP-675, 206
    Urelumab BMS-663513 CD137
    Utomilumab PF-05082566 CD137
    Varlilumab CDX 1127 CD27
    Vonlerolizumab RG7888, MOXR0916, OX40
    pogalizumab
  • In one embodiment of a combination treatment with a TLR7 agonist, the anti-cancer immunotherapy agent is an antagonistic anti-CTLA-4, anti-PD-1, or anti-PD-L1 antibody. The cancer can be lung cancer (including non-small cell lung cancer), pancreatic cancer, kidney cancer, head and neck cancer, lymphoma (including Hodgkin's lymphoma), skin cancer (including melanoma and Merkel skin cancer), urothelial cancer (including bladder cancer), gastric cancer, hepatocellular cancer, or colorectal cancer.
  • In another embodiment of a combination treatment with a TLR7 agonist, the anti-cancer immunotherapy agent is an antagonistic anti-CTLA-4 antibody, preferably ipilimumab.
  • In another embodiment of a combination treatment with a TLR7 agonist, the anti-cancer immunotherapy agent is an antagonistic anti-PD-1 antibody, preferably nivolumab or pembrolizumab.
  • The TLR7 agonists disclosed herein also are useful as vaccine adjuvants.
  • The practice of this invention can be further understood by reference to the following examples, which are provided by way of illustration and not of limitation.
    • Analytical Procedures NMR
  • The following conditions were used for obtaining proton nuclear magnetic resonance (NMR) spectra: NMR spectra were taken in either 400 Mz or 500 Mhz Bruker instrument using either DMSO-d6 or CDCl3 as solvent and internal standard. The crude NMR data was analyzed by using either ACD Spectrus version 2015-01 by ADC Labs or MestReNova software.
  • Chemical shifts are reported in parts per million (ppm) downfield from internal tetramethylsilane (TMS) or from the position of TMS inferred by the deuterated NMR solvent. Apparent multiplicities are reported as: singlet-s, doublet-d, triplet-t, quartet-q, or multiplet-m. Peaks that exhibit broadening are further denoted as br. Integrations are approximate. It should be noted that integration intensities, peak shapes, chemical shifts and coupling constants can be dependent on solvent, concentration, temperature, pH, and other factors. Further, peaks that overlap with or exchange with water or solvent peaks in the NMR spectrum may not provide reliable integration intensities. In some cases, NMR spectra may be obtained using water peak suppression, which may result in overlapping peaks not being visible or having altered shape and/or integration.
    • Liquid Chromatography
  • The following preparative and/or analytical liquid chromatography methods were used:
  • Preparative HPLC/MS Method A: Column: XBridge C18, 200 mm×19 mm, 5- m particles; Mobile Phase A: 5:95 acetonitrile: water with 0.05% TFA; Mobile Phase B: 95:5 acetonitrile: water with 0.05% TFA; Gradient: 0-47% B over 20 minutes, then a 0-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25° C.
  • Preparative HPLC/MS Method B: Column: XBridge C18, 150 mm×19 mm, 5- m particles; Mobile Phase A: water with 0.05% TFA; Mobile Phase B: acetonitrile with 0.05% TFA; Gradient: a 2-minute hold at 10% B, 10-100% B over 20 minutes, then a 3-minute hold at 100% B; Flow Rate: 19 mL/min; Column Temperature: 25° C.
  • Preparative HPLC/MS Method C: Column: XBridge C18, 200 mm×19 mm, 5-am particles; Mobile Phase A: 5:95 acetonitrile: water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10 mM 5 ammonium acetate; Gradient: 1-65% B over 20 minutes, then a 0-minute hold at 100% B; Flow rate: 20 mL/min; Column Temperature: 25° C.
  • Analytical LC/MS Method D: Column: Waters XBridge C18, 2.1 mm×50 mm, 1.7 am particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% TFA; Mobile Phase B: 95:5 acetonitrile: water 0.1% TFA; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.50 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm).
  • Analytical LC/MS Method E: Column: Acquity UPLC BEH C18, 2.1 mm×50 mm, 1.7 am particles; Mobile Phase A: water with 0.1% formic acid; Mobile Phase B: acetonitrile with 0.1% formic acid; Temperature: 40° C.; Gradient: a 0.2 min hold at 5% B; 5% B to 95% B over 2.3 min, then a 0.20 min hold at 95% B; Flow: 1 mL/min; Detection: UV (254 nm & 220 nm).
  • Analytical LC/MS Method F: Column: Acquity UPLC BEH C18, 2.1 mm×50 mm, 1.7 am particles; Mobile Phase A: water with 0.1% formic acid; Mobile Phase B: acetonitrile with 0.1% formic acid; Temperature: 40° C.; Gradient: a 0.2 min hold at 50% B; 50% B to 95% B over 2.3 min, then a 0.20 min hold at 95% B; Flow: 1 mL/min; Detection: UV (254 nm & 220 nm).
    • Synthesis—General Procedures
  • Generally, the procedures disclosed herein produce a mixture of regioisomers, alkylated at the 1H or 2H position of the pyrazolopyrimidine ring system (which are also referred to as N1 and N2 regioisomers, respectively, alluding to the nitrogen that is alkylated). For brevity, the N2 regioisomers are not shown, but it is to be understood that they are present in the initial product mixture and separated at a later time, for example by preparative HPLC.
  • Figure US20230130516A1-20230427-C00161
  • The mixture of regioisomers can be separated at an early stage of the synthesis and the remaining synthetic steps carried out with the 1H regioisomer or, alternatively, the synthesis can be progressed carrying the mixture of regioisomers and separation effected at a later stage, as desired.
  • The compounds of the present disclosure can be prepared by a number of methods well known to one skilled in the art of synthetic organic chemistry. These methods include those described below, or variations thereof. Preferred methods include, but are not limited to, those described below in the Schemes below. The Schemes are intended to be generic, but in some instances a feature may be depicted specifically (e.g., a methyl ester or particular regioisomer) as a matter of convenience.
  • Figure US20230130516A1-20230427-C00162
  • Ra can be, in Scheme 1 and other occurrences thereof, for example,
  • Figure US20230130516A1-20230427-C00163
  • or other suitable moiety. RbNHRc is, in Scheme 1 and other occurrences thereof, a primary or secondary amine. Ra, Rb, and/or Rc can have functional groups masked by protecting group that is removed at the appropriate time during the synthetic process.
  • Compound 9 can be prepared by a synthetic sequence outlined in Scheme 1. Quinoline 1 (CAS Reg. No. 82867-40-6) is converted to hydrazine intermediate 2 with BOC protected hydrazine. After treatment with hydrochloric acid, intermediate 3 is obtained. Intermediate 4 is obtained by mixing ethyl-2-chloro-2-oxoacetate and (Z)-N,N-dimethyl-2-nitroethen-1-amine, and then adding intermediate 3. Intermediate 4 is converted to intermediate 5 by reducing the nitro group to an amine group with zinc. By treating intermediate 5 with 1,3-bis(methoxycarbonyl)-2-thioseudourea with acetic acid and then sodium methoxide, intermediate 6 is obtained. Intermediate 7 is synthesized by reaction of intermediate 6 with RaNH2 in the presence of BOP and DBU. After hydroxylation with NaOH, intermediate 8 is obtained. In the last step of Scheme 1, compound 9 is prepared by amide coupling with RbNHRc.
  • Figure US20230130516A1-20230427-C00164
  • Scheme 2 above shows an alternative method for the preparation of intermediate 6, by coupling quinoline 1 and methyl 4-nitro-1H-pyrazole-5-carboxylate (CAS Reg. No. 138786-86-9) to form intermediate 10. Intermediate 11 is obtained by reducing the nitro group of intermediate 10 to an amine group with zinc. Intermediate 6 is obtained by treating intermediate 11 with 1,3-bis(methoxycarbonyl)-2-thiopseudourea with acetic acid and then sodium methoxide, as shown in Step 3 of Scheme 2.
  • Figure US20230130516A1-20230427-C00165
  • Scheme 3 above shows an alternative method for preparing compound 9, by hydroxylation of intermediate 6 to form acid 12. After amide coupling, intermediate 13 is obtained. In the last step, compound 9 is obtained by treating intermediate 13 with RaNH2 in the presence of BOP and DBU.
  • Figure US20230130516A1-20230427-C00166
    Figure US20230130516A1-20230427-C00167
  • Rd is, in Scheme 4 and other occurrences thereof, for example, H, F, CO2Me (or Et), or cyano. Re is, in Scheme 4 and other occurrences thereof, for example, H or CO2Me (or Et) or a protecting group.
  • The method of Scheme 4 above can be used to to prepare compound 20. Bromination of compound 14 with NBS (N-bromosuccinimide) forms intermediate 15. Intermediate 16 is obtained by coupling intermediate 15 with a quinoline compound where Rd is a carboxylate ester. (We have observed that having a bromine at the C3 position generally leads to a higher N1/N2 ratio in the product mixture.) The bromine group of intermediate 16 is removed by catalytic hydrogenation to afford intermediate 17. The carboxylic ester in intermediate 17 is reduced with LiAlH4 or LiBH4 to generate intermediate 18. Intermediate 19 is obtained by treating intermediate 18 with thionyl chloride. Compound 20 is obtained by treating with an amine RbNHRc. If Re comprises a carbamate or other protecting group, the latter may be removed at this stage with sodium hydroxide or appropriate deprotecting reagent.
  • Figure US20230130516A1-20230427-C00168
  • Scheme 5 above shows an alternative method for the preparation of compound 20 by reductive amination. Intermediate 17 is reduced to amine 18a (in the instance in which Rd is a cyano group). Amine 18a is then subjected to reductive amination with a corresponding ketone to form compound 20.
  • Figure US20230130516A1-20230427-C00169
  • Scheme 6 above shows a method for the preparation of compound 23. Starting with intermediate 19 (where Rd is carboxylic ester and Re is carbamate protecting group), methylation can be effected by treating intermediate 19 with 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane and PdCl2(dppf)-CH2Cl2 adduct to afford intermediate 21. After hydrolysis with sodium hydroxide, intermediate 22 is obtained. In the final step, compound 23 is obtained by amide formation of intermediate 22 with RbNHRc.
  • Figure US20230130516A1-20230427-C00170
    Figure US20230130516A1-20230427-C00171
  • Rf is, in Scheme 7 and other occurrences thereof, an amide or amine moiety and Hal is halogen, such as Cl or Br.
  • Compound 30 can be prepared the method of Scheme 7 above, by coupling a pyrazolopyrimidine core and a quinoline moiety. The nitro group of starting material 24 is reduced to an amine group of compound 25. Pyrazolopyrimidine 26 is obtained by treating intermediate 25 with 1,3-bis(methoxycarbonyl)-2-thiopseudourea with acetic acid and then sodium methoxide. Quinoline compound 27 is prepared similarly to the reactions described in other Schemes hereinabove. The coupling of pyrazolopyrimidine 26 with quinoline 27 affords intermediate 28. Intermediate 29 is obtained by treating intermediate 28 with amine RaNH2 in the presence of BOP and DBU. In the last step, carbamate protecting group of intermediate 29 is removed with sodium hydroxide to generate compound 30.
  • Figure US20230130516A1-20230427-C00172
    Figure US20230130516A1-20230427-C00173
    Figure US20230130516A1-20230427-C00174
  • Scheme 8 above shows how compounds where W is
  • Figure US20230130516A1-20230427-C00175
  • with n equals 0 can be made.
  • Starting material 31 (CAS Reg. No. 611-32-5) is converted to intermediate 32 by bromination. After coupling with tert-butyl 4-(3,3,4,4-tetramethylborolan-1-yl)-3,6-dihydropyridine-1(2H)-carboxylate, intermediate 33 is obtained. Intermediate 34 is obtained by hydrogenation. After treated with NBS and AIBN, Intermediate 35 is obtained. Intermediate 37 is obtained by mixing intermediate 35 and 36 with base. By coupling with intermediate 38, Intermediate 37 is converted to intermediate 39. Iodo group of intermediate 39 is removed by reduction to form intermediate 40. By hydrolysis with Sodium Hydroxide and acids, Compound 41 is obtained. Compound 42 is obtained by reductive amination of Compound 41 with a ketone RbRc(═O).
    • Synthesis—Specific Examples
  • To further illustrate the foregoing, the following non-limiting, the following exemplary synthetic schemes are included. Variations of these examples within the scope of the the claims are within the purview of one skilled in the art and are considered to fall within the scope of this disclosure. The reader will recognize that the skilled artisan, provided with the present disclosure and skilled in the relevant art, will be able to prepare and use the compounds disclosed herein without exhaustive examples.
  • Analytical data for compounds numbered 100 and higher are found in Table A.
    • Example 1—Compound 111
  • Figure US20230130516A1-20230427-C00176
  • Step 1. TEA (1.493 mL, 10.71 mmol) was added to a solution of methyl 8-(bromo-methyl)quinoline-5-carboxylate (1 g, 3.57 mmol), tert-butyl hydrazinecarboxylate (2.359 g, 17.85 mmol) in DMF (4 mL). The reaction mixture was stirred at 75° C. for 4 h, diluted with 100 mL of water, and extracted with EtOAc (3×75 mL). The organic phases were combined, concentrated and purified by column chromatography: Column: 40 g CombiFlash column; Mobile Phase A: hexanes; Mobile Phase B: ethyl acetate; Gradient: a 1 min hold at 0% B, 0-50% B over 14 min, then a 3 min hold at 100% B; Flow Rate: 40 mL/min; Column Temperature: 25° C. The fractions containing expected product were combined, concentrated and dried under high vacuum for 1 h. to yield methyl 8-((2-(tert-butoxycarbonyl)hydrazineyl)methyl)quinoline-5-carboxylate (0.71 g, 60.0% yield).
  • LC-MS m/z 332.2 [M+H]+; Retention Time: 1.61 min (Method E).
  • Step 2. HCl in dioxane (5.36 mL, 21.43 mmol) was added to a solution of methyl 8-((2-(tert-butoxycarbonyl)hydrazineyl)methyl)quinoline-5-carboxylate (0.71 g, 2.143 mmol) in MeOH (10 mL). The reaction mixture was stirred at RT overnight, after which it turned into a slurry. The precipitate was collected by filtration and dried under high vacuum for 1 h to yield the HCl salt of methyl 8-(hydrazineylmethyl)quinoline-5-carboxylate (0.58 g, 1.705 mmol, 79.6% yield).
  • LC-MS m/z 232.1 [M+H]+; Retention Time: 1.05 min (Method E).
  • Step 3. A solution of (Z)-N,N-dimethyl-2-nitroethen-1-amine (1.528 g, 13.16 mmol) in DCM (26 mL) and pyridine (17.49 mL, 216 mmol) was cooled to −10° C. Ethyl 2-chloro-2-oxoacetate (2.226 mL, 19.89 mmol) was added slowly. The reaction mixture was warmed to RT over 2 h and stirred at RT overnight. The reaction mixture was concentrated to 20 mL. Methyl 8-(hydrazineylmethyl)quinoline-5-carboxylate HCl salt (1 g, 4.32 mmol) was added. The resultant mixture was stirred at RT for 2 h. The reaction mixture was concentrated and purified by reverse phase column chromatography: Column: 50 g CombiFlash Aq column; Mobile Phase A: water with 0.05 TFA; Mobile Phase B: acetonitrile with 0.05% TFA; Gradient: a 1 min hold at 0% B, 0-50% B over 12 min, then a 3 min hold at 100% B; Flow Rate: 40 mL/min; Column Temperature: 25° C. The fractions containing the expected product were combined and freeze-dried to yield methyl 8-((5-(ethoxycarbonyl)-4-nitro-1H-pyrazol-1-yl)methyl)quinoline-5-carboxylate (627 mg, 1.633 mmol, 37.8% yield) as a solid.
  • LC-MS m/z 385.2 [M+H]+; Retention Time: 2.22 min (Method E).
  • Step 4. Zinc (358 mg, 5.48 mmol) was added to a solution of methyl 8-((5-(ethoxycarbonyl)-4-nitro-1H-pyrazol-1-yl)methyl)quinoline-5-carboxylate (421 mg, 1.095 mmol) and ammonium formate (691 mg, 10.95 mmol) in MeOH (3 mL) and THF (5 mL). The reaction mixture was stirred at RT for 1 h. LCMS analysis showed the reaction was complete. The reaction mixture was filtered, concentrated, and freeze-dried with acetonitrile and water to yield crude methyl 8-((4-amino-5-(ethoxycarbonyl)-1H-pyrazol-1-yl)methyl)quinoline-5-carboxylate (285 mg, 0.804 mmol, 73.5%).
  • LC-MS m/z 355.2 [M+H]+; Retention Time: 1.83 min (Method E).
  • Step 5. Acetic acid (0.64623 mL, 11.28 mmol) and TFA (0.07 mL) were added to a mixture of 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea (279 mg, 1.355 mmol) and methyl 8-((4-amino-5-(ethoxycarbonyl)-1H-pyrazol-1-yl)methyl)quinoline-5-carboxylate (400 mg, 1.129 mmol) in MeOH (20 mL). The reaction mixture was stirred at RT overnight. LCMS analysis showed conversion to an intermediate (LC-MS m/z 513.3 [M+H]+). NaOMe (4.2 mL, 33.87 mmol) was added. The reaction mixture stirred at RT for 1 h. Acetic acid was added to adjust the pH to 5. The product was collected by filtration and dried under high vacuum for overnight to yield methyl 8-((7-hydroxy-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylate (313 mg, 0.765 mmol, 67.9% yield). LC-MS m/z 409.2 [M+H]+; Retention Time: 1.67 min (Method E).
  • Step 6. ((1H-Benzo[d][1,2,3]triazol-1-yl)oxy)tris(dimethylamino)phosphonium hexafluorophosphate(V) (401 mg, 0.906 mmol) was added to a solution of methyl 8-((7-hydroxy-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylate (185 mg, 0.453 mmol), (S)-3-aminohexan-1-ol (HCl salt, 348 mg, 2.265 mmol) and 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine (0.305 mL, 2.039 mmol) in DMSO (1.5 mL). The reaction mixture was stirred at 70° C. overnight and worked up with EtOAc, brine, and water. The combined organic phases were concentrated and dried under high vacuum to yield a crude intermediate (165 mg, LC-MS m/z 508.2 [M+H]+). To a solution of the crude intermediate (165 mg) in dioxane (0.6 mL), NaOH (10 N, 0.3 mL) was added. The reaction mixture was stirred at 70° C. for 5 h, neutralized with 0.2 mL of acetic acid, and purified by Method B. The fractions containing expected product were combined and freeze-dried to yield (S)-8-((5-amino-7-((1-hydroxyhexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-quinoline-5-carboxylic acid (82 mg, 0.188 mmol, 41.6% yield for 2 steps).
  • LC-MS m/z 436.2 [M+H]+; Retention Time: 1.33 min (Method E).
  • Step 7. DIPEA (0.032 mL, 0.184 mmol) was added to a solution of (S)-8-((5-amino-7-((1-hydroxyhexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylic acid (20 mg, 0.046 mmol), 2-(piperazin-1-yl)ethan-1-ol (0.023 mL, 0.184 mmol) and HATU (26.2 mg, 0.069 mmol) in DMF (0.5 mL). The reaction mixture was stirred at 20° C. for 3 h, neutralized with 0.05 mL acetic acid, and purified by Method C. Fractions containing Compound 111 were combined and dried via centrifugal evaporation (2.74 mg, 0.005 mmol, 14.5%).
  • The following compounds were analogously prepared: Compound 108, Compound 112, Compound 113, Compound 114, Compound 125, Compound 126, Compound 127, Compound 128, Compound 129, Compound 130, Compound 131, Compound 132, Compound 133, Compound 134, Compound 135, Compound 136, and Compound 137.
    • Example 2—Compound 121
  • Figure US20230130516A1-20230427-C00177
  • Step 1. LiCl (0.908 g, 21.42 mmol) was added to a solution of methyl 8-(bromo-methyl)quinoline-5-carboxylate (3 g, 10.71 mmol) in DMF (20 mL). The reaction mixture was stirred at RT for 30 min. LCMS analysis showed the starting material converted to a chloro intermediate (LC-MS m/z 236.1 [M+H]+). Methyl 4-nitro-1H-pyrazole-5-carboxylate (3 g, 17.53 mmol) and Cs2CO3 (6.98 g, 21.42 mmol) were added. The reaction mixture was stirred at RT overnight. LCMS analysis showed the reaction was complete and generated 2 isomers (retention time: 1.874 min & 1.992 min at 3 min acidic run, M+H/z 371.1). The reaction mixture was worked up with EtOAc, water and brine. The organic phases were combined, concentrated and purified by column chromatography: Column: 80 g CombiFlash column; Mobile Phase A: hexanes; Mobile Phase B: ethyl acetate; Gradient: a 2 min hold at 0% B, 0-40% B over 24 min, then a 3 min hold at 100% B; Flow Rate: 60 mL/min; Column Temperature: 25° C. The early fractions with 1.992 min retention time were combined, concentrated and dried under vacuum to yield methyl 8-((5-(methoxycarbonyl)-4-nitro-1H-pyrazol-1-yl)methyl)quinoline-5-carboxylate (635 mg, 1.715 mmol, 16.01% yield).
  • LC-MS m/z 371.1 [M+H]+; Retention Time: 1.87 min (Method E).
  • Step 2. Zinc (785 mg, 12.00 mmol) was added portion-wise over 1 h to a solution of methyl 8-((5-(methoxycarbonyl)-4-nitro-1H-pyrazol-1-yl)methyl)quinoline-5-carboxylate (635 mg, 1.715 mmol) in MeOH (7 mL) and THF (15 mL). The reaction mixture was stirred at RT for 2 h, diluted with EtOAc (50 mL), and filtered. The filtrate was concentrated and dried to yield methyl 8-((4-amino-5-(methoxycarbonyl)-1H-pyrazol-1-yl)methyl)quinoline-5-carboxylate salt (685 mg, 2.013 mmol, 117% yield).
  • LC-MS m/z 341.1 [M+H]+; Retention Time: 1.61 min (Method E).
  • Step 3. Acetic acid (0.530 mL, 9.26 mmol) and TFA (0.4 mL) were added to a solution of 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea (458 mg, 2.221 mmol) and methyl 8-((4-amino-5-(methoxycarbonyl)-1H-pyrazol-1-yl)methyl)quinoline-5-carboxylate (630 mg, 1.851 mmol) in MeOH (15 mL). The reaction mixture was stirred at RT overnight. LCMS analysis showed the reaction was complete, affording an intermediate (LC-MS m/z 499.2 [M+H]+). Sodium methanolate (5.78 mL, 46.3 mmol) was added. The reaction mixture was stirred at RT for 10 min. LCMS analysis showed reaction was complete and another intermediate had formed (LC-MS m/z 409.2 [M+H]+). The reaction mixture was concentrated to dryness. 2 mL of DMF and 1 mL of NaOH in water (10 N) were added to the residue. The reaction mixture was stirred at 60° C. for 3 h, neutralized with 1 mL of acetic acid, and concentrated under vacuum. The residue was purified by reverse phase column chromatography: Column: 150 g CombiFlash Aq column; Mobile Phase A: water with 0.05 TFA; Mobile Phase B: acetonitrile with 0.05% TFA; Gradient: a 2 min hold at 0% B, 0-40% B over 23 min, then a 4 min hold at 100% B; Flow Rate: 75 mL/min; Column Temperature: 25° C. The fractions containing expected product were combined and freeze-dried to yield 8-((5-amino-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylic acid (265 mg, 0.788 mmol, 42.6% yield). LC-MS m/z 337.1 [M+H]+; Retention Time: 1.05 min (Method E).
  • Step 4. DIPEA (50 uL) was added to a solution of 8-((5-amino-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylic acid (28 mg, 0.083 mmol) and HATU (38.0 mg, 0.100 mmol) in DMF (0.5 mL). The reaction mixture was stirred at RT for 1 h, neutralized with 0.1 ml of acetic acid, and purified by Method B. The fractions containing the expected product were combined and freeze-dried to yield 8-((5-amino-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-N-(1-methylpiperidin-4-yl)quinoline-5-carboxamide(25 mg, 0.058 mmol, 69.7%).
  • LC-MS m/z 433.2 [M+H]+; Retention Time: 0.96 min (Method E).
  • Step 5. ((1H-benzo[d][1,2,3]triazol-1-yl)oxy)tris(dimethylamino)phosphonium hexafluorophosphate(V) (51.1 mg, 0.116 mmol) was added to a solution of 8-((5-amino-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-N-(1-methylpiperidin-4-yl)quinoline-5-carboxamide (25 mg, 0.058 mmol), 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine (0.039 mL, 0.260 mmol) and (S)-3-aminohexan-1-ol (27.1 mg, 0.231 mmol) in DMSO (1.25 mL). The reaction mixture was stirred at 70° C. for 5 h and freeze-dried with acetonitrile and water. The residue was purified by Method C. Fractions containing the desired product were combined and dried via centrifugal evaporation to yield Compound 121 (9.39 mg, 0.018 mmol, 30.4%).
  • The following compounds were analogously prepared: Compound 115, Compound 116, Compound 117, Compound 118, Compound 122, Compound 124, and Compound 138.
    • Example 3—Compound 110
  • Figure US20230130516A1-20230427-C00178
  • Step 1. ((1H-benzo[d][1,2,3]triazol-1-yl)oxy)tris(dimethylamino)phosphonium hexafluorophosphate(V) (26.0 mg, 0.059 mmol) was added to a solution of methyl (7-hydroxy-1-(quinolin-8-ylmethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (10.3 mg, 0.029 mmol; prepared analogously per Example 1 from 8-(bromomethyl)quinoline), (S)-3-aminohexan-1-ol (17.23 mg, 0.147 mmol) and 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine (8.79 μl, 0.059 mmol) in DMSO (0.5 mL). The reaction mixture was stirred at 70° C. for 3 h, neutralized with 0.2 mL acetic acid, and purified by Method B. The fractions containing expected product were combined and freeze-dried to yield methyl (S)-(7-((1-hydroxyhexan-3-yl)amino)-1-(quinolin-8-ylmethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (7.3 mg, 0.016 mmol, 55.2% yield).
  • LC-MS m/z 450.1 [M+H]+; Retention Time: 1.64 min (Method E).
  • Step 2. Aqueous NaOH (0.3 mL, 3.00 mmol) was added to methyl (S)-(7-((1-hydroxy-hexan-3-yl)amino)-1-(quinolin-8-ylmethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (7.3 mg, 0.016 mmol) in dioxane (0.6 mL). The reaction mixture was stirred at 70° C. for 4 h, neutralized with HOAc, and purified by Method B to yield Compound 110 (0.80 mg, 0.002 mmol, 12.6%).
    • Example 4—Compound 119
  • Figure US20230130516A1-20230427-C00179
  • Step 1. 1-Bromopyrrolidine-2,5-dione (N-bromo succinimide (NBS), 2.059 g, 11.57 mmol) was added to a solution of methyl (7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (2.2 g, 10.52 mmol) in DMF (20 mL). The reaction mixture was stirred at RT for 1 h and with EtOAc, water and brine. The organic phases were combined, concentrated and dried under high vacuum for 1 h to yield methyl (3-bromo-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (2.85 g, 9.89 mmol, 94% yield).
  • LC-MS m/z 288.0; 290.0 [M+H]+; Retention Time: 1.07 min (Method E).
  • Steps 2 & 3. LiCl (143 mg, 3.37 mmol) was added to a solution of methyl 8-(bromomethyl)quinoline-5-carboxylate (236 mg, 0.842 mmol) in DMF (3 mL). The reaction mixture was stirred at RT for 30 min. LCMS analysis showed complete formation of the chloro intermediate, LC-MS m/z 236.1 [M+H]+. Methyl (3-bromo-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (291 mg, 1.010 mmol) and Cs2CO3 (1098 mg, 3.37 mmol) were added. The reaction mixture was stirred at RT for 120 h and worked up with EtOAc, water and brine. The organic phases were combined, concentrated and purified by column chromatography: Column: 24 g CombiFlash column; Mobile Phase A: hexanes; Mobile Phase B: ethyl acetate; Gradient: a 1 min hold at 0% B, 0-70% B over 11 min, then a 2 min hold at 100% B; Flow Rate: 35 mL/min; Column Temperature: 25° C. The fractions containing product were combined, concentrated and dried under high vacuum to yield methyl 8-((3-bromo-7-hydroxy-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylate (167 mg, 0.343 mmol, 40.7% yield).
  • LC-MS m/z 487.1; 489.1 [M+H]+; Retention Time: 1.89 min (Method E).
  • Step 4. ((1H-Benzo[d][1,2,3]triazol-1-yl)oxy)tris(dimethylamino)phosphonium hexafluorophosphate(V) (178 mg, 0.402 mmol) was added to a solution of methyl 8-((3-bromo-7-hydroxy-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylate (98 mg, 0.201 mmol), (S)-3-aminohexan-1-ol HCl salt (155 mg, 1.006 mmol) and 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine (92 mg, 0.603 mmol) in DMSO (2.5 mL). The reaction mixture was stirred at 70° C. overnight, neutralized with HOAc, and purified (Method B). The fractions containing the product were combined and freeze-dried to yield methyl (S)-8-((3-bromo-7-((1-hydroxyhexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylate (63 mg, 0.107 mmol, 53.4% yield). LC-MS m/z 586.2 [M+H]+; Retention Time: 2.00 min (Method E).
  • Step 5. A mixture of methyl (S)-8-((3-bromo-7-((1-hydroxyhexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylate (50 mg, 0.085 mmol), K2CO3 (41.2 mg, 0.298 mmol) and PdCl2(dppf)-CH2Cl2 adduct (6.24 mg, 8.53 μmol) in dioxane (0.35 mL) and H2O (0.07 mL) was bubbled with N2 for 1 min. 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (TMB, 107 mg, 0.853 mmol) was added, bubbled with N2 for 1 min, then sealed and stirred at 110° C. overnight. LCMS analysis showed the disappearance of starting material and formation of a new major peak (LC-MS m/z 464.3 [M+H]+). Dioxane (0.43 mL) and 0.2 mL of 5N NaOH were added. The reaction mixture was stirred at 60° C. for 2 h, neutralized with 0.2 mL of acetic acid and purified by Method B. The fractions containing (S)-8-((5-amino-7-((1-hydroxyhexan-3-yl)amino)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-quinoline-5-carboxylic acid were combined and freeze-dried (29 mg, 0.065 mmol, 76% yield). LC-MS m/z 450.3 [M+H]+. Retention Time: 1.40 min (Method E).
  • Step 6. DIPEA (0.019 mL, 0.107 mmol) was added to a solution of (S)-8-((5-amino-7-((1-hydroxyhexan-3-yl)amino)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylic acid (12 mg, 0.027 mmol), tetrahydro-2H-pyran-4-amine (10.80 mg, 0.107 mmol) and HATU (15.23 mg, 0.040 mmol) in DMF (0.5 mL). The reaction mixture was stirred at 20° C. for 0.5 h, neutralized with 0.05 mL acetic acid, and purified by Method C. Fractions containing Compound 119 were combined and dried via centrifugal evaporation (3.49 mg, 0.007 mmol, 24.3%).
  • Compound 120 and Compound 123 were analogously prepared.
    • Example 5—Compound 109
  • Figure US20230130516A1-20230427-C00180
  • Step 1. To a solution of methyl 8-(bromomethyl)quinoline-5-carboxylate (236 mg, 0.842 mmol) in DMF (3 mL), LiCl (236 mg, 5.57 mmol) was added. The reaction mixture was stirred at RT for 2 h. LCMS analysis showed the reaction was complete (chloro intermediate, LC-MS m/z 236.1 [M+H]+). 3-Bromo-N7-butyl-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine (200 mg, 0.701 mmol) and Cs2CO3 (914 mg, 2.81 mmol) were added. The reaction mixture was stirred at RT for over weekend. LCMS analysis showed the reaction was complete with 2 isomers corresponding to desired mass (LC-MS m/z 484.2; 486.2 [M+H]+). The reaction mixture was worked up with EtOAc, water and brine. The organic phases were combined, concentrated and purified with column chromatography: Column: 40 g CombiFlash column; Mobile Phase A: hexanes; Mobile Phase B: ethyl acetate; Gradient: a 1 min hold at 0% B, 0-100% over 14 min, then a 3 min hold at 100% B; Flow Rate: 40 mL/min; Column Temperature: 25° C. he fractions containing product were combined, concentrated and dried under high vacuum to yield methyl 8-((5-amino-3-bromo-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylate (161 mg, 0.332 mmol, 47.5%).
  • LC-MS m/z 484.2; 486.2 [M+H]+; Retention Time: 1.85 min (Method E).
  • Step 2. To a solution of methyl 8-((5-amino-3-bromo-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylate (161 mg, 0.332 mmol) in MeOH (10 mL), Pd—C(10%, 53 mg) was added. The reaction mixture was stirred under hydrogen balloon overnight and filtered. The filtrate was concentrated and dried under high vacuum to yield methyl 8-((5-amino-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-4-carboxylate (128 mg, 0.316 mmol, 95.2%).
  • LC-MS m/z 406.3 [M+H]+. Retention Time: 1.67 min (Method E).
  • Step 3. To a solution of methyl 8-((5-amino-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylate (60 mg, 0.148 mmol) in THF (1 mL) and MeOH (0.1 mL), LiBH4 in THF (0.740 mL, 0.740 mmol) was added. The reaction mixture was stirred at 40° C. for 1 h, neutralized with 0.07 mL of HOAc, and purified with Method B. The fractions containing expected product were combined and freeze-dried to yield (8-((5-amino-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinolin-5-yl)methanol (25 mg, 0.066 mmol, 44.8%). LC-MS m/z 378.3 [M+H]+. Retention Time: 1.45 min (Method E).
  • Step 4. To a solution of (8-((5-amino-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinolin-5-yl)methanol (25 mg, 0.066 mmol) in THF (1 mL), sulfurous dichloride (0.024 mL, 0.331 mmol) was added. The reaction mixture was stirred at RT for 5 min. LCMS analysis showed the reaction was complete (LC-MS m/z 396.3 [M+H]+). The reaction mixture was concentrated under vacuum and co-evaporated with dry DCM (2×5 mL). The residue was dried under high vacuum for 10 min and dissolved in DMF (1 mL). Tetrahydro-2H-pyran-4-amine (67.0 mg, 0.662 mmol) was added. The reaction mixture was stirred at 25° C. for 4 h and purified with Method A. Fractions containing the desired product were combined and dried via centrifugal evaporation to yield Compound 109 (14.49 mg, 0.021 mmol, 31.9%).
  • Compound 101 and Compound 107 were analogously prepared.
    • Example 6—Compound 102
  • Figure US20230130516A1-20230427-C00181
  • Step 1. Imidazole (1.452 g, 21.33 mmol) was added to a solution of (S)-3-aminohexan-1-ol (1 g, 8.53 mmol) and tert-butylchlorodiphenylsilane (TBPDSCl3.28 mL, 12.80 mmol) in DMF (6 mL). The reaction mixture was stirred at RT overnight and worked up with EtOAc, water and brine. The organic phases were combined, concentrated and purified by column chromatography: Column: 40 g CombiFlash column; Mobile Phase A: hexanes; Mobile Phase B: ethyl acetate; Gradient: a 1 min hold at 0% B, 0-100% over 14 min, then a 3 min hold at 100% B; Flow Rate: 40 mL/min; Column Temperature: 25° C. The fractions containing the expected product were combined, concentrated and dried under high vacuum to yield (S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-amine (2.09 g, 5.88 mmol, 68.9% yield).
  • LC-MS m/z 356.2 [M+H]+; Retention Time: 2.51 min (Method E).
  • Step 2. BOP (433 mg, 0.979 mmol) was added to a solution of methyl 8-((7-hydroxy-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylate (200 mg, 0.490 mmol), (S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-amine (871 mg, 2.449 mmol) and DBU (0.148 mL, 0.979 mmol) in DMSO (3 mL). The reaction mixture was stirred at 70° C. for 3 h, neutralized with 0.2 mL acetic acid, and purified by reverse phase column chromatography: Column: 50 g CombiFlash Aq column; Mobile Phase A: water with 0.05 TFA; Mobile Phase B: acetonitrile with 0.05% TFA; Gradient: a 0.75 min hold at 0% B, 0-50% B over 8.75 min, then a 1.5 min hold at 100% B; Flow Rate: 35 mL/min; Column Temperature: 25° C. The fractions containing methyl (S)-8-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-5-((methoxy-carbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylate were combined and freeze-dried (258 mg, 0.346 mmol, 70.6% yield).
  • LC-MS m/z 746.3 [M+H]+. Retention Time: 2.57 min (Method E).
  • Step 3. LiBH4 (2N, 0.4 mL) was added to a solution of methyl (S)-8-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinoline-5-carboxylate (121 mg, 0.162 mmol) in THF (1.8 mL) and MeOH (0.2 mL). The reaction mixture was stirred at 40° C. for 1 h, neutralized with 0.2 mL acetic acid, and purified by Method B. The fractions containing methyl (S)-(7-((1-((tert-butyl-diphenylsilyl)oxy)hexan-3-yl)amino)-1-((5-(hydroxymethyl)quinolin-8-yl)methyl)-1H-pyrazolo-[4,3-d]pyrimidin-5-yl)carbamate were combined and freeze-dried (43 mg, 0.060 mmol, 36.9%).
  • LC-MS m/z 718.3 [M+H]+. Retention Time: 2.51 min (Method E).
  • Step 4. SOCl2 (0.024 mL, 0.334 mmol) was added to a solution of methyl (S)-(7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-1-((5-(hydroxymethyl)quinolin-8-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (48 mg, 0.067 mmol) in THF (1 mL). The reaction mixture was stirred at RT for 5 min. LCMS analysis showed that the starting material was completely converted to a chloro intermediate (LC-MS m/z 736.3 [M+H]+). The reaction mixture was concentrated under vacuum and co-evaporated with dry DCM (2×5 mL). The residue was dried under high vacuum for 10 min to a residue. The residue was dissolved in DMF (1 ml) and DIEA (0.070 mL, 0.401 mmol) and 3-methoxyazetidine (34.9 mg, 0.401 mmol) were added. The reaction mixture was stirred at 70° C. for 30 min and freeze-dried with acetonitrile and water to yield crude methyl (S)-(7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-1-((5-((3-methoxyazetidin-1-yl)methyl)quinolin-8-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (52.1 mg, 0.066 mmol, 99%).
  • LC-MS m/z 787.3 [M+H]+. Retention Time: 2.60 min (Method E).
  • Step 5. NaOH in water (0.3 ml, 3.00 mmol) was added to a solution of methyl (S)-(7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-1-((5-((3-methoxyazetidin-1-yl)methyl)-quinolin-8-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (52.1 mg, 0.066 mmol) in 1,4-dioxane (0.6 mL). The reaction mixture was stirred at 70° C. for 3 h, neutralized with 0.3 mL HCl (12 M), and freeze-dried with acetonitrile and water to afford a crude intermediate. To a mixture of intermediate (143 mg crude) in MeOH (0.8 ml), HCl (12M, 0.3 mL) was added. The slurry was stirred at RT for 1 h, diluted with acetonitrile (10 mL) and water (10 mL), and freeze-dried to give crude product. The crude product was dissolved in 1 mL of DMSO and filtered. The filtrate was purified by Method C. Fractions containing the desired product were combined and dried via centrifugal evaporation to yield Compound 102 (7.62 mg, 0.016 mmol, 24.3%).
  • The following compounds were analogously prepared: Compound 103, Compound 104, Compound 105, Compound 106, Compound 139, and Compound 140.
  • Example 7—Compound 141
  • Figure US20230130516A1-20230427-C00182
  • Step 1. Bromine (3.60 ml, 69.8 mmol) was added to a solution of 8-methylquinoline (9.51 ml, 69.8 mmol) and silver sulfate (32.7 g, 105 mmol) in concentrated H2SO4 (98%, 100 mL) cooled to 0° C. in an ice batch. The reaction mixture was stirred at 25° C. for 4 h and diluted with ice. NH4OH solution was added slowly (14. 8 M) raise the pH above 7. The reaction mixture was extracted with EtOAc (4×250 mL). The organic phases were combined, concentrated and purified by column chromatography: Column: 80 g CombiFlash column; Mobile Phase A: hexanes; Mobile Phase B: ethyl acetate; Gradient: a 3 min hold at 0% B, 0-10% over 45 min, then a 3 min hold at 10% B; Flow Rate: 85 mL/min; hexanes with 0.05% TEA; Column Temperature: 25° C. The fractions containing expected product were combined, concentrated and dried on reduced vacuum for 30 min to yield 5-bromo-8-methylquinoline (13.1 g, 59.0 mmol, 84% yield). LC-MS m/z 222.1 & 224.1 [M+H]+; Retention Time: 2.05 min (Method E).
  • Step 2. A mixture of 5-bromo-8-methylquinoline (1 g, 4.50 mmol), tert-butyl 4-(3,3,4,4-tetramethylborolan-1-yl)-3,6-dihydropyridine-1(2H)-carboxylate (1.787 g, 5.85 mmol) and 5-bromo-8-methylquinoline (1 g, 4.50 mmol), tert-butyl 4-(3,3,4,4-tetramethylborolan-1-yl)-3,6-dihydropyridine-1(2H)-carboxylate (1.787 g, 5.85 mmol) in DMF (15 mL) was bubbled with N2 for 3 min. PdCl2(dppf) (0.329 g, 0.450 mmol) was added. N2 was bubbled for another 2 min. The reaction vessel was sealed. The reaction mixture was stirred at 80° C. for 5 h, diluted with EtOAc, and filtered through CELITE. The filtrate was concentrated and was purified by column chromatography: Column: 80 g CombiFlash column; Mobile Phase A: hexanes; Mobile Phase B: ethyl acetate; Gradient: a 3 min hold at 0% B, 0-10% over 45 min, then a 3 min hold at 10% B; Flow Rate: 85 mL/min; hexanes with 0.05% TEA; Column Temperature: 25° C. The desired fractions were concentrated to yield tert-butyl 4-(8-methylquinolin-5-yl)-3,6-dihydro-pyridine-1(2H)-carboxylate (1.28 g, 3.95 mmol, 88% yield).
  • LC-MS m/z 324.9 [M+H]+; Retention Time: 1.98 min (Method E).
  • 1H NMR (400 MHz, DMSO-d6) δ 8.93 (dd, J=4.1, 1.8 Hz, 1H), 8.35 (dd, J=8.5, 1.8 Hz, 1H), 7.64-7.49 (m, 2H), 7.32 (d, J=7.2 Hz, 1H), 5.74 (s, 1H), 4.06 (q, J=2.8 Hz, 2H), 3.64 (t, J=5.6 Hz, 2H), 2.71 (d, J=0.9 Hz, 3H), 2.44 (ddt, J=7.9, 5.6, 2.7 Hz, 2H), 1.46 (s, 9H).
  • Step 3. A mixture of tert-butyl 4-(8-methylquinolin-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate (1.35 g, 4.16 mmol) and Pd—C(0.222 g, 0.21 mmol) in MeOH (15 mL) was stirred under hydrogen balloon. The reaction was monitored with LCMS. The reaction was 40% completed in 8 hrs. The reaction mixture was filtered and the filtrate was concentrated and purified by column chromatography: Column: 40 g CombiFlash column; Mobile Phase A: hexanes; Mobile Phase B: ethyl acetate; Gradient: a 1 min hold at 0% B, 0-10% over 14 min, then a 1 min hold at 10% B; Flow Rate: 40 mL/min; hexanes with 0.05% TEA; Column Temperature: 25° C. The fractions containing expected product were combined, concentrated and dried under high vacuum to yield tert-butyl 4-(8-methylquinolin-5-yl)piperidine-1-carboxylate (0.412 g, 1.262 mmol, 30.3% yield).
  • LC-MS m/z 324.9 [M+H]+; Retention Time: 1.98 min (Method E).
  • 1H NMR (400 MHz, DMSO-d6) δ 8.93 (dd, J=4.1, 1.6 Hz, 1H), 8.64 (dd, J=8.7, 1.6 Hz, 1H), 7.61-7.53 (m, 2H), 7.38 (dd, J=7.5, 1.5 Hz, 1H), 4.13 (d, J=12.9 Hz, 2H), 3.64-3.46 (m, 1H), 3.31 (s, 1H), 2.69 (s, 3H), 1.87-1.78 (m, 2H), 1.60 (qd, J=12.5, 4.1 Hz, 2H), 1.44 (s, 9H).
  • Step 4. AIBN (14.59 mg, 0.089 mmol) was added to a solution of tert-butyl 4-(8-methylquinolin-5-yl)piperidine-1-carboxylate (290 mg, 0.888 mmol) and NBS (190 mg, 1.066 mmol) in CCl4 (4 mL). The reaction mixture was stirred at RT overnight. LCMS analysis showed 30% conversion to an intermediate (2.393 min at Method E, M+H/z=405.2; 407.2). Extra AIBN (14.59 mg, 0.089 mmol) was added. The reaction mixture was stirred at RT overnight. LCMS analysis showed 50% conversion. The reaction mixture was worked up with EtOAc, water and brine. The organic phases were concentrated and dried under vacuum to yield crude intermediate tert-butyl 4-(8-(bromomethyl)quinolin-5-yl)piperidine-1-carboxylate (349 mg).
  • Cs2CO3 (868 mg, 2.67 mmol) was added to a solution of methyl (7-hydroxy-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (298 mg, 0.888 mmol) and crude intermediate tert-butyl 4-(8-(bromomethyl)quinolin-5-yl)piperidine-1-carboxylate (349 mg) in DMF (3 mL). The reaction mixture was stirred at 25° C. for 30 min. LCMS showed reaction was completed. The reaction mixture was worked up with EtOAc, water and brine. The organics were combined, concentrated and purified by column chromatography: Column: 24 g CombiFlash column; Mobile Phase A: hexanes; Mobile Phase B: ethyl acetate; Gradient: a 1 min hold at 0% B, 0-100% over 14 min, then a 1 min hold at 100% B; Flow Rate: 25 mL/min; Column Temperature: 25° C. The fractions containing desired product were concentrated to yield tert-butyl 4-(8-((7-hydroxy-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinolin-5-yl)piperidine-1-carboxylate (135 mg, 0.205 mmol, 23.04% yield). LC-MS m/z [M+H]+; Retention Time: min (Method E).
  • Step 5. DBU (0.371 mL, 2.464 mmol) was added to a solution of tert-butyl 4-(8-((7-hydroxy-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinolin-5-yl)piperidine-1-carboxylate (325 mg, 0.493 mmol), (S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-amine (350 mg, 0.986 mmol) and BOP (436 mg, 0.986 mmol) in DMSO (4.5 mL). The reaction mixture was stirred at 45° C. for 4 h and worked up with EtOAc, water and brine. The organic phases were combined, concentrated and purified by column chromatography: Column: 12 g CombiFlash column; Mobile Phase A: hexanes; Mobile Phase B: ethyl acetate; Gradient: a 1 min hold at 0% B, 0-10% over 15 min, then a 1 min hold at 10% B; Flow Rate: 20 mL/min; Column Temperature: 25° C. The fractions containing desired product were concentrated and dried under reduced pressure to yield tert-butyl (S)-4-(8-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-quinolin-5-yl)piperidine-1-carboxylate (315 mg, 0.316 mmol, 64.1% yield). LC-MS m/z 997.6 [M+H]+; Retention Time: 2.56 min (Method F).
  • 1H NMR (400 MHz, DMSO-d6) δ 9.72 (s, 1H), 8.98 (dd, J=4.2, 1.6 Hz, 1H), 8.78-8.70 (m, 1H), 7.66 (dd, J=8.7, 4.2 Hz, 1H), 7.53-7.46 (m, 2H), 7.42-7.13 (m, 10H), 6.82 (s, 1H), 6.21 (s, 2H), 4.56 (s, 2H), 3.58 (s, 4H), 3.48 (s, 2H), 2.91 (s, 5H), 2.68 (s, 1H), 2.53 (s, 1H), 1.74 (d, J=12.8 Hz, 2H), 1.58 (s, 1H), 1.53-1.47 (m, 1H), 1.43 (s, 9H), 0.99 (s, 1H), 0.86 (s, 9H), 0.72 (t, J=7.3 Hz, 3H).
  • Step 6. Zinc (168 mg, 2.57 mmol) was added to a solution of tert-butyl (S)-4-(8-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinolin-5-yl)piperidine-1-carboxylate (256 mg, 0.257 mmol) in MeOH (4 mL) and AcOH (2 mL). The reaction mixture was stirred at 25° C. for 1 h and worked up with EtOAc, water and brine. The organic phases were combined, concentrated and generated intermediate tert-butyl (S)-4-(8-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinolin-5-yl)piperidine-1-carboxylate (186 mg).
  • LC-MS m/z 871.7 [M+H]+; Retention Time: 1.82 min (Method F).
  • NaOH (10 N, 1 mL) was added to a solution of the intermediate (186 mg) in dioxane (4 mL). The reaction mixture was stirred at 78° C. overnight and worked up with EtOAc, water and brine. The organic phases were concentrated and dried under vacuum to yield tert-butyl (S)-4-(8-((5-amino-7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)quinolin-5-yl)piperidine-1-carboxylate (151 mg, 0.186 mmol, 72.3% yield). LC-MS m/z 813.7 [M+H]+; Retention Time: 2.48 min (Method E).
  • Step 7. TFA (0.5 mL) was added to a solution of tert-butyl (S)-4-(8-((5-amino-7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-quinolin-5-yl)piperidine-1-carboxylate (32 mg, 0.039 mmol) in DCM (0.5 mL), The reaction mixture was stirred at 25° C. for 30 min. LCMS showed Boc protecting group removed. The reaction mixture was concentrated and dissolved in Dioxane (0.5 ml). To it, HCl (12 N, 0.5 mL) was added. The reaction mixture was stirred at RT for 15 min and concentrated and purified by Method C. Fractions containing the desired product were combined and dried via centrifugal evaporation to yield Compound 141 (2.4 mg, 0.005 mmol, 13.0%).
    • Example 8—Compound 142
  • Figure US20230130516A1-20230427-C00183
  • A solution of (S)-3-((5-amino-1-((5-(piperidin-4-yl)quinolin-8-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino)hexan-1-ol (20 mg, 0.042 mmol) in DMF (0.6 mL) was treated with Molecular Sieves, tetrahydro-4H-pyran-4-one (21.09 mg, 0.211 mmol) and 1 drop of HOAc, followed by sodium triacetoxyborohydride (35.7 mg, 0.169 mmol). The reaction mixture was stirred at RT overnight and purified by Method C to yield Compound 142 (5.0 mg, 8.55 μmol, 20.28% yield).
  • Compound 143 was analogously prepared.
    • Example 9—Starting Materials and Intermediates
  • The Charts below show schemes for making compounds that could be useful as starting materials or intermediates for the preparation of TLR7 agonists disclosed herein. The schemes can be adapted to make other, analogous compounds that could be used as starting materials or intermediates. The reagents employed are well known in the art and in many instances their use has been demonstrated in the preceding Examples.
    • Chart 1
  • Figure US20230130516A1-20230427-C00184
    • Chart 2
  • Figure US20230130516A1-20230427-C00185
    • Chart 3
  • Figure US20230130516A1-20230427-C00186
    • Biological Activity
  • The biological activity of compounds disclosed herein as TLR7 agonists can be assayed by the procedures following.
    • Human TLR7 Agonist Activity Assay
  • This procedure describes a method for assaying human TLR7 (hTLR7) agonist activity of the compounds disclosed in this specification.
  • Engineered human embryonic kidney blue cells (HEK-Blue™ TLR cells; Invivogen) possessing a human TLR7-secreted embryonic alkaline phosphatase (SEAP) reporter transgene were suspended in a non-selective, culture medium (DMEM high-glucose (Invitrogen), supplemented with 10% fetal bovine serum (Sigma)). HEK-Blue™ TLR7 cells were added to each well of a 384-well tissue-culture plate (15,000 cells per well) and incubated 16-18 h at 37° C., 5% CO2. Compounds (100 nl) were dispensed into wells containing the HEK-Blue™ TLR cells and the treated cells were incubated at 37° C., 5% CO2. After 18 h treatment ten microliters of freshly-prepared Quanti-Blue™ reagent (Invivogen) was added to each well, incubated for 30 min (37° C., 5% CO2) and SEAP levels measured using an Envision plate reader (OD=620 nm). The half maximal effective concentration values (EC50; compound concentration which induced a response halfway between the assay baseline and maximum) were calculated.
    • Induction of Type I Interferon Genes (MX-1) and CD69 in Human Blood
  • The induction of Type I interferon (IFN) MX-1 genes and the B-cell activation marker CD69 are downstream events that occur upon activation of the TLR7 pathway. The following is a human whole blood assay that measures their induction in response to a TLR7 agonist.
  • Heparinized human whole blood was harvested from human subjects and treated with test TLR7 agonist compounds at 1 mM. The blood was diluted with RPMI 1640 media and Echo was used to predot 10 nL per well giving a final concentration of 1 uM (10 nL in 10 uL of blood). After mixing on a shaker for 30 sec, the plates were covered and placed in a 37° C. chamber for o/n=17 hrs. Fixing/lysis buffer was prepared (5×->1× in H2O, warm at 37° C.; Cat #BD 558049) and kept the perm buffer (on ice) for later use.
  • For surface markers staining (CD69): prepared surface Abs: 0.045 ul hCD14-FITC (ThermoFisher Cat #MHCD1401)+0.6 ul hCD19-ef450 (ThermoFisher Cat #48-0198-42)+1.5 ul hCD69-PE (cat #BD555531)+0.855 ul FACS buffer. Added 3 ul/well, spin1000 rpm for 1 min and mixed on shaker for 30 sec, put on ice for 30 min. Stop stimulation after 30 minutes with 70 uL of prewarmed 1× fix/lysis buffer and use Feliex mate to resuspend (15 times, change tips for each plate) and incubate at 37 C for 10 minutes.
  • Centrifuge at 2000 rpm for 5 minutes aspirate with HCS plate washer, mix on shaker for 30 sec and then wash with 70 uL in dPBS and pelleted 2×s (2000 rpm for 5 min) and 50 ul wash in FACS buffer pelleted 1×s (2000 rpm for 5 min). Mix on shaker for 30 sec. For Intracellular markers staining (MX-1): Add 50 ul of BD Perm buffer III and mix on shaker for 30 sec. Incubate on ice for 30 minutes (in the dark). Wash with 50 uL of FACS buffer 2× (spin @2300 rpm×5 min after perm) followed by mixing on shaker for 30 sec. Resuspended in 20 ul of FACS buffer containing MX1 antibody ( )(4812)-Alexa 647: Novus Biologicals #NBP2-43704AF647) 20 ul FACS bf+0.8 ul hIgG+0.04 ul MX-1. Spin 1000 rpm for 1 min, mix on shaker for 30 se and the samples were incubated at RT in the dark for 45 minutes followed by washing 2×FACS buffer (spin @2300 rpm×5 min after perm). Resuspend 20 ul (35 uL total per well) of FACS buffer and cover with foil and place in 4° C. to read the following day. Plates were read on iQuePlus. The results were loaded into toolset and IC50 curves are generated in curve master. The y-axis 100% is set to 1 uM of resiquimod.
    • Induction of TNF-Alpha and Type I IFN Response Genes in Mouse Blood
  • The induction of TNF-alpha and Type I IFN response genes are downstream events that occur upon activation of the TLR7 pathway. The following is an assay that measures their induction in whole mouse blood in response to a TLR7 agonist.
  • Heparinized mouse whole blood was diluted with RPMI 1640 media with Pen-Strep in the ratio of 5:4 (50 uL whole blood and 40 uL of media). A volume of 90 uL of the diluted blood was transferred to wells of Falcon flat bottom 96-well tissue culture plates, and the plates were incubated at 4° C. for 1 h. Test compounds in 100% DMSO stocks were diluted 20-fold in the same media for concentration response assays, and then 10 uL of the diluted test compounds were added to the wells, so that the final DMSO concentration was 0.5%. Control wells received 10 uL media containing 5% DMSO. The plates were then incubated at 37° C. in a 5% CO2 incubator for 17 h. Following the incubation, 100 uL of the culture medium as added to each well. The plates were centrifuged and 130 uL of supernatant was removed for use in assays of TNFa production by ELISA (Invitrogen, Catalog Number 88-7324 by Thermo-Fisher Scientific). A 70 uL volume of mRNA catcher lysis buffer (1×) with DTT from the Invitrogen mRNA Catcher Plus kit (Cat #K1570-02) was added to the remaining 70 uL sample in the well, and was mixed by pipetting up and down 5 times. The plate was then shaken at room temperature for 5-10 min, followed by addition of 2 uL of proteinase K (20 mg/mL) to each well. Plates were then shaken for 15-20 min at RT. The plates were then stored at −80° C. until further processing.
  • The frozen samples were thawed and mRNA was extracted using the Invitrogen mRNA Catcher Plus kit (Cat #K1570-02) according to the manufacturer's instructions. Half yield of mRNA from RNA extraction were used to synthesize cDNA in 20 μL reverse transcriptase reactions using Invitrogen SuperScript IV VILO Master Mix (Cat #11756500). TaqMan® real-time PCR was performed using QuantStudio Real-Time PCR system from ThermoFisher (Applied Biosystems). All real-time PCR reactions were run in duplicate using commercial predesigned TaqMan assays for mouse IFIT1, IFIT3, MX1 and PPIA gene expression and TaqMan Master Mix. PPIA was utilized as the housekeeping gene. The recommendations from the manufacturer were followed. All raw data (Ct) were normalized by average housekeeping gene (Ct) and then the comparative Ct (ΔΔCt) method were utilized to quantify relative gene expression (RQ) for experimental analysis.
    • Definitions
  • “Aliphatic” means a straight- or branched-chain, saturated or unsaturated, non-aromatic hydrocarbon moiety having the specified number of carbon atoms (e.g., as in “C3 aliphatic,” “C1-5 aliphatic,” “C1-C5 aliphatic,” or “C1 to C5 aliphatic,” the latter three phrases being synonymous for an aliphatic moiety having from 1 to 5 carbon atoms) or, where the number of carbon atoms is not explicitly specified, from 1 to 4 carbon atoms (2 to 4 carbons in the instance of unsaturated aliphatic moieties). A similar understanding is applied to the number of carbons in other types, as in C2-4 alkene, C4-C7 cycloaliphatic, etc. In a similar vein, a term such as “(CH2)1-3” is to be understand as shorthand for the subscript being 1, 2, or 3, so that such term represents CH2, CH2CH2, and CH2CH2CH2.
  • “Alkyl” means a saturated aliphatic moiety, with the same convention for designating the number of carbon atoms being applicable. By way of illustration, C1-C4 alkyl moieties include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, t-butyl, 1-butyl, 2-butyl, and the like. “Alkanediyl” (sometimes also referred to as “alkylene”) means a divalent counterpart of an alkyl group, such as
  • Figure US20230130516A1-20230427-C00187
  • “Alkenyl” means an aliphatic moiety having at least one carbon-carbon double bond, with the same convention for designating the number of carbon atoms being applicable. By way of illustration, C2-C4 alkenyl moieties include, but are not limited to, ethenyl (vinyl), 2-propenyl (allyl or prop-2-enyl), cis-1-propenyl, trans-1-propenyl, E- (or Z-) 2-butenyl, 3-butenyl, 1,3-butadienyl (but-1,3-dienyl) and the like.
  • “Alkynyl” means an aliphatic moiety having at least one carbon-carbon triple bond, with the same convention for designating the number of carbon atoms being applicable. By way of illustration, C2-C4 alkynyl groups include ethynyl (acetylenyl), propargyl (prop-2-ynyl), 1-propynyl, but-2-ynyl, and the like.
  • “Cycloaliphatic” means a saturated or unsaturated, non-aromatic hydrocarbon moiety having from 1 to 3 rings, each ring having from 3 to 8 (preferably from 3 to 6) carbon atoms. “Cycloalkyl” means a cycloaliphatic moiety in which each ring is saturated. “Cycloalkenyl” means a cycloaliphatic moiety in which at least one ring has at least one carbon-carbon double bond. “Cycloalkynyl” means a cycloaliphatic moiety in which at least one ring has at least one carbon-carbon triple bond. By way of illustration, cycloaliphatic moieties include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, and adamantyl. Preferred cycloaliphatic moieties are cycloalkyl ones, especially cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. “Cycloalkanediyl” (sometimes also referred to as “cycloalkylene”) means a divalent counterpart of a cycloalkyl group. Similarly, “bicycloalkanediyl” (osr “bicycloalkylene”) and “spiroalkanediyl” (or “spiroalkylene”) refer to divalent counterparts of a bicycloalkyl and spiroalkyl (or “spirocycloalkyl”) group. By way of illustration, an example of a
  • Figure US20230130516A1-20230427-C00188
  • moiety is
  • Figure US20230130516A1-20230427-C00189
  • and an example of a
  • Figure US20230130516A1-20230427-C00190
  • moiety is
  • Figure US20230130516A1-20230427-C00191
  • “Heterocycloaliphatic” means a cycloaliphatic moiety wherein, in at least one ring thereof, up to three (preferably 1 to 2) carbons have been replaced with a heteroatom independently selected from N, O, or S, where the N and S optionally may be oxidized and the N optionally may be quaternized. Preferred cycloaliphatic moieties consist of one ring, 5- to 6-membered in size. Similarly, “heterocycloalkyl,” “heterocycloalkenyl,” and “heterocycloalkynyl” means a cycloalkyl, cycloalkenyl, or cycloalkynyl moiety, respectively, in which at least one ring thereof has been so modified. Exemplary heterocycloaliphatic moieties include aziridinyl, azetidinyl, 1,3-dioxanyl, oxetanyl, tetrahydrofuryl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothiopyranyl sulfone, morpholinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, 1,3-dioxolanyl, tetrahydro-1,1-dioxothienyl, 1,4-dioxanyl, thietanyl, and the like. “Heterocycloalkylene” means a divalent counterpart of a heterocycloalkyl group.
  • “Alkoxy,” “aryloxy,” “alkylthio,” and “arylthio” mean —O(alkyl), —O(aryl), —S(alkyl), and —S(aryl), respectively. Examples are methoxy, phenoxy, methylthio, and phenylthio, respectively.
  • “Halogen” or “halo” means fluorine, chlorine, bromine or iodine, unless a narrower meaning is indicated.
  • “Aryl” means a hydrocarbon moiety having a mono-, bi-, or tricyclic ring system (preferably monocyclic) wherein each ring has from 3 to 7 carbon atoms and at least one ring is aromatic. The rings in the ring system may be fused to each other (as in naphthyl) or bonded to each other (as in biphenyl) and may be fused or bonded to non-aromatic rings (as in indanyl or cyclohexylphenyl). By way of further illustration, aryl moieties include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthryl, anthracenyl, and acenaphthyl. “Arylene” means a divalent counterpart of an aryl group, for example 1,2-phenylene, 1,3-phenylene, or 1,4-phenylene.
  • “Heteroaryl” means a moiety having a mono-, bi-, or tricyclic ring system (preferably 5- to 7-membered monocyclic) wherein each ring has from 3 to 7 carbon atoms and at least one ring is an aromatic ring containing from 1 to 4 heteroatoms independently selected from from N, O, or S, where the N and S optionally may be oxidized and the N optionally may be quaternized. Such at least one heteroatom containing aromatic ring may be fused to other types of rings (as in benzofuranyl or tetrahydroisoquinolyl) or directly bonded to other types of rings (as in phenylpyridyl or 2-cyclopentylpyridyl). By way of further illustration, heteroaryl moieties include pyrrolyl, furanyl, thiophenyl (thienyl), imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridyl, N-oxopyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolynyl, quinazolinyl, cinnolinyl, quinozalinyl, naphthyridinyl, benzofuranyl, indolyl, benzothiophenyl, oxadiazolyl, thiadiazolyl, phenothiazolyl, benzimidazolyl, benzotriazolyl, dibenzofuranyl, carbazolyl, dibenzothiophenyl, acridinyl, and the like. “Heteroarylene” means a divalent counterpart of a heteroaryl group.
  • Where it is indicated that a moiety may be substituted, such as by use of “unsubstituted or substituted” or “optionally substituted” phrasing as in “unsubstituted or substituted C1-C5 alkyl” or “optionally substituted heteroaryl,” such moiety may have one or more independently selected substituents, preferably one to five in number, more preferably one or two in number. Substituents and substitution patterns can be selected by one of ordinary skill in the art, having regard for the moiety to which the substituent is attached, to provide compounds that are chemically stable and that can be synthesized by techniques known in the art as well as the methods set forth herein. Where a moiety is identified as being “unsubstituted or substituted” or “optionally substituted,” in a preferred embodiment such moiety is unsubstituted.
  • “Arylalkyl,” (heterocycloaliphatic)alkyl,” “arylalkenyl,” “arylalkynyl,” “biarylalkyl,” and the like mean an alkyl, alkenyl, or alkynyl moiety, as the case may be, substituted with an aryl, heterocycloaliphatic, biaryl, etc., moiety, as the case may be, with the open (unsatisfied) valence at the alkyl, alkenyl, or alkynyl moiety, for example as in benzyl, phenethyl, N-imidazoylethyl, N-morpholinoethyl, and the like. Conversely, “alkylaryl,” “alkenylcycloalkyl,” and the like mean an aryl, cycloalkyl, etc., moiety, as the case may be, substituted with an alkyl, alkenyl, etc., moiety, as the case may be, for example as in methylphenyl (tolyl) or allylcyclohexyl. “Hydroxyalkyl,” “haloalkyl,” “alkylaryl,” “cyanoaryl,” and the like mean an alkyl, aryl, etc., moiety, as the case may be, substituted with one or more of the identified substituent (hydroxyl, halo, etc., as the case may be).
  • For example, permissible substituents include, but are not limited to, alkyl (especially methyl or ethyl), alkenyl (especially allyl), alkynyl, aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, halo (especially fluoro), haloalkyl (especially trifluoromethyl), hydroxyl, hydroxyalkyl (especially hydroxyethyl), cyano, nitro, alkoxy, —O(hydroxyalkyl), —O(haloalkyl) (especially —OCF3), —O(cycloalkyl), —O(heterocycloalkyl), —O(aryl), alkylthio, arylthio, ═O, ═NH, ═N(alkyl), ═NOH, ═NO(alkyl), —C(═O)(alkyl), —C(═O)H, —CO2H, —C(═O)NHOH, —C(═O)O(alkyl), —C(═O)O(hydroxyalkyl), —C(═O)NH2, —C(═O)NH(alkyl), —C(═O)N(alkyl)2, —OC(═O)(alkyl), —OC(═O)(hydroxyalkyl), —OC(═O)O(alkyl), —OC(═O)O(hydroxyalkyl), —OC(═O)NH2, —OC(═O)NH(alkyl), —OC(═O)N(alkyl)2, azido, —NH2, —NH(alkyl), —N(alkyl)2, —NH(aryl), —NH(hydroxyalkyl), —NHC(═O)(alkyl), —NHC(═O)H, —NHC(═O)NH2, —NHC(═O)NH(alkyl), —NHC(═O)N(alkyl)2, —NHC(═NH)NH2, —OSO2(alkyl), —SH, —S(alkyl), —S(aryl), —S(cycloalkyl), —S(═O)alkyl, —SO2(alkyl), —SO2NH2, —SO2NH(alkyl), —SO2N(alkyl)2, and the like.
  • Where the moiety being substituted is an aliphatic moiety, preferred substituents are aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, halo, hydroxyl, cyano, nitro, alkoxy, —O(hydroxyalkyl), —O(haloalkyl), —O(cycloalkyl), —O(heterocycloalkyl), —O(aryl), alkylthio, arylthio, ═O, ═NH, ═N(alkyl), ═NOH, ═NO(alkyl), —CO2H, —C(═O)NHOH, —C(═O)O(alkyl), —C(═O)O(hydroxyalkyl), —C(═O)NH2, —C(═O)NH(alkyl), —C(═O)N(alkyl)2, —OC(═O)(alkyl), —OC(═O)(hydroxyalkyl), —OC(═O)O(alkyl), —OC(═O)O(hydroxyalkyl), —OC(═O)NH2, —OC(═O)NH(alkyl), —OC(═O)N(alkyl)2, azido, —NH2, —NH(alkyl), —N(alkyl)2, —NH(aryl), —NH(hydroxyalkyl), —NHC(═O)(alkyl), —NHC(═O)H, —NHC(═O)NH2, —NHC(═O)NH(alkyl), —NHC(═O)N(alkyl)2, —NHC(═NH)NH2, —OSO2(alkyl), —SH, —S(alkyl), —S(aryl), —S(═O)alkyl, —S(cycloalkyl), —SO2(alkyl), —SO2NH2, —SO2NH(alkyl), and —SO2N(alkyl)2. More preferred substituents are halo, hydroxyl, cyano, nitro, alkoxy, —O(aryl), ═O, ═NOH, ═NO(alkyl), —OC(═O)(alkyl), —OC(═O)O(alkyl), —OC(═O)NH2, —OC(═O)NH(alkyl), —OC(═O)N(alkyl)2, azido, —NH2, —NH(alkyl), —N(alkyl)2, —NH(aryl), —NHC(═O)(alkyl), —NHC(═O)H, —NHC(═O)NH2, —NHC(═O)NH(alkyl), —NHC(═O)N(alkyl)2, and —NHC(═NH)NH2. Especially preferred are phenyl, cyano, halo, hydroxyl, nitro, C1-C4 alkyoxy, O(C2-C4 alkanediyl)OH, and O(C2-C4 alkanediyl)halo.
  • Where the moiety being substituted is a cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl moiety, preferred substituents are alkyl, alkenyl, alkynyl, halo, haloalkyl, hydroxyl, hydroxyalkyl, cyano, nitro, alkoxy, —O(hydroxyalkyl), —O(haloalkyl), —O(aryl), —O(cycloalkyl), —O(heterocycloalkyl), alkylthio, arylthio, —C(═O)(alkyl), —C(═O)H, —CO2H, —C(═O)NHOH, —C(═O)O(alkyl), —C(═O)O(hydroxyalkyl), —C(═O)NH2, —C(═O)NH(alkyl), —C(═O)N(alkyl)2, —OC(═O)(alkyl), —OC(═O)(hydroxyalkyl), —OC(═O)O(alkyl), —OC(═O)O(hydroxyalkyl), —OC(═O)NH2, —OC(═O)NH(alkyl), —OC(═O)N(alkyl)2, azido, —NH2, —NH(alkyl), —N(alkyl)2, —NH(aryl), —NH(hydroxyalkyl), —NHC(═O)(alkyl), —NHC(═O)H, —NHC(═O)NH2, —NHC(═O)NH(alkyl), —NHC(═O)N(alkyl)2, —NHC(═NH)NH2, —OSO2(alkyl), —SH, —S(alkyl), —S(aryl), —S(cycloalkyl), —S(═O)alkyl, —SO2(alkyl), —SO2NH2, —SO2NH(alkyl), and —SO2N(alkyl)2. More preferred substituents are alkyl, alkenyl, halo, haloalkyl, hydroxyl, hydroxyalkyl, cyano, nitro, alkoxy, —O(hydroxyalkyl), —C(═O)(alkyl), —C(═O)H, —CO2H, —C(═O)NHOH, —C(═O)O(alkyl), —C(═O)O(hydroxyalkyl), —C(═O)NH2, —C(═O)NH(alkyl), —C(═O)N(alkyl)2, —OC(═O)(alkyl), —OC(═O)(hydroxyalkyl), —OC(═O)O(alkyl), —OC(═O)O(hydroxyalkyl), —OC(═O)NH2, —OC(═O)NH(alkyl), —OC(═O)N(alkyl)2, —NH2, —NH(alkyl), —N(alkyl)2, —NH(aryl), —NHC(═O)(alkyl), —NHC(═O)H, —NHC(═O)NH2, —NHC(═O)NH(alkyl), —NHC(═O)N(alkyl)2, and —NHC(═NH)NH2. Especially preferred are C1-C4 alkyl, cyano, nitro, halo, and C1-C4alkoxy.
  • Where a range is stated, as in “C1-C5 alkyl” or “5 to 10%,” such range includes the end points of the range, as in C1 and C5 in the first instance and 5% and 10% in the second instance.
  • Unless particular stereoisomers are specifically indicated (e.g., by a bolded or dashed bond at a relevant stereocenter in a structural formula, by depiction of a double bond as having E or Z configuration in a structural formula, or by use stereochemistry-designating nomenclature or symbols), all stereoisomers are included within the scope of the invention, as pure compounds as well as mixtures thereof. Unless otherwise indicated, racemates, individual enantiomers (whether optically pure or partially resolved), diastereomers, geometrical isomers, and combinations and mixtures thereof are all encompassed by this invention.
  • Those skilled in the art will appreciate that compounds may have tautomeric forms (e.g., keto and enol forms), resonance forms, and zwitterionic forms that are equivalent to those depicted in the structural formulae used herein and that the structural formulae encompass such tautomeric, resonance, or zwitterionic forms.
  • “Pharmaceutically acceptable ester” means an ester that hydrolyzes in vivo (for example in the human body) to produce the parent compound or a salt thereof or has per se activity similar to that of the parent compound. Suitable esters include C1-C5 alkyl, C2-C5 alkenyl or C2-C5 alkynyl esters, especially methyl, ethyl or n-propyl.
  • “Pharmaceutically acceptable salt” means a salt of a compound suitable for pharmaceutical formulation. Where a compound has one or more basic groups, the salt can be an acid addition salt, such as a sulfate, hydrobromide, tartrate, mesylate, maleate, citrate, phosphate, acetate, pamoate (embonate), hydroiodide, nitrate, hydrochloride, lactate, methyl-sulfate, fumarate, benzoate, succinate, mesylate, lactobionate, suberate, tosylate, and the like. Where a compound has one or more acidic groups, the salt can be a salt such as a calcium salt, potassium salt, magnesium salt, meglumine salt, ammonium salt, zinc salt, piperazine salt, tromethamine salt, lithium salt, choline salt, diethylamine salt, 4-phenylcyclohexylamine salt, benzathine salt, sodium salt, tetramethylammonium salt, and the like. Polymorphic crystalline forms and solvates are also encompassed within the scope of this invention.
  • “Subject” refers to an animal, including, but not limited to, a primate (e.g., human), monkey, cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse. The terms “subject” and “patient” are used interchangeably herein in reference, for example, to a mammalian subject, such as a human.
  • The terms “treat,” “treating,” and “treatment,” in the context of treating a disease or disorder, are meant to include alleviating or abrogating a disorder, disease, or condition, or one or more of the symptoms associated with the disorder, disease, or condition; or to slowing the progression, spread or worsening of a disease, disorder or condition or of one or more symptoms thereof. The “treatment of cancer”, refers to one or more of the following effects: (1) inhibition, to some extent, of tumor growth, including, (i) slowing down and (ii) complete growth arrest; (2) reduction in the number of tumor cells; (3) maintaining tumor size; (4) reduction in tumor size; (5) inhibition, including (i) reduction, (ii) slowing down or (iii) complete prevention, of tumor cell infiltration into peripheral organs; (6) inhibition, including (i) reduction, (ii) slowing down or (iii) complete prevention, of metastasis; (7) enhancement of anti-tumor immune response, which may result in (i) maintaining tumor size, (ii) reducing tumor size, (iii) slowing the growth of a tumor, (iv) reducing, slowing or preventing invasion and/or (8) relief, to some extent, of the severity or number of one or more symptoms associated with the disorder.
  • In the formulae of this specification, a wavy line (
    Figure US20230130516A1-20230427-P00001
    ) transverse to a bond or an asterisk (*) at the end of the bond denotes a covalent attachment site. For instance, a statement that R is
  • Figure US20230130516A1-20230427-C00192
  • or that R is
  • Figure US20230130516A1-20230427-C00193
  • in the formula
  • Figure US20230130516A1-20230427-C00194
  • means
  • Figure US20230130516A1-20230427-C00195
  • In the formulae of this specification, a bond traversing an aromatic ring between two carbons thereof means that the group attached to the bond may be located at any of the positions of the aromatic ring made available by removal of the hydrogen that is implicitly there (or explicitly there, if written out). By way of illustration:
  • Figure US20230130516A1-20230427-C00196
  • represents
  • Figure US20230130516A1-20230427-C00197
  • Figure US20230130516A1-20230427-C00198
  • represents
  • Figure US20230130516A1-20230427-C00199
  • and
  • Figure US20230130516A1-20230427-C00200
  • represents
  • Figure US20230130516A1-20230427-C00201
  • This disclosure includes all isotopes of atoms occurring in the compounds described herein. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include 13C and 14C. Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed. By way of example, a C1-C3 alkyl group can be undeuterated, partially deuterated, or fully deuterated and “CH3” includes CH3, 13CH3, 14CH3, CH2T, CH2D, CHD2, CD3, etc. In one embodiment, the various elements in a compound are present in their natural isotopic abundance.
  • Those skilled in the art will appreciate that certain structures can be drawn in one tautomeric form or another—for example, keto versus enol—and that the two forms are equivalent.
    • Acronyms and Abbreviations
  • Table C provides a list of acronyms and abbreviations used in this specification, along with their meanings.
  • TABLE C
    ACRONYM OR ABBREVIATION MEANING OR DEFINITION
    AIBN Azobisisobutyronitrile
    Alloc Allyloxycarbonyl
    Aq. Aqueous
    ACN Acenonitrile
    Boc t-Butyloxycarbonyl
    BOP (Benzotriazol-1-yloxy)tris(dimethylamino)-
    phosphonium hexafluorophosphate (V)
    BOP (Benzotriazol-1-yloxy)tris(dimethylamino)-
    phosphonium hexafluorophosphate (V)
    DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene
    DCM Dichloromethane
    DIAD Diisopropyl azodicarboxylate
    DIPEA, DIEA N,N-diisopropylethylamine, also known as
    Hünig′s base
    DMA N,N-Dimethylacetamide
    DMAP 4-(Dimethylamino)pyridine
    DMF N,N-dimethylformamide
    DMSO Dimethyl sulfoxide
    DTDP 2,2′-dithiodipyridine
    DTPA Diethylenetriaminepentaacetic acid
    EEDQ Ethyl 2-ethoxyquinoline-1(2H)-carboxylate
    Fmoc Fluorenylmethyloxycarbonyl
    HATU Hexafluorophosphate Azabenzotriazole Tetramethyl
    Uronium; 1-[Bis(dimethylamino)-methylene]-1H-1,2,3-
    triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate
    HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid, N-(2-
    Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid)
    HPLC High pressure liquid chromatography
    Hunig's base See DIPEA, DIEA
    LCMS, LC-MS, LC/MS Liquid chromatography-mass spectrometry
    mCPBA m-chloroperbenzoic acid
    MS Mass spectrometry
    MsCl Methanesylfonyl chloride, mesyl chloride
    NBS, NCS, NIS N-Bromosuccinimide, N-chlorosuccinimide, and
    N-iodosuccinimide, respectively
    NMR Nuclear magnetic resonance
    PEG Poly(ethylene glycol)
    PTFE Poly(tetrafluoroethylene)
    RT (in context of liquid chromatography) Retention time, in min
    RT (in the context of reaction conditions) Room (ambient) temperature, circa 25° C.
    Sat. Saturated
    Soln Solution
    TBDPS tert-Butyldiphenylsilyl
    TBS t-Butyldimethylsilyl group
    TEA Triethylamine
    TEAA Triethylammonium acetate
    TFA Trifluoroacetic acid
    THF Tetrahydrofuran
    • REFERENCES
    • Full citations for the following references cited in abbreviated fashion by first author (or inventor) and date earlier in this specification are provided below. Each of these references is incorporated herein by reference for all purposes.
    • Akinbobuyi et al., Tetrahedron Lett. 2015, 56, 458, “Facile syntheses of functionalized toll-like receptor 7 agonists”.
    • Akinbobuyi et al., Bioorg. Med. Chem. Lett. 2016, 26, 4246, “Synthesis and immunostimulatory activity of substituted TLR7 agonists.”
    • Barberis et al., US 2012/0003298 A1 (2012).
    • Beesu et al., J. Med. Chem. 2017, 60, 2084, “Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines.”
    • Berghöfer et al., J. Immunol. 2007, 178, 4072, “Natural and Synthetic TLR7 Ligands Inhibit CpG-A- and CpG-C-Oligodeoxynucleotide-Induced IFN-α Production.”
    • Bonfanti et al., US 2014/0323441 A1 (2015) [2015a].
    • Bonfanti et al., US 2015/0299221 A1 (2015) [2015b].
    • Bonfanti et al., US 2016/0304531 A1 (2016).
    • Carson et al., US 2013/0202629 A1 (2013).
    • Carson et al., U.S. Pat. No. 8,729,088 B2 (2014).
    • Carson et al., U.S. Pat. No. 9,050,376 B2 (2015).
    • Carson et al., US 2016/0199499 A1 (2016).
    • Chan et al., Bioconjugate Chem. 2009, 20, 1194, “Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates.”
    • Chan et al., Bioconjugate Chem. 2011, 22, 445, “Synthesis and Characterization of PEGylated Toll Like Receptor 7 Ligands.”
    • Chen et al., U.S. Pat. No. 7,919,498 B2 (2011).
    • Coe et al., U.S. Pat. No. 9,662,336 B2 (2017).
    • Cortez and Va, Medicinal Chem. Rev. 2018, 53, 481, “Recent Advances in Small-Molecule TLR7 Agonists for Drug Discovery”.
    • Cortez et al., US 2017/0121421 A1 (2017).
    • Cortez et al., U.S. Pat. No. 9,944,649 B2 (2018).
    • Dellaria et al., WO 2007/028129 A1 (2007).
    • Desai et al., U.S. Pat. No. 9,127,006 B2 (2015).
    • Ding et al., WO 2016/107536 A1 (2016).
    • Ding et al., US 2017/0273983 A1 (2017) [2017a].
    • Ding et al., WO 2017/076346 A1 (2017) [2017b].
    • Gadd et al., Bioconjugate Chem. 2015, 26, 1743, “Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity.”
    • Graupe et al., U.S. Pat. No. 8,993,755 B2 (2015).
    • Embrechts et al., J. Med. Chem. 2018, 61, 6236, “2,4-Diaminoquinazolines as Dual Toll Like Receptor (TLR) 7/8 Modulators for the Treatment of Hepatitis B Virus.”
    • Halcomb et al., U.S. Pat. No. 9,161,934 B2 (2015).
    • Hashimoto et al., US 2009/0118263 A1 (2009).
    • He et al., U.S. Pat. No. 10,487,084 B2 (2019) [2019a].
    • He et al., U.S. Pat. No. 10,508,115 B2 (2019) [2019b].
    • Hirota et al., U.S. Pat. No. 6,028,076 (2000).
    • Holldack et al., US 2012/0083473 A1 (2012).
    • Isobe et al., U.S. Pat. No. 6,376,501 B1 (2002).
    • Isobe et al., JP 2004137157 (2004).
    • Isobe et al., J. Med. Chem. 2006, 49 (6), 2088, “Synthesis and Biological Evaluation of Novel 9-Substituted-8-Hydroxyadenine Derivatives as Potent Interferon Inducers.”
    • Isobe et al., U.S. Pat. No. 7,521,454 B2 (2009) [2009a].
    • Isobe et al., US 2009/0105212 A1 (2009) [2009b].
    • Isobe et al., US 2011/0028715 A1 (2011).
    • Isobe et al., U.S. Pat. No. 8,148,371 B2 (2012).
    • Jensen et al., WO 2015/036044 A1 (2015).
    • Jones et al., U.S. Pat. No. 7,691,877 B2 (2010).
    • Jones et al., US 2012/0302598 A1 (2012).
    • Kasibhatla et al., U.S. Pat. No. 7,241,890 B2 (2007).
    • Koga-Yamakawa et al., Int. J. Cancer 2013, 132 (3), 580, “Intratracheal and oral administration of SM-276001: A selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer.”
    • Li et al., U.S. Pat. No. 9,902,730 B2 (2018).
    • Lioux et al., U.S. Pat. No. 9,295,732 B2 (2016).
    • Lund et al., Proc. Nat'l Acad. Sci (USA) 2004, 101 (15), 5598, “Recognition of single-stranded RNA viruses by Toll-like receptor 7.”
    • Maj et al., U.S. Pat. No. 9,173,935 B2 (2015).
    • McGowan et al., US 2016/0168150 A1 (2016) [2016a].
    • McGowan et al., U.S. Pat. No. 9,499,549 B2 (2016) [2016b].
    • McGowan et al., J. Med. Chem. 2017, 60, 6137, “Identification and Optimization of Pyrrolo[3,2-d]pyrimidine Toll-like Receptor 7 (TLR7) Selective Agonists for the Treatment of Hepatitis B.”
    • Musmuca et al., J. Chem. Information & Modeling 2009, 49 (7), 1777, “Small-Molecule Interferon Inducers. Toward the Comprehension of the Molecular Determinants through Ligand-Based Approaches.”
    • Nakamura et al., Bioorg. Med. Chem. Lett. 2013, 13, 669, “Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor agonists with high water solubility.”
    • Ogita et al., US 2007/0225303 A1 (2007).
    • Ota et al., WO 2019/124500 A1 (2019).
    • Pilatte et al., WO 2017/216293 A1 (2017).
    • Poudel et al., U.S. Pat. No. 10,472,361 B2 (2019) [2019a].
    • Poudel et al., U.S. Pat. No. 10,494,370 B2 (2019) [2019b].
    • Poudel et al., US 2020/0038403 A1 (2020) [2020a].
    • Poudel et al., US 2020/0039986 A1 (2020) [2020b].
    • Purandare et al., WO 2019/209811 A1 (2019).
    • Pryde, U.S. Pat. No. 7,642,350 B2 (2010).
    • Sato-Kaneko et al., JCI Insight 2017, 2, e93397, “Combination Immunotherapy with TLR Agonists and Checkpoint Inhibitors Suppresses Head and Neck Cancer”.
    • Smits et al., The Oncologist 2008, 13, 859, “The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy”.
    • Vasilakos and Tomai, Expert Rev. Vaccines 2013, 12, 809, “The Use of Toll-like Receptor 7/8 Agonists as Vaccine Adjuvants”.
    • Vernejoul et al., US 2014/0141033 A1 (2014).
    • Young et al., U.S. Pat. No. 10,457,681 B2 (2019).
    • Yu et al., PLoS One 2013, 8 (3), e56514, “Toll-Like Receptor 7 Agonists: Chemical Feature Based Pharmacophore Identification and Molecular Docking Studies.”
    • Zhang et al., Immunity 2016, 45, 737, “Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA.”
    • Zhang et al., WO 2018/095426 A1 (2018)>
    • Zurawski et al., US 2012/0231023 A1 (2012).
  • The foregoing detailed description of the invention includes passages that are chiefly or exclusively concerned with particular parts or aspects of the invention. It is to be understood that this is for clarity and convenience, that a particular feature may be relevant in more than just the passage in which it is disclosed, and that the disclosure herein includes all the appropriate combinations of information found in the different passages. Similarly, although the various figures and descriptions herein relate to specific embodiments of the invention, it is to be understood that where a specific feature is disclosed in the context of a particular figure or embodiment, such feature can also be used, to the extent appropriate, in the context of another figure or embodiment, in combination with another feature, or in the invention in general.
  • Further, while the present invention has been particularly described in terms of certain preferred embodiments, the invention is not limited to such preferred embodiments. Rather, the scope of the invention is defined by the appended claims.

Claims (18)

1. A compound having a structure according to formula I
Figure US20230130516A1-20230427-C00202
wherein
Ar is
Figure US20230130516A1-20230427-C00203
W is H, halo, C1-C3 alkyl, CN, (C1-C4 alkanediyl)OH,
Figure US20230130516A1-20230427-C00204
each X is independently N or CR2;
R1 is (C1-C5 alkyl),
(C2-C5 alkenyl),
(C1-C8 alkanediyl)0-1(C3-C6 cycloalkyl),
(C1-C8 alkanediyl)0-1(C5-C10 spiroalkyl),
(C2-C8 alkanediyl)OH,
(C2-C8 alkanediyl)O(C1-C3 alkyl),
(C1-C4 alkanediyl)0-1(5-6 membered heteroaryl),
(C1-C4 alkanediyl)0-1phenyl,
(C1-C4 alkanediyl)CF3,
(C2-C8 alkanediyl)N[C(═O)](C1-C3 alkyl),
or
(C2-C8 alkanediyl)NRxRy;
each R2 is independently H, O(C1-C3 alkyl), S(C1-C3 alkyl), SO2(C1-C3 alkyl), C1-C3 alkyl, O(C3-C4 cycloalkyl), S(C3-C4 cycloalkyl), SO2(C3-C4 cycloalkyl), C3-C4 cycloalkyl, Cl, F, CN, or [C(═O)]0-1NRxRy;
R3 is H, halo, OH, CN,
NH2,
NH[C(═O)]0-1(C1-C5 alkyl),
N(C1-C5 alkyl)2,
NH[C(═O)]0-1(C1-C4 alkanediyl)0-1(C3-C8 cycloalkyl),
NH[C(═O)]0-1(C1-C4 alkanediyl)0-1(C4-C10 bicycloalkyl),
NH[C(═O)]0-1(C1-C4 alkanediyl)0-1(C5-C10 spiroalkyl),
N(C3-C6 cycloalkyl)2,
O(C1-C4 alkanediyl)0-1(C3-C8 cycloalkyl),
O(C1-C4 alkanediyl)0-1(C4-C8 bicycloalkyl),
O(C1-C4 alkanediyl)0-1(C5-C10 spiroalkyl),
O(C1-C4 alkanediyl)0-1(C1-C6 alkyl),
N[C1-C3 alkyl]C(═O)(C1-C6 alkyl),
NH(SO2)(C1-C8 alkyl),
NH(SO2)(C1-C4 alkanediyl)0-1(C3-C8 cycloalkyl),
NH(SO2)(C1-C4 alkanediyl)0-1(C4-C10 bicycloalkyl),
NH(SO2)(C1-C4 alkanediyl)0-1(C5-C10 spiroalkyl),
a 6-membered aromatic or heteroaromatic moiety,
a 5-membered heteroaromatic moiety, or
a moiety having the structure
Figure US20230130516A1-20230427-C00205
R4 is NH2,
NH(C1-C5 alkyl),
N(C1-C5 alkyl)2,
NH(C1-C4 alkanediyl)0-1(C3-C8 cycloalkyl),
NH(C1-C4 alkanediyl)0-1(C4-C10 bicycloalkyl),
NH(C1-C4 alkanediyl)0-1(C5-C10 spiroalkyl),
N(C3-C6 cycloalkyl)2,
or
a moiety having the structure
Figure US20230130516A1-20230427-C00206
R5 is H, C1-C5 alkyl, C2-C5 alkenyl, C3-C6 cycloalkyl, halo, O(C1-C5 alkyl), (C1-C4 alkanediyl)OH, (C1-C4 alkanediyl)O(C1-C3 alkyl), phenyl, NH(C1-C5 alkyl), 5 or 6 membered heteroaryl,
Figure US20230130516A1-20230427-C00207
R6 is NH2,
(NH)0-1(C1-C5 alkyl),
N(C1-C5 alkyl)2,
(NH)0-1(C1-C4 alkanediyl)0-1(C3-C8 cycloalkyl),
(NH)0-1(C1-C4 alkanediyl)0-1(C4-C10 bicycloalkyl),
(NH)0-1(C1-C4 alkanediyl)0-1(C5-C10 spiroalkyl),
N(C3-C6 cycloalkyl)2,
or
a moiety having the structure
Figure US20230130516A1-20230427-C00208
Rx and Ry are independently H or C1-C3 alkyl or Rx and Ry combine with the nitrogen to which they are bonded to form a 3- to 7-membered heterocycle;
n is 1, 2, or 3;
and
p is 0, 1, 2, or 3;
wherein in R1, R2, R3, R4, R5, and R6
an alkyl, cycloalkyl, alkanediyl, bicycloalkyl, spiroalkyl, cyclic amine, 6-membered aromatic or heteroaromatic moiety, 5-membered heteroaromatic moiety or a moiety of the formula
Figure US20230130516A1-20230427-C00209
is optionally substituted with one or more substituents selected from OH, halo, CN, (C1-C3 alkyl), O(C1-C3 alkyl), C(═O)(C1-C3 alkyl), SO2(C1-C3 alkyl), NRxRy, (C1-C4 alkanediyl)OH, (C1-C4 alkanediyl)O(C1-C3 alkyl); and
an alkyl, alkanediyl, cycloalkyl, bicycloalkyl, spiroalkyl, or a moiety of the formula
Figure US20230130516A1-20230427-C00210
may have a CH2 group replaced by O, SO2, CF2, C(═O), NH, N[C(═O)]0-1(C1-C3 alkyl), N[C(═O)]0-1(C1-C4 alkanediyl)0-1CF3,
or
N[C(═O)]0-1(C1-C4 alkanediyl)0-1(C3-C5 cycloalkyl).
2. A compound according to claim 1, having a structure according to formula (Ia)
Figure US20230130516A1-20230427-C00211
3. A compound according to claim 1, having a structure according to formula (Ib)
Figure US20230130516A1-20230427-C00212
4. A compound according to claim 3, wherein R3 is
Figure US20230130516A1-20230427-C00213
5. A compound according to claim 4, wherein
R1 is
Figure US20230130516A1-20230427-C00214
and
R5 is H or Me.
6. A compound according to claim 1, having a structure according to formula (Ic)
Figure US20230130516A1-20230427-C00215
7. A compound according to claim 6, wherein R4 is
Figure US20230130516A1-20230427-C00216
8. A compound according to claim 7, wherein
R1 is
Figure US20230130516A1-20230427-C00217
and
R5 is H or Me.
9. A compound having a structure according to formula (Id)
Figure US20230130516A1-20230427-C00218
wherein W is
Figure US20230130516A1-20230427-C00219
10. A method of treating a cancer, comprising administering to a patient suffering from such cancer a therapeutically effective combination of an anti-cancer immunotherapy agent and a compound according to claim 1.
11. A method according to claim 10, wherein the anti-cancer immunotherapy agent is an antagonistic anti-CTLA-4, anti-PD-1, or anti-PD-L1 antibody.
12. A method according to claim 10, wherein the cancer is lung cancer (including non-small cell lung cancer), pancreatic cancer, kidney cancer, head and neck cancer, lymphoma (including Hodgkin's lymphoma), skin cancer (including melanoma and Merkel skin cancer), urothelial cancer (including bladder cancer), gastric cancer, hepatocellular cancer, or colorectal cancer.
13. A method according to claim 12, wherein the anti-cancer immunotherapy agent is ipilimumab, nivolumab, or pembrolizumab.
14. A compound having a structure according to formula (Ie)
Figure US20230130516A1-20230427-C00220
wherein
R1 is
Figure US20230130516A1-20230427-C00221
R5 is H or Me; and
R7 is H, C1-C5 alkyl, or C3-C6 cycloalkyl; wherein the cycloalkyl group optionally has a CH2 group replaced by O, NH, or N(C1-C3)alkyl.
15. A method of treating a cancer, comprising administering to a patient suffering from such cancer a therapeutically effective combination of an anti-cancer immunotherapy agent and a compound according to claim 9.
16. A method according to claim 15, wherein the anti-cancer immunotherapy agent is an antagonistic anti-CTLA-4, anti-PD-1, or anti-PD-L1 antibody.
17. A method according to claim 15, wherein the cancer is lung cancer (including non-small cell lung cancer), pancreatic cancer, kidney cancer, head and neck cancer, lymphoma (including Hodgkin's lymphoma), skin cancer (including melanoma and Merkel skin cancer), urothelial cancer (including bladder cancer), gastric cancer, hepatocellular cancer, or colorectal cancer.
18. A method according to claim 17, wherein the anti-cancer immunotherapy agent is ipilimumab, nivolumab, or pembrolizumab.
US17/792,878 2020-01-27 2021-01-26 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS Pending US20230130516A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/792,878 US20230130516A1 (en) 2020-01-27 2021-01-26 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062966092P 2020-01-27 2020-01-27
US202063057661P 2020-07-28 2020-07-28
US17/792,878 US20230130516A1 (en) 2020-01-27 2021-01-26 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
PCT/US2021/014979 WO2021154665A1 (en) 2020-01-27 2021-01-26 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS

Publications (1)

Publication Number Publication Date
US20230130516A1 true US20230130516A1 (en) 2023-04-27

Family

ID=74626256

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/792,878 Pending US20230130516A1 (en) 2020-01-27 2021-01-26 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS

Country Status (6)

Country Link
US (1) US20230130516A1 (en)
EP (1) EP4097101A1 (en)
JP (1) JP2023512229A (en)
KR (1) KR20220132594A (en)
CN (1) CN115135655A (en)
WO (1) WO2021154665A1 (en)

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001448A1 (en) 1996-07-03 1998-01-15 Japan Energy Corporation Novel purine derivatives
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
JP4331944B2 (en) 2001-04-17 2009-09-16 大日本住友製薬株式会社 New adenine derivatives
WO2003037860A2 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
BR0314761A (en) 2002-09-27 2005-07-26 Sumitomo Pharma Adenine Compound and its Use
JP2004137157A (en) 2002-10-16 2004-05-13 Sumitomo Pharmaceut Co Ltd Medicine comprising new adenine derivative as active ingredient
EP1728792A4 (en) 2004-03-26 2010-12-15 Dainippon Sumitomo Pharma Co 8-oxoadenine compound
MX2007013780A (en) 2005-05-04 2008-02-05 Pfizer Ltd 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c.
RS20080128A (en) 2005-09-02 2009-05-06 Pfizer Inc., Hydroxy substituted 1h-imidazopyridines and methods
US20090105212A1 (en) 2005-09-22 2009-04-23 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
US20090118263A1 (en) 2005-09-22 2009-05-07 Dainippon Sumitomo Pharma Co., Ltd. Novel Adenine Compound
MX2008010611A (en) 2006-02-17 2008-11-12 Pfizer Ltd 3 -deazapurine derivatives as tlr7 modulators.
EP2510946B1 (en) 2007-02-07 2015-08-05 The Regents of The University of California Conjugates of synthetic tlr agonists and uses therefor
TW200902018A (en) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
WO2008118454A2 (en) 2007-03-23 2008-10-02 Amgen Inc. Derivatives of quinoline or benzopyrazine and their uses for the treatment of (inter alia) inflammatory diseases, autoimmune diseases or various kinds of cancer
NZ582090A (en) 2007-06-29 2012-05-25 Gilead Sciences Inc Purine derivatives and their use as modulators of toll-like receptor 7
ATE501136T1 (en) 2007-08-03 2011-03-15 Pfizer Ltd IMIDAZOPYRIDINONE
PT2364314E (en) 2008-12-09 2014-06-09 Gilead Sciences Inc Modulators of toll-like receptors
US8729088B2 (en) 2009-02-11 2014-05-20 The Regents Of The University Of California Toll-like receptor modulators and treatment of diseases
US8962652B2 (en) 2009-10-22 2015-02-24 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
WO2011139348A2 (en) 2010-04-30 2011-11-10 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
WO2011134669A1 (en) 2010-04-30 2011-11-03 Telormedix Sa Methods for inducing an immune response
JP6026405B2 (en) 2010-04-30 2016-11-16 テロルメディクス エセアー Phospholipid drug analogues
US20120083473A1 (en) 2010-09-21 2012-04-05 Johanna Holldack Treatment of conditions by toll-like receptor modulators
US20120231023A1 (en) 2011-03-08 2012-09-13 Baylor Research Institute Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells
MX347596B (en) 2011-11-09 2017-05-03 Janssen Sciences Ireland Uc Purine derivatives for the treatment of viral infections.
NZ702364A (en) 2012-07-13 2016-09-30 Janssen Sciences Ireland Uc Macrocyclic purines for the treatment of viral infections
NZ704224A (en) 2012-08-24 2018-04-27 Glaxosmithkline Llc Pyrazolopyrimidine compounds
LT2906563T (en) 2012-10-10 2018-06-11 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
EP2732825B1 (en) 2012-11-19 2015-07-01 Invivogen Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
US9295732B2 (en) 2013-02-22 2016-03-29 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
MX366481B (en) 2013-03-29 2019-07-09 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections.
PT3030563T (en) 2013-06-27 2017-11-15 Janssen Sciences Ireland Uc Pyrrolo [3,2-d] pyrimidine derivatives for the treatment of viral infections and other diseases
WO2015023858A2 (en) 2013-08-16 2015-02-19 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
WO2015036044A1 (en) 2013-09-13 2015-03-19 Telormedix Sa Cationic lipid vehicles for delivery of tlr7 agonists for specific targeting of human cd14+ monocytes in whole blood
EA032487B1 (en) 2014-05-01 2019-06-28 Новартис Аг COMPOUNDS AND COMPOSITIONS AS Toll-LIKE RECEPTOR 7 AGONISTS
EP3137470B1 (en) 2014-05-01 2021-04-07 Novartis AG Compounds and compositions as toll-like receptor 7 agonists
WO2016023511A1 (en) 2014-08-15 2016-02-18 正大天晴药业集团股份有限公司 Pyrrolopyrimidine compounds used as tlr7 agonist
CN105732635A (en) 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 Toll-like receptor 7 agonist
MA44334A (en) 2015-10-29 2018-09-05 Novartis Ag ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
BR112018008880B1 (en) 2015-11-05 2023-01-17 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 7-(THIAZOL-5-IL) PYRROLOPYRMIDINE, ITS USE, AND PHARMACEUTICAL COMPOSITION
AU2017286380B2 (en) 2016-06-16 2021-02-04 Janssen Pharmaceutica Nv Azabenzimidazole derivatives as PI3K beta inhibitors
TWI760390B (en) * 2016-11-28 2022-04-11 大陸商江蘇恆瑞醫藥股份有限公司 Heteroaryl fused pyrazole derivatives, a preparation method thereof and pharmaceutical use thereof
US10487084B2 (en) * 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) * 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
SG11202005535UA (en) 2017-12-21 2020-07-29 Sumitomo Dainippon Pharma Co Ltd Combination drug including tlr7 agonist
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor

Also Published As

Publication number Publication date
CN115135655A (en) 2022-09-30
JP2023512229A (en) 2023-03-24
KR20220132594A (en) 2022-09-30
WO2021154665A1 (en) 2021-08-05
EP4097101A1 (en) 2022-12-07

Similar Documents

Publication Publication Date Title
US9403832B2 (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
US9604989B2 (en) Imidazopyridazines as Akt kinase inhibitors
KR102268155B1 (en) Tetrahydropyrazolopyrimidine compounds
US20150005309A1 (en) Substituted imidazopyrazines as akt kinase inhibitors
US8987286B2 (en) Substituted pyrimido[1,2-b]indazoles and their use as modulators of the Pi3K/Akt pathway
US20230130516A1 (en) 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US11344549B2 (en) 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof
US20230348468A1 (en) 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US20230118688A1 (en) 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US20230140430A1 (en) 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US20230041738A1 (en) 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US20230131192A1 (en) 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US20230122249A1 (en) 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US20230127326A1 (en) C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US20230144824A1 (en) 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US20240199612A1 (en) Imidazopyridinyl inhibitors of plasma kallikrein

Legal Events

Date Code Title Description
AS Assignment

Owner name: BRISTOL-MYERS SQUIBB COMPANY, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHANG, QIAN;GANGWAR, SANJEEV;GAVAI, ASHVINIKUMAR V.;AND OTHERS;SIGNING DATES FROM 20210831 TO 20220629;REEL/FRAME:061482/0386

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION